U.S. patent application number 16/555912 was filed with the patent office on 2020-07-23 for methods and compositions for recombinant dengue viruses for vaccine and diagnostic development.
The applicant listed for this patent is The University of North Carolina at Chapel Hill. Invention is credited to Ralph Baric, Aravinda Desilva, Emily Gallichotte, Scott Royal, Jesica Swanstrom, Douglas Widman, Boyd Yount.
Application Number | 20200230224 16/555912 |
Document ID | / |
Family ID | 55858450 |
Filed Date | 2020-07-23 |
View All Diagrams
United States Patent
Application |
20200230224 |
Kind Code |
A1 |
Baric; Ralph ; et
al. |
July 23, 2020 |
METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE
AND DIAGNOSTIC DEVELOPMENT
Abstract
The present invention provides compositions and methods of use
comprising a chimeric dengue virus E glycoprotein comprising a
dengue virus E glycoprotein backbone, which comprises amino acid
substitutions that introduce an epitope that is recognized by an
antibody from a dengue virus serotype that is different from the
dengue virus serotype of the dengue virus E glycoprotein
backbone.
Inventors: |
Baric; Ralph; (Haw River,
NC) ; Widman; Douglas; (Carrboro, NC) ; Yount;
Boyd; (Hillsborough, NC) ; Gallichotte; Emily;
(Carrboro, NC) ; Royal; Scott; (Carrboro, NC)
; Desilva; Aravinda; (Chapel Hill, NC) ;
Swanstrom; Jesica; (Morrisville, NC) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The University of North Carolina at Chapel Hill |
Chapel Hill |
NC |
US |
|
|
Family ID: |
55858450 |
Appl. No.: |
16/555912 |
Filed: |
August 29, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15523899 |
May 2, 2017 |
10398768 |
|
|
PCT/US2015/058610 |
Nov 2, 2015 |
|
|
|
16555912 |
|
|
|
|
62074053 |
Nov 2, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 39/12 20130101;
C07K 2319/40 20130101; C07K 14/005 20130101; C12N 2770/24122
20130101; C12N 2770/24171 20130101; G01N 2333/18 20130101; C07K
2317/21 20130101; A61K 2039/575 20130101; C12N 2770/24123 20130101;
C07K 16/1063 20130101; G01N 2469/20 20130101; Y02A 50/53 20180101;
C12N 7/00 20130101; G01N 2333/185 20130101; A61K 2039/5258
20130101; C12N 2770/24134 20130101; Y02A 50/386 20180101; Y02A
50/30 20180101; A61P 31/14 20180101; G01N 33/56983 20130101 |
International
Class: |
A61K 39/12 20060101
A61K039/12; C07K 16/10 20060101 C07K016/10; C12N 7/00 20060101
C12N007/00; C07K 14/005 20060101 C07K014/005; G01N 33/569 20060101
G01N033/569 |
Goverment Interests
STATEMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with government support under Grant
Nos. AI057157, A1097560, AI107731 and AI109761, awarded by the
National Institutes of Health. The United States government has
certain rights in the invention.
Claims
1. A chimeric dengue virus E glycoprotein comprising a dengue virus
E glycoprotein backbone that comprises amino acid substitutions
that introduce an epitope that is recognized by an antibody that is
reactive with a dengue virus serotype that is different from the
dengue virus serotype of the dengue virus E glycoprotein backbone,
wherein the dengue virus E glycoprotein backbone is from dengue
virus serotype 4 and the antibody is reactive with dengue virus
serotype 3.
Description
STATEMENT OF PRIORITY
[0001] This application is a continuation application of U.S.
patent application Ser. No. 15/523,899, filed May 2, 2017 and
issued as U.S. patent Ser. No. 10/398,768 on Sep. 3, 2019, which is
a 35 U.S.C. .sctn. 371 national phase application of International
Application Serial No. PCT/US2015/058610, filed Nov. 2, 2015, which
claims the benefit, under 35 U.S.C. .sctn. 119(e), of U.S.
Provisional Application Ser. No. 62/074,053, filed Nov. 2, 2014,
the entire contents of each of which are incorporated by reference
herein.
STATEMENT REGARDING ELECTRONIC FILING OF A SEQUENCE LISTING
[0003] A Sequence Listing in ASCII text format, submitted under 37
C.F.R. .sctn. 1.821, entitled 5470-723CT ST25.txt, 153,078 bytes in
size, generated on Aug. 28, 2019 and filed via EFS-Web, is provided
in lieu of a paper copy. This Sequence Listing is incorporated by
reference into the specification for its disclosures.
FIELD OF THE INVENTION
[0004] The present invention is directed to dengue virus vaccines
that induce neutralizing antibodies against more than one dengue
virus serotype from a single source.
BACKGROUND OF THE INVENTION
[0005] Dengue virus (DENV) is a mosquito-borne flavivirus that is
spreading at an unprecedented rate and has developed into a major
health and economic burden in over 50 countries. Current DENV
vaccines protecting against all four DENV serotypes must be
delivered as a "tetravalent" formulation of four viruses or four
recombinant proteins, each intended to confer protection against
that serotype. The correct mix of serotypes in the tetravalent
cocktail to achieve a balanced antibody response is not known,
underscored by the recent failure of the most advanced tetravalent
live attenuated chimeric virus to provide clinically meaningful
protection in a large phase 2B trial in Thailand (Sabchareon et
al., 2012). Viral interference is thought to contribute to failure
as one or more virus serotypes out-compete the others.
[0006] The present invention overcomes previous shortcomings in the
art by providing chimeric dengue viruses that induce neutralizing
antibodies against more than one dengue virus serotype from a
single source.
SUMMARY OF THE INVENTION
[0007] In one aspect, the present invention provides a chimeric
dengue virus E glycoprotein comprising a dengue virus E
glycoprotein backbone that comprises amino acid substitutions that
introduce an epitope that is recognized by an antibody that is
reactive with a dengue virus serotype that is different from the
dengue virus serotype of the dengue virus E glycoprotein backbone,
wherein the dengue virus E glycoprotein backbone is from dengue
virus serotype 4 and the antibody is reactive with dengue virus
serotype 3.
[0008] In a further aspect, the present invention provides a
chimeric dengue virus E glycoprotein comprising a dengue virus E
glycoprotein backbone that comprises amino acid substitutions that
introduce a protein domain from a dengue virus serotype that is
different from the dengue virus serotype of the dengue virus E
glycoprotein backbone, wherein the dengue virus E glycoprotein
backbone is from dengue virus serotype 4 and the protein domain is
from dengue virus serotype 2.
[0009] In another aspect, the present invention provides a chimeric
dengue virus E glycoprotein comprising a dengue virus E
glycoprotein backbone that comprises amino acid substitutions that
introduce an epitope that is recognized by an antibody that is
reactive with a dengue virus serotype that is different from the
dengue virus serotype of the dengue virus E glycoprotein backbone,
wherein the dengue virus E glycoprotein backbone is from dengue
virus serotype 2 and the antibody is reactive with dengue virus
serotype 1.
[0010] Also provided herein is a method of producing an immune
response to a dengue virus in a subject (e.g., a subject in need
thereof), comprising administering to the subject an effective
amount of the E glycoprotein of this invention, the flavivirus
particle of this invention, the VLP of this invention, the nucleic
acid molecule of this invention, the population of this invention,
and/or the composition of this invention and any combination
thereof.
[0011] Additionally provided herein is a method of treating a
dengue virus infection in a subject (e.g., a subject in need
thereof), comprising administering to the subject an effective
amount of the E glycoprotein of this invention, the flavivirus
particle of this invention, the VLP of this invention, the nucleic
acid molecule of this invention, the population of this invention,
and/or the composition of this invention and any combination
thereof.
[0012] Further provided herein is a method of preventing a disorder
associated with dengue virus infection in a subject (e.g., a
subject in need thereof), comprising administering to the subject
an effective amount of the E glycoprotein of this invention, the
flavivirus particle of this invention, the VLP of this invention,
the nucleic acid molecule of this invention, the population of this
invention, and/or the composition of this invention and any
combination thereof.
[0013] As an additional aspect, the present invention provides a
method of protecting a subject from the effects of dengue virus
infection, comprising administering to the subject an effective
amount of the E glycoprotein of this invention, the flavivirus
particle of this invention, the VLP of this invention, the nucleic
acid molecule of this invention, the population of this invention,
and/or the composition of this invention and any combination
thereof.
[0014] In further aspects, the present invention provides methods
of identifying the presence of a neutralizing antibody to specific
dengue virus serotypes or combinations thereof (e.g., 4/3, 4/2,
2/1) in a biological sample from a subject, comprising: a)
administering a composition comprising a particular E glycoprotein
this invention to the subject in an amount effective to induce an
antibody response to the E glycoprotein; b) contacting a biological
sample from the subject with flavivirus particles comprising the
particular E glycoprotein above under conditions whereby
neutralization of the flavivirus particles can be detected; and c)
detecting neutralization in step (b), thereby identifying the
presence of a neutralizing antibody to the specific dengue virus
serotypes or combinations thereof in the biological sample from the
subject.
[0015] The present invention additionally provides a method of
identifying the presence of a neutralizing antibody to specific
dengue virus serotypes or combinations thereof (e.g., 4/3, 4/2,
2/1) in a biological sample from a subject, comprising: a)
contacting a biological sample from a subject that has been
administered a particular E glycoprotein of this invention with
flavivirus particles comprising the E glycoprotein under conditions
whereby neutralization of the flavivirus particles can be detected;
and b) detecting neutralization in step (a), thereby identifying
the presence of a neutralizing antibody to the specific dengue
virus serotypes or combinations thereof in the biological sample
from the subject.
[0016] In other embodiments, the present invention provides a
method of identifying an immunogenic composition that induces a
neutralizing antibody to specific dengue virus serotypes or
combinations thereof (e.g., 4/3, 4/2, 2/1) in a subject,
comprising: a) administering an immunogenic composition comprising
a particular E glycoprotein of this invention to a subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
under conditions whereby neutralization of the flavivirus particles
can be detected; c) determining if the biological sample comprises
an antibody that neutralizes flavivirus particles comprising the E
glycoprotein of step (a); and d) identifying the immunogenic
composition as inducing a neutralizing antibody to the specific
dengue virus serotypes or combinations thereof in the subject if
the biological sample comprises an antibody that neutralizes
flavivirus particles comprising the E glycoprotein of (a).
[0017] Further provided herein is a method of identifying an
immunogenic composition that induces a neutralizing antibody to
specific dengue virus serotypes or combinations thereof (e.g., 4/3,
4/2, 2/1) in a subject, the method comprising: a) contacting a
biological sample from a subject that has been administered an
immunogenic composition comprising a particular E glycoprotein of
this invention with flavivirus particles comprising the E
glycoprotein under conditions whereby neutralization of the
flavivirus particles can be detected; b) determining if the
biological sample comprises an antibody that neutralizes flavivirus
particles comprising the E glycoprotein of step (a); and c)
identifying the immunogenic composition as inducing a neutralizing
antibody to the specific dengue virus serotypes or combinations
thereof in the subject if the biological sample comprises an
antibody that neutralizes flavivirus particles comprising the E
glycoprotein of (a).
[0018] The present invention also provides a method of detecting an
antibody to a specific dengue virus serotype or combination thereof
in a sample, comprising; a) contacting the sample with a particular
E glycoprotein of this invention under conditions whereby an
antigen/antibody complex can form; and b) detecting formation of an
antigen/antibody complex, thereby detecting an antibody to the
specific dengue virus serotype or combination thereof in the
sample.
[0019] Additionally provided herein is a method of identifying an
antibody to a specific dengue virus serotype or combination thereof
in a biological sample from a subject, comprising: a) administering
a composition comprising a particular E glycoprotein of this
invention to the subject in an amount effective to induce an
antibody response to the E glycoprotein; b) contacting a biological
sample from the subject with the E glycoprotein of (a) under
conditions whereby an antigen/antibody complex can form; and c)
detecting formation of an antigen/antibody complex, thereby
identifying an antibody to dengue virus serotype 3 and/or 4 in the
biological sample from the subject.
[0020] A further aspect of the invention provides a method of
identifying an antibody to a specific dengue virus serotype or
combinations thereof in a biological sample from a subject,
comprising: a) contacting a biological sample from a subject that
has been administered an immunogenic composition comprising a
particular E glycoprotein of this invention with the E glycoprotein
under conditions whereby an antigen/antibody complex can form; and
c) detecting formation of an antigen/antibody complex, thereby
identifying an antibody dengue virus serotype 3 and/or 4 in the
biological sample from the subject.
[0021] The present invention additionally provides a method of
identifying an immunogenic composition that induces an antibody to
a specific dengue virus serotype or combination thereof in a
subject, the method comprising: a) contacting a biological sample
from a subject that has been administered an immunogenic
composition comprising a particular E glycoprotein of this
invention with the E glycoprotein under conditions whereby an
antigen/antibody complex can form; and b) detecting formation of an
antigen/antibody complex, thereby identifying an immunogenic
composition that induces an antibody to the specific dengue virus
serotype or combination thereof in the subject.
[0022] A further embodiment of the invention is a method of
identifying an immunogenic composition that induces a neutralizing
antibody to a specific dengue virus serotype or combination thereof
in a subject, comprising: a) administering an immunogenic
composition comprising a particular E glycoprotein to a subject in
an amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c detecting formation an
antigen/antibody complex, thereby identifying an immunogenic
composition that induces a neutralizing antibody to the specific
dengue virus serotype or combination thereof in the subject.
[0023] Additionally provided herein is a dengue virus particle, a
flavivirus particle and/or a virus like particle (VLP) comprising
the E glycoprotein of this invention.
[0024] An isolated nucleic acid molecule encoding the E
glycoprotein of this invention is also provided herein, as well as
an isolated nucleic acid molecule encoding the dengue virus
particle, flavivirus particle or VLP of this invention.
[0025] The present invention also provides a composition comprising
the E glycoprotein of this invention in a pharmaceutically
acceptable carrier and also provides a composition comprising the
nucleic acid molecule of this invention, the vector of this
invention, the particle of this invention and/or the population of
this invention, in a pharmaceutically acceptable carrier.
[0026] The present invention further provides the E glycoprotein of
this invention, the dengue virus particle of this invention, the
flavivirus particle of this invention, the VLP of this invention,
the nucleic acid molecule of this invention, the vector of this
invention, the population of this invention and/or the composition
of this invention, singly or in any combination, for use in the
manufacture of a medicament for producing an immune response to a
dengue virus in a subject, for treating a dengue virus infection in
a subject in need thereof, for preventing a dengue virus infection
in a subject and/or for protecting a subject from the effects of
dengue virus infection.
[0027] Also provided herein is the use of the E glycoprotein of
this invention, the dengue virus particle of this invention, the
flavivirus particle of this invention, the VLP of this invention,
the nucleic acid molecule of this invention, the vector of this
invention, the population of this invention and/or the composition
of this invention, singly or in any combination, for use in
producing an immune response to a dengue virus in a subject, in
treating a dengue virus infection in a subject in need thereof, in
preventing a dengue virus infection in a subject and/or in
protecting a subject from the effects of dengue virus
infection.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] FIG. 1. Design of infectious cDNA clones of DENV3 and 4 and
generation of recombinant DENV4/3 viruses. (A) Genome schematic of
DENV3 and DENV4 infectious clone design including restriction
endonucleases used to generate subgenomic fragments. Size of
subgenomic fragments indicates positions in DENV genome where
breaks were made to circumvent bacterial instability and toxicity.
(B) Amino acids changed in DENV4 E protein by transplantation of
DENV3 sequences to generate DENV4 M12, M14, and M16 respectively.
Amino acid number represents residue from start of E protein of
DENV4. Ribbon structure of DENV3 E protein dimer with AA
transferred into DENV4 M12 (C; green residues), DENV4 M14 (D;
green+cyan residues), and DENV4 M16 (E; green+cyan+orange residues)
indicated. Colors correspond to highlighted AA residues in (B).
[0029] FIG. 2. Growth characteristics of rDENV4/3 on mammalian
cells. (A) DENV3, DENV4, DENV4 M12, DENV4 M14, and DENV4 M16 were
propagated on C6/36 cells until maximal cytopathology was observed
(typically 4 days post-inoculation) and harvested for titration on
Vero-81 cells. Infectious titers are presented as ffu/ml cell
culture supernatant. (B) Infectious foci size and morphology of WT
and rDENV viruses on Vero-81 cells.
[0030] FIG. 3. Growth characteristics of rDENV4/3 on arthropod
cells. (A) Multi-step growth curve analysis of DENV3, DENV4, DENV4
M12, DENV4 M14, and DENV4 M16 inoculated on C6/36 cells at an
MOI=0.01. Cell culture supernatants were titrated on C6/36 cells as
described. (B) Infectious focus size and morphology of WT and rDENV
on C6/36 cells.
[0031] FIG. 4. Binding and neutralization of hmAb 5J7 on rDENV4/3.
(A) ELISA OD values for DENV3-specific hmAb 5J7 on DENV3, DENV4,
DENV4 M14, and DENV4 M16. 5J7 did not bind DENV4 M12 and displayed
an identical curve to WT DENV4 (data not shown). Neutralization
assays on Vero-81 (B) and U937-DC-SIGN (C) for DENV3, DENV4, DENV4
M12, M14, and M16. Data presented as .mu.g/ml required to
neutralize 50% of viral infectivity.
[0032] FIG. 5. Polyclonal DENV3 serum neutralization. (A-D) Sera
collected from human donors recovered from primary DENV3 infection
were assayed against DENV3, DENV4, DENV4 M12, and DENV4 M14 on
Vero-81 cells to assess sensitivity to DENV3 humoral immune
responses. (E-G) Sera collected from human donors recovered from
primary DENV3 infection were assayed against DENV3, DENV4, DENV4
M14, and DENV4 M16 on U937-DC-SIGN cells to assess sensitivity to
DENV3 humoral immune responses.
[0033] FIG. 6. Polyclonal DENV4 serum neutralization. (A) Sera
collected from human donors recovered from primary DENV4 infection
were assayed against DENV3, DENV4, DENV4 M12, and DENV4 M14 on
Vero-81 cells to assess sensitivity to DENV4 humoral immune
responses. (B-D) Sera collected from human donors recovered from
primary DENV4 infection were assayed against DENV3, DENV4, DENV4
M14, and DENV4 M16 on U937-DC-SIGN cells to assess sensitivity to
DENV4 humoral immune responses.
[0034] FIG. 7. Heterotypic serum neutralization. (A, B) Sera
collected from human donors recovered from primary DENV1 infection
were assayed against DENV1, DENV3, DENV4 M12, and DENV4 M14 on
Vero-81 cells to assess sensitivity to non-specific humoral immune
responses. (C, D) Sera collected from human donors recovered from
primary DENV2 infection were assayed against DENV2, DENV3, DENV4
M12, and DENV4 M14 on Vero-81 cells to assess sensitivity to DENV4
humoral immune responses.
[0035] FIG. 8. Design of infectious cDNA clones of DENV1 and 2 and
generation of recombinant DENV2/1 viruses. (A) Genome schematic of
DENV1 and DENV2 infectious clone design including restriction
endonucleases used to generate subgenomic fragments. Size of
subgenomic fragments indicates positions in DENV genome where
breaks were made to circumvent bacterial instability and toxicity.
(B) Amino acids changed in DENV2 E protein by transplantation of
DENV1 sequences to generate DENV2-1F4E. Amino acid number
represents residue from start of E protein of DENV2. (C) Ribbon
structure of DENV2 E protein dimer with AA transferred into
DENV2-1F4E.
[0036] FIG. 9. Growth characteristics of rDENV2/1. DENV1, DENV2,
and DENV2-1F4E were propagated on C6/36 cells until maximal
cytopathology was observed (typically 4 days post-inoculation) and
harvested for titration on Vero-81 (A) or C6/36 (B) cells.
Infectious titers are presented as ffu/ml cell culture supernatant.
(C) Multi-step growth curve analysis of DENV1, DENV2, and
DENV2-1F4E inoculated on C6/36 cells at an MOI=0.01. Cell culture
supernatants were titrated on C6/36 cells as described. (D)
Infectious foci size and morphology of WT and DENV2-1F4E viruses on
C6/36 cells.
[0037] FIG. 10. Binding and neutralization of hmAb 1F4 on rDENV2/1
(A) ELISA OD values for DENV1-specific hmAb 1F4 on DENV1, DENV2,
and DENV2-1F4E. Neutralization assays on C6/36 (B) and U937-DC-SIGN
(C) for DENV1, DENV2, and DENV2-1F4E. Data presented as .mu.g/ml
required to neutralize 50% of viral infectivity.
[0038] FIG. 11. Polyclonal DENV1 and DENV2 serum neutralization. (A
and B) Sera collected from human donors recovered from primary
DENV1 infection were assayed against DENV1, DENV2, and DENV2-1F4E
on U937-DC-SIGN cells to assess sensitivity to DENV1 humoral immune
responses. (C-E) Sera collected from human donors recovered from
primary DENV2 infection were assayed against DENV1, DENV2, and
DENV2-1F4E on U937-DC-SIGN cells to assess sensitivity to DENV2
humoral immune responses.
[0039] FIG. 12. Murine survival. Interferon .alpha./.beta./.gamma.
deficient mice on a C57BL/6 background were inoculated
intraperitoneally with 3.3.times.10.sup.6 ffu DENV1, DENV2, or
DENV2-1F4E. Mice were monitored for weight loss and clinical
illness for 56 days.
[0040] FIG. 13. Design and construction of DV4-EDIII-DV2 virus. (A)
Amino acid alignment of DENV2 and DENV4 linear envelope domain III
(EDIII) sequence, residues 296-395 of entire E sequence (99 aa
total). Residues differing between DENV2 and DENV4 are highlighted
grey. Recombinant DENV4 virus containing EDIII from DENV3,
rDENV4/2, replaces differing residues from DENV4 with those from
DENV2, highlighted in light grey. (B) Cartoon (left) and space
filling (right) crystal structure model of DENV2 E protein dimer,
with swapped residues colored. (C) Reverse genetics system for
manipulating DENV genome, top=DENV2, bottom=DENV4. DENV genome is
divided into four plasmid cassettes which can be individually
mutated, ligated together, and electroporated into cells to
generate recombinant virus. DENV4-A cassette contains the envelope
gene, EDIII is highlighted in grey. Replacing EDIII residues with
those from DENV2, in DENV4 backbone creates DV4-EDIII-DV2
virus.
[0041] FIG. 14. DENV4 and DV4-EDIII-DV2 virions have similar
maturation profiles. Viruses were grown in C6/C36 cells, culture
supernatant was collected and centrifuged to remove any cellular
debris. Samples were run on 12% SDS-PAGE gel and blots were probed
with anti-E (4G2) and anti-PrM (2H12 and 5L20) antibodies. DENV2
has substantial levels of PrM present, indicating either incomplete
Furin processing or PrM dissociation. PrM bands are not detectable
in either DENV4 or DV4-EDIII-DV2 samples.
[0042] FIG. 15. DV4-EDIII-DV2 has 2 log growth attenuation in Vero
cells relative to parental viruses. (A) Vero-81 cells were infected
at an MOI=0.01. Viral supernatants were collected every 24 hours
and subsequently titered on Vero-81 cells. (B) DENV forms
infectious foci in Vero-81 cells (DENV2, DENV4 and DV4-EDIII-DV2
fixed 5, 4 and 6 days post-infection, respectively). DV4-EDIII-DV2
foci are smaller than both parental viruses.
[0043] FIG. 16. DV4-EDIII-DV2 has no growth attenuation in C6/C36
cells. (A) C6/C36 cells were infected at an MOI=0.01. Viral
supernatants were collected every 24 hours and subsequently titered
on C6/C36 cells. (B) DENV forms infectious foci in C6/C36 cells
(DENV2, DENV4 and DV4-EDIII-DV2 fixed 4, 3 and 5 days
post-infection, respectively). With additional day(s) of growth,
DV4-EDIII-DV2 foci reach sizes comparable to parental viruses.
[0044] FIG. 17. Transfer of binding and neutralization of
DV4-EDIII-DV2 by type-specific DENV2 human MAb. (A) Summary table
of human MAb 2D22, a strongly neutralizing DV2 MAb that binds to a
quaternary epitope. (B) Previously generated 2D22 escape mutant
resulted in one escape mutation, R323G, mapping to EDIII. (C) ELISA
assay shows transferred partial binding of 2D22 to DV4-EDIII-DV2,
above levels of parental DV4 but not to DV2 levels. (D) ELISA
binding of cross-reactive control antibody, 2J20, shows comparable
levels of virus present and maintained virus structural integrity.
(E) Vero-81 based Focus Reduction Neutralization Test (FRNT) was
performed using 2D22 and FRNT.sub.50 (concentration of antibody
required to neutralize 50% of infection) values were calculated.
(F) U937+DC-SIGN based neutralization assay (Neut) was performed
using 2D22 and Neut.sub.50 values were calculated. In both assays
(E, F), DV4-EDIII-DV2 gained neutralization to 2D22 to levels
higher than DV2. DV4 was not neutralized with the maximum
concentration of 2D22 in either assay.
[0045] FIG. 18. DV4-EDIII-DV2 gained neutralization to many
additional DV2 type-specific MAbs. (A, B, E) DENV E protein dimer
crystal structure with escape mutant or scanning alanine mutation
residues (from Table 2) are indicated residue 382 for DVC3.7,
residue 311 for DVC10.16, and residues 101 and 108 for DVC13.6
respectively. (C, D, F-I) Vero-81 FRNT assay for each MAb. With the
exception of 3F9, DV4-EDIII-DV2 neutralization to the given MAbs
was transferred to levels equal to or higher than that of the
parental DV2 virus. 3F9 does not bind DV4-EDIII-DV2 (ELISA binding
data not shown).
[0046] FIG. 19. DV4-EDIII-DV2 is not neutralized by a DV4
type-specific EDIII MAb. (A) DENV E protein dimer crystal structure
with scanning alanine mutation residues (from Table 2) indicated at
residues 331 and 361. (B) Vero-81 FRNT assay shows DV-E88 is not
capable of neutralizing DV4-EDIII-DV2 or DV2, but can neutralize
the parental DV4.
[0047] FIG. 20. DV4-EDIII-DV2 gained neutralization to polyclonal
DENV2 immune sera. (A-L) Vero-81 FRNT assay shows gain of
polyclonal immune sera neutralization to DV4-EDIII-DV2, comparable
to levels of DV2 neutralization, indicating transfer of EDIII from
DV2 into DV4 is sufficient to transfer majority of DENV2
neutralization. *=FNRT.sub.50<20
[0048] FIG. 21. DV$-EDIII-DV2 maintained neutralization to
polyclonal DENV4 immune sera. (A-F) Vero-81 FRNT assay shows
DV4-EDIII-DV2 maintains majority neutralization, indicating
transfer of EDIII from DV2 does not disrupt the DV4 neutralizing
epitope. *=FNRT.sub.50<20
[0049] FIG. 22. DV4-EDIII-DV2 gains DV2 sera neutralization and
preserves DV4 sera neutralization. (A) Summary of DV2 polyclonal
neutralization data presented in FIG. 19. (B) Summary of DV4
polyclonal neutralization data presented in FIG. 20. Samples with
FNRT.sub.50<20 graphed at sera dilution factor of 19.
[0050] FIG. 23. DV4-EDIII-DV2 does not gain neutralization to
heterotypic polyclonal immune sera. Vero-81 FRNT assay shows no
gain of neutralization to heterotypic (A) DENV1 or (B) DENV3
polyclonal immune sera above either parental DV2 or DV4
neutralization titers. Samples with FNRT.sub.50<20 graphed at
sera dilution factor of 19.
[0051] FIG. 24. Design and construction of rDENV4/2 virus. (A)
Residues from DENV2 (right) can be moved into DENV4 backbone,
generating a recombinant DENV4/2 virus (rDENV4/2). (B) Reverse
genetics system for manipulating the DENV genome. Top=DENV2,
bottom=DENV4. The DENV genome is divided into four plasmid
cassettes which can be individually mutated, ligated together, and
electroporated into cells to generate recombinant virus. The
DENV4-A cassette contains the envelope gene where mutations are
made. Replacing the DENV4 residues with those from DENV2 creates an
rDENV4/2 virus, built entirely on the DENV4 genetic backbone.
[0052] FIG. 25. A new method for serotype identification by RT-PCR
and confirmation of DENV4 backbone recombinant virus. (A) Design of
RT-PCT primers for serotype-specific RT-PCR. Primers utilize a
common sense oligonucleotide targeting the highly conserved 3' end
NS1 gene. Serotype-specific antisense primers target the highly
divergent NS2A gene. (B) Viruses were grown in C6/36 cells, culture
supernatant was collected and centrifuged to remove any cellular
debris. Viral RNA was isolated using QIAGEN QIAmp Viral RNA
Miniprep Kit. PCR was run for 35 cycles, and PCR product was
analyzed on a 1.5% Ultrapure agarose gel. Control RNA
(DV1/DV2/DV3/DV4) and water are run as positive and negative
controls. Expected product sizes: DV1=205 bp, DV2=539 bp, DV3=455
bp, DV4=401 bp.
[0053] FIG. 26. Restriction fragment length polymorphism
distinguishes rDENV4/2 from parental DENV4. (A) Restriction
fragment length polymorphism (RFLP) designed to distinguish
rDENV4/2 (bottom) from parental DENV4 (top). Mutations (represented
as asterisks) introduced into the DENV4 E genome to generate
rDENV4/2 disrupt an XmnI restriction enzyme site present in DENV4.
(B) PCR products are gel purified and digested with XmnI. Digest
products were analyzed on a 1.5% Ultrapure agarose gel. Expected
product sizes: full length undigested=1031 bp, digested
products=931 bp and 113 bp.
[0054] FIG. 27. DENV4 and rDENV4/2 virions have similar maturation
profiles. Viruses grown in C6/36 cells, culture supernatant was
collected and centrifuged to remove any cellular debris. Samples
were run on a 12% SDS-PAGE gel and blots were probed with anti-E
(4G2) and anti-PrM (2H12 and 5L20) antibodies. DENV2 has
substantial levels of PrM present, indicating either incomplete
Furin processing or PrM dissociation. PrM bands are not detected in
either DENV4 or rDENV4/2 samples.
[0055] FIG. 28. rDENV4/2 has a 2 log growth attenuation in Vero
cells relative to parental viruses. (A) Vero-81 cells were infected
at an MOI=0.01. Viral supernatants were collected every 24 hrs. and
subsequently titered on Vero-81 cells. (B) DENV forms infectious
foci in Vero-81 cells (DENV2, DENV4, and rDENV4/2) fixed 5, 4, and
6 days post-infection, respectively). rDENV4/2 foci are smaller
than both parental viruses.
[0056] FIG. 29. rDENV4/2 has no growth attenuation in C6/36 cells
and forms similar infectious foci relative to parental viruses. (A)
C6/36 cells were infected at an MOI=0.01. Viral supernatants were
collected every 24 hrs. and subsequently titered on C6/36 cells.
(B) DENV forms infectious foci on C6/36 cells (DENV2, DEVN4, and
rDENV4/2 fixed 4, 3, and 5 days post-infection, respectively). With
additional day(s) of growth, rDENV4/2 foci reach sizes comparable
with parental viruses.
[0057] FIG. 30. Transfer of binding and neutralization of rDENV4/2
by type-specific DENV2 human MAb. (A) Summary table of human MAb
2D22, a strongly neutralizing DV2 MAb that binds to a quaternary
epitope. (B) ELISA assay shows transferred partial binding of 2D22
to rDENV4/2, above levels of parental DV4 but not to DV2 levels.
(C) ELISA binding of cross-reactive control antibody, 2J20, shows
comparable levels of virus present and maintained virus integrity.
(D) Vero-81 based Focus Reduction Neutralization Test (FRNT) was
performed using 2D22 and FRNT.sub.50 (concentration of antibody
required to neutralize 50% of infection) values were calculated.
(E) U937+DC-SIGN based neutralization assay (Neut) was performed
using 2D22 and Neut.sub.50 values were calculated. In both assays
(E, F) rDENV4/2 gained neutralization to 2D22 to levels higher than
DV2. DV4 was not neutralized with the maximum concentration of 2D22
in either assay.
[0058] FIG. 31. rDENV4/2 gains neutralization to DENV2 polyclonal
immune sera while preserving neutralization to DENV4 polyclonal
sera. Vero-81 FRNT assay shows rDENV4/2 (A) gains neutralization to
DENV2 polyclonal immune sera to levels comparable to parental
DENV2. (B) rDENV4/2 shows no loss to neutralization by DENV4
polyclonal immune sera. rDENV4/2 shows no gain of neutralization to
heterotypic (C) DENV1 and (D) DENV3 polyclonal immune sera above
either parental DENV2 or DENV4 neutralization titers. Sera from
individuals with either nature infection, or experimental
vaccination are coded as indicated. Samples with FRNT.sub.50<20
graphed at sera dilution factor of 19.
[0059] FIG. 32A. Alignment of recombinant DENV4/2 sequences. The
amino acid sequences of wild-type DENV2, recombinant DV4-EDIII-DV2
and wild-type DENV4 are shown, along with a consensus sequence and
amino acid conservation percentage.
[0060] FIG. 32B. Alignment of recombinant DENV2/1 sequences. The
amino acid sequences of wild-type DENV1, recombinant DENV2-1F4E and
wild-type DENV2 are shown, along with a consensus sequence and
amino acid conservation percentage.
[0061] FIG. 32C. Alignment of recombinant DENV4/3 sequences. The
amino acid sequences of wild-type DENV3, recombinant DENV4 M12,
DENV4 M14, DENV4 M16 and wild-type DENV4 are shown, along with a
consensus sequence and amino acid conservation percentage.
DETAILED DESCRIPTION OF THE INVENTION
[0062] The present invention is based on the unexpected discovery
that one or more epitope regions that define one or more DENV
serotypes can be transferred into a protein backbone of a different
DENV serotype to create a chimeric molecule that contains antibody
targets for multiple serotypes, thereby functioning as a
multivalent (e.g., bivalent, trivalent or tetravalent) vaccine that
can induce neutralizing antibodies against two, three or four
different DENV serotypes from a single source or fewer than four
sources. Thus, the present invention provides a platform for
construction of a chimeric dengue virus E glycoprotein backbone
that comprises amino acid substitutions that introduce one or more
epitomes that are recognized by respective antibodies that are
reactive with one or more than one dengue virus serotype that is
different from the dengue virus serotype of the dengue virus E
glycoprotein backbone.
[0063] In some embodiments, that dengue virus E glycoprotein
backbone is from dengue virus serotype 1. In some embodiments, the
dengue virus E glycoprotein backbone can be from dengue virus
serotype 2, dengue virus serotype 3 or dengue virus serotype 4.
[0064] In some embodiments, the antibody that is reactive with a
dengue virus serotype that is different from the dengue virus
serotype of the dengue virus E glycoprotein backbone is an antibody
that is reactive with dengue virus serotype 1, dengue virus
serotype 2, dengue virus type 3 or dengue virus serotype 4.
[0065] In some embodiments, one or more dengue virus protein
domains from one or more respective dengue virus serotypes can be
introduced into a dengue virus E glycoprotein backbone of a
different dengue virus serotype.
[0066] It would be understood that any combination of a first
dengue virus serotype for the dengue virus E glycoprotein backbone
and a dengue virus epitope or dengue virus protein domain as
identified in a second, third and/or fourth dengue virus serotype,
respectively, can be used, provided that the first dengue virus
serotype and the second, third and/or fourth dengue virus serotype
are different (i.e., the second, third and/or fourth serotypes are
not the same serotype as the first dengue virus serotype and/or the
second, third and/or fourth dengue virus serotypes are different
from one another).
[0067] Thus, in some embodiments, the present invention provides a
chimeric dengue virus E glycoprotein comprising a dengue virus E
glycoprotein backbone that comprises amino acid substitutions that
introduce an epitope that is recognized by an antibody that is
reactive with a dengue virus serotype that is different from the
dengue virus serotype of the dengue virus E glycoprotein backbone,
wherein the dengue virus E glycoprotein backbone is from dengue
virus serotype 4 and the antibody is reactive with dengue virus
serotype 3. In some embodiments, the antibody is monoclonal
antibody 5J7 and in some embodiments, the E glycoprotein can
comprise, consist essentially of, or consist of the amino acid
sequence:
TABLE-US-00001 (WT_DENV4, SEQ ID NO: 1)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAK
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGDGNHMFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA,
wherein said amino acid sequence comprises all or less than all in
any combination, of the following amino acid substitutions: T49E,
K51T, E52Q, V53L, L55T, T58K, Y59L, S122L, G123E, K124P, T126E,
N128K, L129V, I132Y, M199L, K200T, T205A, L207M, K210R, L214F,
A222S, V2701, D271Q, S272N, G273S, D274G, N276T, H277S and M2781,
and wherein said amino acid sequence can further comprise one or
more of the following amino acid substitutions in any combination:
A71D, T148Q, D225T, V229P, D307K, K321Q and V362P.
[0068] In some embodiments, the chimeric dengue virus E
glycoprotein described above as a 4/3 dengue virus glycoprotein can
comprise, consist essentially of or consist of the amino acid
sequence:
TABLE-US-00002 (DENV4_M12, SEQ ID NO: 2)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGPIEGKVVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA,
or the amino acid sequence:
TABLE-US-00003 (DENV4_M14, SEQ ID NO: 3)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEAT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA,
or the amino acid sequence:
TABLE-US-00004 (DENV4_M16, SEQ ID NO: 4)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEAT
QLATLRKLCIEASISNITTDTRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDQHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGATTSEPHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIKKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSPTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA.
[0069] In some embodiments, the present invention provides a
chimeric dengue virus E glycoprotein comprising a dengue virus E
glycoprotein backbone that comprises amino acid substitutions that
introduce a protein domain from a dengue virus serotype that is
different from the dengue virus serotype of the dengue virus E
glycoprotein backbone, wherein the dengue virus E glycoprotein
backbone is from dengue virus serotype 4 and the protein domain is
from dengue virus serotype 2.
[0070] In some embodiments, the dengue virus E glycoprotein
backbone of dengue virus serotype 4 comprises amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2. In some
embodiments, the antibody is monoclonal antibody 2D22.
[0071] In some embodiments, the protein domain is E glycoprotein
domain III and in some embodiments, the chimeric dengue virus E
glycoprotein described above as 4/2 can comprise, consist
essentially of or consist of the amino acid sequence:
TABLE-US-00005 (DV4-EDIII-DV2, SEQ ID NO: 5)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAK
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGDGNHMFAGHLKCKVRMEKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA.
[0072] In some embodiments, the chimeric dengue virus E
glycoprotein can comprise the amino acid sequence:
TABLE-US-00006 (WT_DENV4, SEQ ID NO: 1)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAK
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGDGNHMFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA,
wherein said amino acid sequence comprises all, or less than all in
any combination, of the following amino acid substitutions: T300S,
S303T, S307K, D309V, M3121, T3201, V3221, K323R, K325Q, A329D,
A331S, V3351, I337F, R340T, V342L, N343E, E345R, K346H, V348L,
V351L, S353T, S354V, T355N, L3571, A358V, E359T, N360E, T361K,
N362D, V364P, T365V, L369A, V3791, G383E, N384P, S385G, A386Q,
T388K, H390N and R393K.
[0073] Further embodiments of this invention include the reciprocal
exchange virus, i.e., a dengue virus E glycoprotein of dengue virus
serotype 2 with amino acid substitutions that introduce a dengue
virus protein domain (e.g., domain III) from dengue virus serotype
4. Any other combination of dengue virus serotype backbone and
substituted dengue virus protein domain from a different dengue
virus serotype is included as an embodiment of this invention,
including, for example the combinations 1/2, 1/3, 1/4, 1/2/3,
1/2/4, 1/3/4, 1/2/3/4, 2/1, 2/3, 2/4, 2/1/3, 2/1/4, 2/3/4, 2/1/3/4,
3/1, 3/2, 3/4, 3/1/2, 3/1/4, 3/2/4, 3/1/2/4, 4/1, 4/2, 4/3, 4/1/3,
4/1/2, 4/3/2, or 4/3/2/1 (wherein the first number of each
combination defines the serotype of the backbone and the second,
third or fourth number of each combination defines the serotype of
the epitope(s) or domain(s) that have been introduced into the
backbone).
[0074] Some embodiments of the present invention provide a chimeric
dengue virus E glycoprotein comprising a dengue virus E
glycoprotein backbone that comprises amino acid substitutions that
introduce an epitope that is recognized by an antibody that is
reactive with a dengue virus serotype that is different from the
dengue virus serotype of the dengue virus E glycoprotein backbone,
wherein the dengue virus E glycoprotein backbone is from dengue
virus serotype 2 and the antibody is reactive with dengue virus
serotype 1. In some embodiments, the antibody is monoclonal
antibody 1F4 and in some embodiments, the chimeric dengue virus E
glycoprotein comprises, consists essentially of or consists of the
amino acid sequence:
TABLE-US-00007 (DENV2-1F4E, SEQ ID NO: 6)
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVT
NPAVLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWG
NGCGLFGKGGIVTCAMFTCKKNMEGKVVQPENLKYSVIVTVHSGEEHAVGN
DTTEHGTTATITPQAPTSEIQLTDYGALTLECSPRTGLDFNEMVLLQMEDK
AWLVHRQWFLDLPLPWLPGADTQESNWIQKETLVTFKNPHAKKQDVVVLGS
QEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMDKLQLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRG
AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILI
GVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA.
[0075] In some embodiments of this invention, the chimeric E
glycoprotein can comprise a dengue virus E glycoprotein backbone of
dengue virus serotype 1, dengue virus serotype 2, or dengue virus
serotype 3, that comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14 or all 15) of the following amino acid
substitutions, in any combination to introduce an epitope from
dengue virus serotype 4 that is reactive with monoclonal antibody
5H2: A at residue 155, V at residue 160, T at residue 161, A at
residue 162, M at residue 163, S at residue 168, S at residue 170,
V at residue 171, V at residue 173, K at residue 174, P at residue
176, D at residue 177, E at residue 180, K at residue 291 and R at
residue 293. Amino acid numbering is based on the amino acid
sequence of WT_DENV4 provided herein.
[0076] The present invention provides additional no limiting
examples of chimeric dengue virus E glycoprotein's of this
invention that can be used in the compositions and methods
described herein in the SEQUENCES section provided herein.
[0077] The present invention also provides various therapeutic
methods, including, for example, method of producing an immune
response to a dengue virus in a subject, comprising administering
to the subject an effective amount of the E glycoprotein of this
invention, the flavivirus particle of this invention, the VLP of
this invention, the nucleic acid molecule of this invention, the
population of this invention, and/or the composition of this
invention and any combination thereof.
[0078] Additionally provided herein is a method of treating a
dengue virus infection in a subject, comprising administering to
the subject an effective amount of the E glycoprotein of this
invention, the flavivirus particle of this invention, the VLP of
this invention, the nucleic acid molecule of this invention, the
population of this invention, and/or the composition of this
invention and any combination thereof.
[0079] In further embodiments, the present invention provides a
method of preventing a disorder associated with dengue virus
infection in a subject, comprising administering to the subject an
effective amount of the E glycoprotein of this invention, the
flavivirus particle of this invention, the VLP of this invention,
the nucleic acid molecule of this invention, the population of this
invention, and/or the composition of this invention and any
combination thereof.
[0080] Also provided herein is a method of protecting a subject
from the effects of dengue virus infection, comprising
administering to the subject an effective amount of the E
glycoprotein of this invention, the flavivirus particle of this
invention, the VLP of this invention, the nucleic acid molecule of
this invention, the population of this invention, and/or the
composition of this invention and any combination thereof.
[0081] The present invention also provides various diagnostic
methods, including, for example, a method of identifying the
presence of a neutralizing antibody to dengue virus serotype 3
and/or 4 in a biological sample from a subject, comprising: a)
administering a composition comprising an E glycoprotein comprising
an E glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 3 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 3 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 4 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 3 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 3
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
above under conditions whereby neutralization of the flavivirus
particles can be detected; and c) detecting neutralization in step
(b), thereby identifying the presence of a neutralizing antibody to
dengue virus serotype 3 and/or 4 in the biological sample from the
subject.
[0082] Further provided herein is a method of identifying the
presence of a neutralizing antibody to dengue virus serotype 2
and/or 4 in a biological sample from a subject, comprising: a)
administering a composition comprising an E glycoprotein comprising
an E glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 4 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 2 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
above under conditions whereby neutralization of the flavivirus
particles can be detected; and c) detecting neutralization in step
(b), thereby identifying the presence of a neutralizing antibody to
dengue virus serotype 2 and/or 4 in the biological sample from the
subject.
[0083] The present invention also provides a method of identifying
the presence of a neutralizing antibody to dengue virus serotype 1
and/or 2 in a biological sample from a subject, comprising: a)
administering a composition comprising an E glycoprotein comprising
an E glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 1 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 1 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 1 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 1
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
above under conditions whereby neutralization of the flavivirus
particles can be detected; and c) detecting neutralization in step
(b), thereby identifying the presence of a neutralizing antibody to
dengue virus serotype 1 and/or 2 in the biological sample from the
subject.
[0084] A method is also provided herein of identifying the presence
of a neutralizing antibody to dengue virus serotype 3 and/or 4 in a
biological sample from a subject, comprising: a) administering a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 3 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 3 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 4 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 3 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 3
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; and b) detecting neutralization in step (a), thereby
identifying the presence of a neutralizing antibody to dengue virus
serotype 3 and/or 4 in the biological sample from the subject.
[0085] Furthermore, the present invention provides a method of
identifying the presence of a neutralizing antibody to dengue virus
serotype 2 and/or 4 in a biological sample from a subject,
comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 2 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
2 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; and b) detecting neutralization in step (a), thereby
identifying the presence of a neutralizing antibody to dengue virus
serotype 2 and/or 4 in the biological sample from the subject.
[0086] In additional embodiments, the present invention provides a
method of identifying the presence of a neutralizing antibody to
dengue virus serotype 1 and/or 2 in a biological sample from a
subject, comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 1 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 1 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 1 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
1 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; and b) detecting neutralization in step (a), thereby
identifying the presence of a neutralizing antibody to dengue virus
serotype 1 and/or 2 in the biological sample from the subject.
[0087] The present invention further provides a method of
identifying an immunogenic composition that induces a neutralizing
antibody to dengue virus serotype 3 and/or 4 in a subject, the
method comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 3 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 3 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 3 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
3 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
under conditions whereby neutralization of the flavivirus particles
can be detected; c) determining if the biological sample comprises
an antibody that neutralizes flavivirus particles comprising the E
glycoprotein of step (a); and d identifying the immunogenic
composition as inducing a neutralizing antibody to dengue virus
serotype 3 and/or 4 in the subject if the biological sample
comprises an antibody that neutralizes flavivirus particles
comprising the E glycoprotein of (a).
[0088] Furthermore, the present invention provides a method of
identifying an immunogenic composition that induces a neutralizing
antibody to dengue virus serotype 2 and/or 4 in a subject, the
method comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 2 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
2 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
under conditions whereby neutralization of the flavivirus particles
can be detected; c) determining if the biological sample comprises
an antibody that neutralizes flavivirus particles comprising the E
glycoprotein of step (a); and d identifying the immunogenic
composition as inducing a neutralizing antibody to dengue virus
serotype 2 and/or 4 in the subject if the biological sample
comprises an antibody that neutralizes flavivirus particles
comprising the E glycoprotein of (a).
[0089] The present invention further provides a method of
identifying an immunogenic composition that induces a neutralizing
antibody to dengue virus serotype 1 and/or 2 in a subject, the
method comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 1 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 1 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 1 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
1 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with flavivirus particles comprising the E glycoprotein of step (a)
under conditions whereby neutralization of the flavivirus particles
can be detected; c) determining if the biological sample comprises
an antibody that neutralizes flavivirus particles comprising the E
glycoprotein of step (a); and d identifying the immunogenic
composition as inducing a neutralizing antibody to dengue virus
serotype 1 and/or 2 in the subject if the biological sample
comprises an antibody that neutralizes flavivirus particles
comprising the E glycoprotein of (a).
[0090] In additional embodiments, the present invention provides a
method of identifying an immunogenic composition that induces a
neutralizing antibody to dengue virus serotype 3 and/or 4 in a
subject, the method comprising: a) contacting a biological sample
from a subject that has been administered an immunogenic
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 3 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 3 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 4 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 3 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 3
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4, with flavivirus
particles comprising the E glycoprotein under conditions whereby
neutralization of the flavivirus particles can be detected; b)
determining if the biological sample comprises an antibody that
neutralizes flavivirus particles comprising the E glycoprotein of
step (a); and c) identifying the immunogenic composition as
inducing a neutralizing antibody to dengue virus serotype 3 and/or
4 in the subject if the biological sample comprises an antibody
that neutralizes flavivirus particles comprising the E glycoprotein
of (a).
[0091] Additionally, the present invention provides a method of
identifying an immunogenic composition that induces a neutralizing
antibody to dengue virus serotype 2 and/or 4 in a subject, the
method comprising: a contacting a biological sample from a subject
that has been administered an immunogenic composition comprising an
E glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 2 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
2 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 with flavivirus particles
comprising the E glycoprotein under conditions whereby
neutralization of the flavivirus particles can be detected; b)
determining if the biological sample comprises an antibody that
neutralizes flavivirus particles comprising the E glycoprotein of
step (a); and c) identifying the immunogenic composition as
inducing a neutralizing antibody to dengue virus serotype 2 and/or
4 in the subject if the biological sample comprises an antibody
that neutralizes flavivirus particles comprising the E glycoprotein
of (a).
[0092] Additionally provided herein is a method of identifying an
immunogenic composition that induces a neutralizing antibody to
dengue virus serotype 1 and/or 2 in a subject, the method
comprising: a) contacting a biological sample from a subject that
has been administered an immunogenic composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 1 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 1 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 1 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
1 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 with flavivirus particles
comprising the E glycoprotein under conditions whereby
neutralization of the flavivirus particles can be detected; b)
determining if the biological sample comprises an antibody that
neutralizes flavivirus particles comprising the E glycoprotein of
step (a); and c) identifying the immunogenic composition as
inducing a neutralizing antibody to dengue virus serotype 1 and/or
2 in the subject if the biological sample comprises an antibody
that neutralizes flavivirus particles comprising the E glycoprotein
of (a).
[0093] The present invention further provides a method of detecting
an antibody to dengue virus serotype 3 and/or 4 in a sample,
comprising: a) contacting the sample with a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
4 comprising amino acid substitutions that introduce an epitope
that is recognized by an antibody that is reactive with dengue
virus serotype 3 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 3 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 3 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
3 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 under conditions whereby
an antigen/antibody complex can form; and b) detecting formation of
an antigen/antibody complex, thereby detecting an antibody to
dengue virus serotype 3 and/or 4 in the sample.
[0094] The present invention also provides a method of detecting an
antibody to dengue virus serotype 2 and/or 4 in a sample,
comprising: a) contacting the sample with a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
4 comprising amino acid substitutions that introduce an epitope
that is recognized by an antibody that is reactive with dengue
virus serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 2 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
2 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 under conditions whereby
an antigen/antibody complex can form; and b) detecting formation of
an antigen/antibody complex, thereby detecting an antibody to
dengue virus serotype 3 and/or 4 in the sample.
[0095] Also provided herein is a method of detecting an antibody to
dengue virus serotype 1 and/or 2 in a sample, comprising; a)
contacting the sample with a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 1 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 1 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 1 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
1 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 under conditions whereby
an antigen/antibody complex can form; and b) detecting formation of
an antigen/antibody complex, thereby detecting an antibody to
dengue virus serotype 1 and/or 2 in the sample.
[0096] Further provided herein is a method of identifying an
antibody to dengue virus serotype 3 and/or 4 in a biological sample
from a subject, comprising: a) administering a composition
comprising an E glycoprotein comprising an E glycoprotein backbone
of serotype 4 comprising amino acid substitutions that introduce an
epitope that is recognized by an antibody that is reactive with
dengue virus serotype 3 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 3
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 3 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
3 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c) detecting formation of an
antigen/antibody complex, thereby identifying an antibody to dengue
virus serotype 3 and/or 4 in the biological sample from the
subject.
[0097] Additionally provided herein is a method of identifying an
antibody to dengue virus serotype 2 and/or 4 in a biological sample
from a subject, comprising: a) administering a composition
comprising an E glycoprotein comprising an E glycoprotein backbone
of serotype 4 comprising amino acid substitutions that introduce an
epitope that is recognized by an antibody that is reactive with
dengue virus serotype 2 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 2 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
2 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c) detecting formation of an
antigen/antibody complex, thereby identifying an antibody to dengue
virus serotype 2 and/or 4 in the biological sample from the
subject.
[0098] In yet further embodiments, the present invention provides a
method of identifying an antibody to dengue virus serotype 1 and/or
2 in a biological sample from a subject, comprising: a)
administering a composition comprising an E glycoprotein comprising
an E glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 1 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 1 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 1 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 1
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c) detecting formation of an
antigen/antibody complex, thereby identifying an antibody to dengue
virus serotype 1 and/or 2 in the biological sample from the
subject.
[0099] A method is additionally provided herein of identifying an
antibody to dengue virus serotype 3 and/or 4 in a biological sample
from a subject, comprising: a) contacting a biological sample from
a subject that has been administered an immunogenic composition
comprising an E glycoprotein comprising an E glycoprotein backbone
of serotype 4 comprising amino acid substitutions that introduce an
epitope that is recognized by an antibody that is reactive with
dengue virus serotype 3 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 3
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 3 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
3 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 with the E glycoprotein
under conditions whereby an antigen/antibody complex can form; and
c) detecting formation of an antigen/antibody complex, thereby
identifying an antibody to dengue virus serotype 3 and/or 4 in the
biological sample from the subject.
[0100] The present invention further provides a method of
identifying an antibody to dengue virus serotype 2 and/or 4 in a
biological sample from a subject, comprising: a) contacting a
biological sample from a subject that has been administered an
immunogenic composition comprising an E glycoprotein comprising an
E glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 4 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 4 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 2 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 with the E glycoprotein
under conditions whereby an antigen/antibody complex can form; and
b) detecting formation of an antigen/antibody complex, thereby
identifying an antibody dengue virus serotype 2 and/or 4 in the
biological sample from the subject.
[0101] The present invention further provides a method of
identifying an antibody to dengue virus serotype 1 and/or 2 in a
biological sample from a subject, comprising: a) contacting a
biological sample from a subject that has been administered an
immunogenic composition comprising an E glycoprotein comprising an
E glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 1 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 1 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 1 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 1
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 with the E glycoprotein
under conditions whereby an antigen/antibody complex can form; and
b) detecting formation of an antigen/antibody complex, thereby
identifying an antibody dengue virus serotype 1 and/or 2 in the
biological sample from the subject.
[0102] The present invention further provides a method of
identifying an immunogenic composition that induces an antibody to
dengue virus serotype 3 and/or 4 in a subject, the method
comprising: a) contacting a biological sample from a subject that
has been administered an immunogenic composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 3 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 3 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 3 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
3 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 with the E glycoprotein
under conditions whereby an antigen/antibody complex can form; and
b) detecting formation of an antigen/antibody complex, thereby
identifying an immunogenic composition that induces an antibody to
dengue virus serotype 3 and/or 4 in the subject.
[0103] Further provided herein is a method of identifying an
immunogenic composition that induces an antibody to dengue virus
serotype 2 and/or 4 in a subject, the method comprising: a
contacting a biological sample from a subject that has been
administered an immunogenic composition comprising an E
glycoprotein of any of claims 6-8 with the E glycoprotein under
conditions whereby an antigen/antibody complex can form; and b)
detecting formation of an antigen/antibody complex, thereby
identifying an immunogenic composition that induces an antibody to
dengue virus serotype 2 and/or 4 in the subject.
[0104] Also provided herein is a method of identifying an
immunogenic composition that induces an antibody to dengue virus
serotype 1 and/or 2 in a subject, the method comprising: a)
contacting a biological sample from a subject that has been
administered an immunogenic composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 2
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 1 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 1 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 1 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
1 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 with the E glycoprotein
under conditions whereby an antigen/antibody complex can form; and
b) detecting formation of an antigen/antibody complex, thereby
identifying an immunogenic composition that induces an antibody to
dengue virus serotype 1 and/or 2 in the subject.
[0105] In some embodiments of the present invention, a method is
provided of identifying an immunogenic composition that induces a
neutralizing antibody to dengue virus serotype 3 and/or 4 in a
subject, comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 3 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 3 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 3 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
3 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b) contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c) detecting formation an
antigen/antibody complex, thereby identifying an immunogenic
composition that induces a neutralizing antibody to dengue virus
serotype 3 and/or 4 in the subject.
[0106] The present invention additionally provides a method of
identifying an immunogenic composition that induces a neutralizing
antibody to dengue virus serotype 2 and/or 4 in a subject,
comprising: a) administering a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 4
comprising amino acid substitutions that introduce an epitope that
is recognized by an antibody that is reactive with dengue virus
serotype 2 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 2 comprising
amino acid substitutions that introduce an epitope that is
recognized by an antibody that is reactive with dengue virus
serotype 4 and/or a composition comprising an E glycoprotein
comprising an E glycoprotein backbone of serotype 4 comprising
amino acid substitutions that introduce a dengue virus protein
domain of dengue virus serotype 2 and/or a composition comprising
an E glycoprotein comprising an E glycoprotein backbone of serotype
2 comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 4 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c) detecting formation an
antigen/antibody complex, thereby identifying an immunogenic
composition that induces a neutralizing antibody to dengue virus
serotype 2 and/or 4 in the subject.
[0107] Also provided herein is a method of identifying an
immunogenic composition that induces a neutralizing antibody to
dengue virus serotype 1 and/or 2 in a subject, comprising: a)
administering a composition comprising an E glycoprotein comprising
an E glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 1 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 1 comprising amino acid
substitutions that introduce an epitope that is recognized by an
antibody that is reactive with dengue virus serotype 2 and/or a
composition comprising an E glycoprotein comprising an E
glycoprotein backbone of serotype 2 comprising amino acid
substitutions that introduce a dengue virus protein domain of
dengue virus serotype 1 and/or a composition comprising an E
glycoprotein comprising an E glycoprotein backbone of serotype 1
comprising amino acid substitutions that introduce a dengue virus
protein domain of dengue virus serotype 2 to the subject in an
amount effective to induce an antibody response to the E
glycoprotein; b contacting a biological sample from the subject
with the E glycoprotein of (a) under conditions whereby an
antigen/antibody complex can form; and c) detecting formation an
antigen/antibody complex, thereby identifying an immunogenic
composition that induces a neutralizing antibody to dengue virus
serotype 1 and/or 2 in the subject.
[0108] In some embodiments, the present invention provides a method
of determining an amount of the antibodies produced to the
transplanted epitope or domain. For example, DENV3 antibodies that
target the 5J7 region could be measured by comparing neutralization
of DENV4 M14 with the parent DENV4, with the expectation that DENV3
antibodies could neutralize some portion of DENv4 M14 but not
parental DENV4.
[0109] The present invention also provides a dengue virus particle,
a flavivirus particle and a virus like particle (VLP) comprising
the chimeric E glycoprotein of this invention. The dengue virus E
glycoprotein of the invention can be present in an intact virus
particle (e.g., a killed or live attenuated virus particle or a
recombinant dengue virus vector) or a virus-like particle (VLP),
which may optionally be an intact dengue virus particle or dengue
virus VLP.
[0110] Also provided is an isolated nucleic acid molecule encoding
the E glycoprotein of this invention, an isolated nucleic acid
molecule encoding the dengue virus particle, the flavivirus
particle or the VLP of this invention, a vector comprising the
nucleic acid molecule of this invention and a population of dengue
virus particles and/or flavivirus particles comprising the dengue
virus particle and/or flavivirus particle this invention.
[0111] Further provided herein is a composition comprising the E
glycoprotein of this invention in a pharmaceutically acceptable
carrier, a composition comprising the nucleic acid molecule of this
invention in a pharmaceutically acceptable carrier, a composition
comprising the virus particle of this invention, a composition
comprising the population of this invention in a pharmaceutically
acceptable carrier and a composition comprising the VLP of this
invention in a pharmaceutically acceptable carrier.
[0112] In some embodiments, production of the chimeras of this
invention can be carried out by introducing some (e.g., 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc.) or all of the amino
acid substitutions identified as part of a dengue virus epitope
and/or dengue virus protein domain into a dengue virus E
glycoprotein backbone or flavivirus E glycoprotein backbone. Not
every amino acid identified as part of a dengue virus epitope or
dengue virus protein domain is required to be substituted to
produce a chimeric protein of this invention. For example, in some
embodiments further substitutions and/or omission of substitutions
of about 1, 2, 3, 4 or 5 amino acids at either end of the
contiguous amino acid sequences identified as part of a dengue
virus epitope or dengue virus domain can be included in the
production of a chimera of this invention. The number of
substitutions necessary to produce the desired conformational
epitope or domain can be readily determined by one of ordinary
skill in the art according to the teachings herein and according to
protocols well known in the art. The amino acid residue numbering
provided in the amino acid sequences set forth here is based on the
respective unmodified (e.g., wild type) E glycoprotein amino acid
sequence of the respective DENV serotype, as provided herein.
However it would be readily understood by one of ordinary skill in
the art that the equivalent amino acid positions in other dengue
virus E glycoprotein amino acid sequences or other flavivirus E
glycoprotein amino acid sequences can be readily identified and
employed in the production of the chimeric proteins of this
invention.
[0113] In some embodiments, the present invention provides a
chimeric flavivirus E glycoprotein in which amino acid
substitutions are made to introduce one or more dengue virus
epitomes into a flavivirus E glycoprotein from a flavivirus that is
not a dengue virus. Thus, in some embodiments, the present
invention provides a flavivirus E glycoprotein comprising a
chimeric E glycoprotein comprising a flavivirus E glycoprotein
backbone that is not a dengue virus E glycoprotein backbone,
wherein the flavivirus E glycoprotein backbone comprises amino acid
substitutes that introduce one or more epitomes that are recognized
by a respective antibody that is reactive with a dengue virus.
[0114] No limiting examples of flaviviruses that can be used
include yellow fever virus (YFV) (e.g., GenBank.RTM. Database
Accession No. JX503529) Japanese encephalitis virus (JEV) (e.g.,
GenBank.RTM. Database Accession No. U14163), West Nile virus (WNV)
(e.g., GenBank.RTM. Database Accession No. DQ211652) and any other
flavivirus now known or later identified.
[0115] It is known in the art that many attempts to produce dengue
virus vaccines result in the production of non-neutralizing
antibodies, which may increase the likelihood of pathology upon
subsequent exposure to natural infection or vaccine. Another
approach to provide an engineered epitope is to deliver all or a
portion of the dengue virus E protein incorporated into another
flavivirus particle or VLP. In representative embodiments, the
heterologous flavivirus is West Nile virus or Yellow Fever virus.
Portions of the E protein can be grafted into the E protein of the
heterologous flavivirus backbone, e.g., to reduce the generation of
non-neutralizing dengue virus antibodies to non-neutralizing
epitopes present in the dengue virus E protein and/or other dengue
virus structural proteins.
[0116] Thus, a chimeric flavivirus or chimeric flavivirus VLP can
present the quaternary dengue virus epitope in proper conformation
while reducing the generation of non-neutralizing antibodies to
other portions of the dengue virus E protein and/or other
structural proteins that are not presented in the chimeric
flavivirus or flavivirus VLP.
[0117] In some embodiments of the invention the individual and
conformational epitopes of the flavivirus E glycoprotein or dengue
virus E glycoprotein can be presented on a synthetic backbone or
support structure so that the epitopes within the synthetic
backbone or support structure mimic the conformation and
arrangement of the epitopes within the structure of the E
glycoprotein, virus particle or VLP.
[0118] In still further embodiments of the invention, the present
invention provides peptide mimitopes (see, Meloen et al. (2000) J.
Mol. Recognit. 13, 352-359) that mimic the individual and
conformational epitopes of the E glycoproteins of the invention.
Mimitopes may be identified using any technique known in the art,
including but not limited to surface stimulation, random peptide
libraries or phage display libraries, as well as an antibody or
antibodies to the individual and conformational epitopes of the E
glycoproteins of the invention.
[0119] The invention further provides a nucleic acid molecule
(e.g., isolated nucleic acid molecule) encoding a dengue virus
peptide, a dengue virus protein domain, a dengue virus polypeptide
or a flavivirus polypeptide of the invention.
[0120] The invention further provides a nucleic acid molecule
(e.g., an isolated nucleic acid molecule) encoding a chimeric
flavivirus particle or a chimeric flavivirus virus-like particle
(VLP) (e.g., a viral coat of the flavivirus particle) of the
invention.
[0121] Also provided is a nucleic acid vector comprising a nucleic
acid molecule of the invention.
[0122] Also provided is a cell (e.g., an isolated cell) comprising
a vector, a nucleic acid molecule, a dengue virus protein, a dengue
virus peptide, a dengue virus protein domain, a flavivirus protein,
a flavivirus peptide, flavivirus protein domain, a chimeric dengue
virus particle, a chimeric dengue virus VLP, a chimeric flavivirus
VLP and/or a chimeric flavivirus particle of this invention, singly
or in any combination.
[0123] The invention also provides immunogenic compositions
comprising the cells, vectors, nucleic acids molecules, dengue
virus proteins, chimeric dengue virus VLPs, chimeric dengue virus
particles, chimeric flavivirus VLPs and/or chimeric flavivirus
particles of the invention, singly or in any combination. In some
embodiments, the immunogenic composition is monovalent. In some
embodiments, the immunogenic composition is multivalent (e.g.,
bivalent, trivalent or tetravalent) for dengue virus serotypes
DEN1, DEN2, DEN 3 and/or DEN4 in any combination. The dengue virus
chimeric E glycoproteins of this invention can be administered to a
subject singly or in any combination, including any combination of
priming and boosting according to such immunization protocols that
are known in the art. The dengue virus chimeric E glycoprotein of
this invention can be 1/2, 1/3, 1/4, 1/2/3, 1/2/4, 1/3/4, 1/2/3/4,
2/1, 2/3, 2/4, 2/1/3, 2/1/4, 2/3/4, 2/1/3/4, 3/1, 3/2, 3/4, 3/1/2,
3/1/4, 3/2/4, 3/1/2/4, 4/1, 4/2, 4/3, 4/1/3, 4/1/2, 4/3/2, or
4/3/2/1 (wherein the first number of each combination defines the
serotype of the backbone and the second, third or fourth number of
each combination defines the serotype of the epitope(s) or
domain(s) that have been introduced into the backbone). In some
embodiments, a prime/boost combination would be used that results
in administration of antigens representative of all four dengue
virus serotypes. Such a prime/boost regimen can include
administration of any combination of antigens in any order to
achieve this result. A nonlimiting example of a prime/boost
protocol can include priming at day 0 and boosting at 3 months and
6 months, or boosting at 6 months and 1 year, respectively. This
protocol could also be modified to include only one boost at either
3 months, 6 months or 1 year.
[0124] The invention encompasses methods of producing an immune
response to a dengue virus in a subject, comprising administering
to the subject an effective amount of a dengue virus protein, a
chimeric dengue virus particle, a chimeric dengue virus VLP, a
chimeric flavivirus VLP, a chimeric flavivirus particle, a nucleic
acid molecule, a vector, a cell and/or immunogenic composition of
the invention, singly or in any combination.
[0125] In some embodiments, the present invention can
advantageously be practiced to induce an immune response against
one, two, three or all four of the DEN1, DEN2, DEN3 and DEN4
serotypes. In some embodiments, the dengue virus chimeric E
glycoprotein of this invention and/or a nucleic acid molecule
encoding the dengue virus chimeric E glycoprotein of this invention
can be administered to a subject singly or in any combination
and/or sequence to induce an immune response (e.g., a balanced
immune response, in which the parameters of dengue immunity being
measured are nearly equivalent for all four DENV serotypes) to all
four DENV serotypes. It is well-known in the art that effective and
safe multivalent dengue vaccines have been a challenge to design
because of the problem of interference among serotypes. For
example, the immune response may be predominantly directed against
only some of the target serotypes. Multiple vaccinations are then
required to try to achieve a response against all serotypes;
however, in the case of dengue virus, this approach can be
dangerous because repeated administrations to a subject with
pre-existing antibodies can lead to more serious complications
and/or disease, such as dengue hemorrhagic fever.
[0126] A still further aspect of the invention is a method of
treating a dengue virus infection, comprising administering to the
subject an effective amount of a dengue virus protein, a dengue
virus protein domain, a dengue virus peptide, a chimeric dengue
virus particle, a chimeric dengue virus VLP, a chimeric flavivirus
VLP a chimeric flavivirus particle, a nucleic acid molecule, a
vector, a cell, and/or immunogenic composition of this invention,
singly or in any combination or sequence of combinations.
[0127] A still further aspect of the invention is a method of
preventing a dengue virus infection, comprising administering to
the subject an effective amount of a dengue virus protein, a dengue
virus protein domain, a dengue virus peptide, a chimeric dengue
virus particle, a chimeric dengue virus VLP, a chimeric flavivirus
VLP a chimeric flavivirus particle, a nucleic acid molecule, a
vector, a cell, and/or immunogenic composition of this invention,
singly or in any combination or sequence of combinations.
[0128] A still further aspect of the invention is a method of
protecting a subject from the effects of dengue virus infection,
comprising administering to the subject an effective amount of a
dengue virus protein, a dengue virus protein domain, a dengue virus
peptide, a chimeric dengue virus particle, a chimeric dengue virus
VLP, a chimeric flavivirus VLP a chimeric flavivirus particle, a
nucleic acid molecule, a vector, a cell, and/or immunogenic
composition of this invention, singly or in any combination or
sequence of combinations.
[0129] By "protecting a subject from the effects of dengue virus
infection" it is meant that the subject does not develop a disease
or disorder caused by a dengue virus infection, or if the subject
does develop a disease or disorder caused by a dengue virus
infection, the disease or disorder is of less severity and/or
symptoms are reduced and/or less severe in the subject in
comparison to what the subject would experience upon infection by a
dengue virus in the absence of the administration of the dengue
virus protein, a dengue virus protein domain, a dengue virus
peptide, a chimeric dengue virus particle, a chimeric dengue virus
VLP, a chimeric flavivirus VLP a chimeric flavivirus particle, a
nucleic acid molecule, a vector, a cell, and/or immunogenic
composition of this invention
[0130] There are four serotypes of dengue virus (DENV-1, DENV-2,
DENV-3 and DENV-4). Within each serotype there are a number of
different strains or genotypes. The dengue virus epitopes and
protein domains of this invention can be derived from any dengue
virus, including all serotypes, strains and genotypes, now known or
later identified.
[0131] In embodiments of the invention, the dengue virus is UNC1017
strain (DEN1), West Pacific 74 strain (DEN1), 516803 strain (DEN2),
UNC2005 strain (DEN2), 516803 strain (DEN2), UNC3001 strain (DEN3),
UNC3043 (DEN3 strain 059.AP-2 from Philippines, 1984), UNC3009
strain (DEN3, D2863, Sri Lanka 1989), UNC3066 (DEN3, strain 1342
from Puerto Rico 1977), CH53489 strain (DEN3), UNC4019 strain
(DEN4), or TVP-360 (DEN4).
[0132] In embodiments of the invention, an "immunogenically active
fragment" of a dengue virus polypeptide (e.g., the E protein)
comprises, consists essentially of or consists of at least about 6,
8, 10, 12, 15, 20, 30, 50, 75, 100, 125, 150, 200, 250, 300, 350,
400, 450 or more amino acids, optionally contiguous amino acids,
and/or less than about 495, 475, 450, 425, 400, 350, 300, 250, 200,
150, 100, 75 or 50 amino acids, optionally contiguous amino acids,
including any combination of the foregoing as long as the lower
limit is less than the upper limit, and the "immunogenically active
fragment" induces an immune response (e.g., IgG and/or IgA that
react with the native antigen), optionally a protective immune
response, against dengue virus in a host and induces the production
of antibodies (e.g., neutralizing antibodies) that specifically
bind to the quaternary dengue virus epitope(s) described
herein.
[0133] The term "epitope" as used herein means a specific
combination of amino acid residues in an amino acid sequence that,
when present in the proper conformation, provides a reactive site
for an antibody (e.g., B cell epitope) or T cell receptor (e.g., T
cell epitope).
[0134] Portions of a given polypeptide that include a B-cell
epitope can be identified using any number of epitope mapping
techniques that are known in the art. (See, e.g., Epitope Mapping
Protocols in Methods in Molecular Biology, Vol. 66, Glenn E.
Morris, Ed., 1996, Humana Press, Totowa, N.J.). For example, linear
epitopes can be determined by, e.g., concurrently synthesizing
large numbers of peptides on solid supports, the peptides
corresponding to portions of the protein molecule, and reacting the
peptides with antibodies while the peptides are still attached to
the supports. Such techniques are known in the art and described
in, e.g., U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl.
Acad. Sci. USA 81:3998-4002; Geysen et al. (1986) Molec. Immunol.
23:709-715.
[0135] Similarly, conformational epitopes can be readily identified
by determining spatial conformation of amino acids such as by,
e.g., x-ray crystallography and 2-dimensional nuclear magnetic
resonance. Antigenic regions of proteins can also be identified
using standard antigenicity and hydropathy plots, such as those
calculated using, e.g., the Omiga version 1.0 software program
available from the Oxford Molecular Group. This computer program
employs the Hopp/Woods method (Hopp et al., Proc. Natl. Acad. Sci
USA (1981) 78:3824-3828) for determining antigenicity profiles and
the Kyte-Doolittle technique (Kyte et al., J. Mol. Biol. (1982)
157:105-132) for hydropathy plots.
[0136] Generally, T-cell epitopes that are involved in stimulating
the cellular arm of a subject's immune system are short peptides of
about 8-25 amino acids. A common way to identify T-cell epitopes is
to use overlapping synthetic peptides and analyze pools of these
peptides, or the individual ones, that are recognized by T cells
from animals that are immune to the antigen of interest, using, for
example, an enzyme-linked immunospot assay (ELISPOT). These
overlapping peptides can also be used in other assays such as the
stimulation of cytokine release or secretion, or evaluated by
constructing major histocompatibility (MHC) tetramers containing
the peptide. Such immunogenically active fragments can also be
identified based on their ability to stimulate lymphocyte
proliferation in response to stimulation by various fragments from
the antigen of interest.
[0137] The present invention can be practiced for prophylactic,
therapeutic and/or diagnostic purposes. In addition, the invention
can be practiced to produce antibodies for any purpose, such as
diagnostic or research purposes, or for passive immunization by
transfer to another subject.
[0138] The present invention further provides a kit comprising one
or more compositions of this invention. It would be well understood
by one of ordinary skill in the art that the kit of this invention
can comprise one or more containers and/or receptacles to hold the
reagents (e.g., antibodies, antigens, nucleic acids) of the kit,
along with appropriate buffers and/or diluents and/or other
solutions and directions for using the kit, as would be well known
in the art. Such kits can further comprise adjuvants and/or other
immunostimulatory or immunomodulating agents, as are well known in
the art.
[0139] The compositions and kits of the present invention can also
include other medicinal agents, pharmaceutical agents, carriers,
diluents, immunostimulatory cytokines, etc. Actual methods of
preparing such dosage forms are known, or will be apparent, to
those skilled in this art.
[0140] Administration to a subject can be by any route known in the
art. As non-limiting examples, the route of administration can be
by inhalation (e.g., oral and/or nasal inhalation), oral, buccal
(e.g., sublingual), rectal, vaginal, topical (including
administration to the airways), intraocular, transdermal, by
parenteral (e.g., intramuscular [e.g., administration to skeletal
muscle], intravenous, intra-arterial, intraperitoneal and the
like), subcutaneous (including administration into the footpad),
intradermal, intrapleural, intracerebral, and/or intrathecal
routes.
[0141] The epitopes, polypeptides, VLPs and viral vectors of the
invention can be delivered per se or by delivering a nucleic acid
(e.g., DNA) that encodes the same.
[0142] Immunomodulatory compounds, such as immunomodulatory
chemokines and cytokines (preferably, CTL inductive cytokines) can
be administered concurrently to a subject.
[0143] Cytokines may be administered by any method known in the
art. Exogenous cytokines may be administered to the subject, or
alternatively, a nucleic acid encoding a cytokine may be delivered
to the subject using a suitable vector, and the cytokine produced
in vivo. In particular embodiments, a viral adjuvant expresses the
cytokine.
[0144] In embodiments of the invention, multiple dosages (e.g.,
two, three or more) of a composition of the invention can be
administered without detectable pathogenicity (e.g., Dengue Shock
Syndrome/Dengue Hemorrhagic Fever).
[0145] In embodiments of the invention, the multivalent vaccines of
the invention do not result in immune interference, e.g., a
balanced immune response is induced against all antigens presented.
In embodiments of the invention, the balanced response results in
protective immunity against DENV-1, DENV-2, DENV-3 and DENV-4.
[0146] In embodiments of the invention, the multivalent vaccine can
be administered to a subject that has anti-dengue maternal
antibodies present.
[0147] It should be appreciated that the invention can be embodied
in different forms and should not be construed as limited to the
embodiments set forth herein. Rather, these embodiments are
provided so that this disclosure will be thorough and complete, and
will fully convey the scope of the invention to those skilled in
the art.
[0148] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. The
terminology used in the description of the invention herein is for
the purpose of describing particular embodiments only and is not
intended to be limiting of the invention.
[0149] As used herein, "a," "an" or "the" can mean one or more than
one. For example, "a" cell can mean a single cell or a multiplicity
of cells.
[0150] Also as used herein, "and/or" refers to and encompasses any
and all possible combinations of one or more of the associated
listed items, as well as the lack of combinations when interpreted
in the alternative ("or").
[0151] The term "about," as used herein when referring to a
measurable value such as an amount of dose (e.g., an amount of a
fatty acid) and the like, is meant to encompass variations of
.+-.20%, .+-.10%, .+-.5%, .+-.1%, .+-.0.5%, or even .+-.0.1% of the
specified amount.
[0152] As used herein, the transitional phrase "consisting
essentially of" means that the scope of a claim is to be
interpreted to encompass the specified materials or steps recited
in the claim, "and those that do not materially affect the basic
and novel characteristic(s)" of the claimed invention. See, In re
Herz, 537 F.2d 549, 551-52, 190 U.S.P.Q. 461, 463 (CCPA 1976)
(emphasis in the original); see also MPEP .sctn. 2111.03. Thus, the
term "consisting essentially of" when used in a claim of this
invention is not intended to be interpreted to be equivalent to
"comprising."
[0153] As used herein, the term "nucleic acid" encompasses both RNA
and DNA, including cDNA, genomic DNA, synthetic (e.g., chemically
synthesized) DNA and chimeras of RNA and DNA. The nucleic acid may
be double-stranded or single-stranded. The nucleic acid may be
synthesized using nucleotide analogs or derivatives (e.g., inosine
or phosphorothioate nucleotides). Such nucleotides can be used, for
example, to prepare nucleic acids that have altered base-pairing
abilities or increased resistance to nucleases.
[0154] As used herein, the term "polypeptide" encompasses both
peptides and proteins (including fusion proteins), unless indicated
otherwise.
[0155] A "fusion protein" is a polypeptide produced when two
heterologous nucleotide sequences or fragments thereof coding for
two (or more) different polypeptides not found fused together in
nature are fused together in the correct translational reading
frame.
[0156] A "recombinant" nucleic acid, polynucleotide or nucleotide
sequence is one produced by genetic engineering techniques.
[0157] A "recombinant" polypeptide is produced from a recombinant
nucleic acid, polypeptide or nucleotide sequence.
[0158] As used herein, an "isolated" polynucleotide (e.g., an
"isolated nucleic acid" or an "isolated nucleotide sequence") means
a polynucleotide at least partially separated from at least some of
the other components of the naturally occurring organism or virus,
for example, the cell or viral structural components or other
polypeptides or nucleic acids commonly found associated with the
polynucleotide. Optionally, but not necessarily, the "isolated"
polynucleotide is present at a greater concentration (i.e., is
enriched) as compared with the starting material (e.g., at least
about a two-fold, three-fold, four-fold, ten-fold, twenty-fold,
fifty-fold, one-hundred-fold, five-hundred-fold, one thousand-fold,
ten thousand-fold or greater concentration). In representative
embodiments, the isolated polynucleotide is at least about 1%, 5%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more pure.
[0159] An "isolated" polypeptide means a polypeptide that is at
least partially separated from at least some of the other
components of the naturally occurring organism or virus, for
example, the cell or viral structural components or other
polypeptides or nucleic acids commonly found associated with the
polypeptide. Optionally, but not necessarily, the "isolated"
polypeptide is present at a greater concentration (i.e., is
enriched) as compared with the starting material (e.g., at least
about a two-fold, three-fold, four-fold, ten-fold, twenty-fold,
fifty-fold, one-hundred-fold, five-hundred-fold, one thousand-fold,
ten thousand-fold or greater concentration). In representative
embodiments, the isolated polypeptide is at least about 1%, 5%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more pure.
[0160] Furthermore, an "isolated" cell is a cell that has been
partially or completely separated from other components with which
it is normally associated in nature. For example, an isolated cell
can be a cell in culture medium and/or a cell in a pharmaceutically
acceptable carrier.
[0161] The terms "immunogen" and "antigen" are used interchangeably
herein and mean any compound (including polypeptides) to which a
cellular and/or humoral immune response can be directed. In
particular embodiments, an immunogen or antigen can induce a
protective immune response against the effects of dengue virus
infection.
[0162] "Effective amount" as used herein refers to an amount of a
vector, nucleic acid, epitope, polypeptide, cell, particle, VLP,
composition or formulation of the invention that is sufficient to
produce a desired effect, which can be a therapeutic and/or
beneficial effect. The effective amount will vary with the age,
general condition of the subject, the severity of the condition
being treated, the particular agent administered, the duration of
the treatment, the nature of any concurrent treatment, the
pharmaceutically acceptable carrier used, and like factors within
the knowledge and expertise of those skilled in the art. As
appropriate, an "effective amount" in any individual case can be
determined by one of ordinary skill in the art by reference to the
pertinent texts and literature and/or by using routine
experimentation.
[0163] The term "immunogenic amount" or "effective immunizing
dose," as used herein, unless otherwise indicated, means an amount
or dose sufficient to induce an immune response (which can
optionally be a protective response) in the treated subject that is
greater than the inherent immunity of non-immunized subjects. An
immunogenic amount or effective immunizing dose in any particular
context can be routinely determined using methods known in the
art.
[0164] The terms "vaccine," "vaccination" and "immunization" are
well-understood in the art, and are used interchangeably herein.
For example, the terms vaccine, vaccination or immunization can be
understood to be a process or composition that increases a
subject's immune reaction to an immunogen (e.g., by providing an
active immune response), and therefore its ability to resist,
overcome and/or recover from infection (i.e., a protective immune
response).
[0165] By the terms "treat," "treating" or "treatment of" (and
grammatical variations thereof) it is meant that the severity of
the subject's condition is reduced, at least partially improved or
ameliorated and/or that some alleviation, mitigation or decrease in
at least one clinical symptom is achieved and/or there is a delay
in the progression of the disease or disorder. In representative
embodiments, the terms "treat," "treating" or "treatment of" (and
grammatical variations thereof) refer to a reduction in the
severity of viremia and/or a delay in the progression of viremia,
with or without other signs of clinical disease.
[0166] A "treatment effective" amount as used herein is an amount
that is sufficient to treat (as defined herein) the subject. Those
skilled in the art will appreciate that the therapeutic effects
need not be complete or curative, as long as some benefit is
provided to the subject.
[0167] The term "prevent," "preventing" or "prevention of" (and
grammatical variations thereof) refer to prevention and/or delay of
the onset and/or progression of a disease, disorder and/or a
clinical symptom(s) in a subject and/or a reduction in the severity
of the onset and/or progression of the disease, disorder and/or
clinical symptom(s) relative to what would occur in the absence of
the methods of the invention. In representative embodiments, the
terms "prevent," "preventing" or "prevention of" (and grammatical
variations thereof) refer to prevention and/or delay of the onset
and/or progression of viremia in the subject, with or without other
signs of clinical disease. The prevention can be complete, e.g.,
the total absence of the disease, disorder and/or clinical
symptom(s). The prevention can also be partial, such that the
occurrence of the disease, disorder and/or clinical symptom(s) in
the subject and/or the severity of onset and/or the progression is
less than what would occur in the absence of the present
invention.
[0168] A "prevention effective" amount as used herein is an amount
that is sufficient to prevent (as defined herein) the disease,
disorder and/or clinical symptom in the subject. Those skilled in
the art will appreciate that the level of prevention need not be
complete, as long as some benefit is provided to the subject.
[0169] The efficacy of treating and/or preventing dengue virus
infection by the methods of the present invention can be determined
by detecting a clinical improvement as indicated by a change in the
subject's symptoms and/or clinical parameters (e.g., viremia), as
would be well known to one of skill in the art.
[0170] Unless indicated otherwise, the terms "protect,"
"protecting," "protection" and "protective" (and grammatical
variations thereof) encompass both methods of preventing and
treating dengue virus infection in a subject, whether against one
or multiple strains, genotypes or serotypes of dengue virus.
[0171] The terms "protective" immune response or "protective"
immunity as used herein indicates that the immune response confers
some benefit to the subject in that it prevents or reduces the
incidence and/or severity and/or duration of disease or any other
manifestation of infection. For example, in representative
embodiments, a protective immune response or protective immunity
results in reduced viremia, whether or not accompanied by clinical
disease. Alternatively, a protective immune response or protective
immunity may be useful in the therapeutic treatment of existing
disease.
[0172] An "active immune response" or "active immunity" is
characterized by "participation of host tissues and cells after an
encounter with the immunogen. It involves differentiation and
proliferation of immunocompetent cells in lymphoreticular tissues,
which lead to synthesis of antibody or the development of
cell-mediated reactivity, or both." Herbert B. Herscowitz,
Immunophysiology: Cell Function and Cellular Interactions in
Antibody Formation, in IMMUNOLOGY: BASIC PROCESSES 117 (Joseph A.
Bellanti ed., 1985). Alternatively stated, an active immune
response is mounted by the host after exposure to immunogens by
infection or by vaccination. Active immunity can be contrasted with
passive immunity, which is acquired through the "transfer of
preformed substances (antibody, transfer factor, thymic graft,
interleukin-2) from an actively immunized host to a non-immune
host." Id.
[0173] A "subject" of the invention includes any animal susceptible
to dengue virus infection. Such a subject is generally a mammalian
subject (e.g., a laboratory animal such as a rat, mouse, guinea
pig, rabbit, primates, etc.), a farm or commercial animal (e.g., a
cow, horse, goat, donkey, sheep, etc.), or a domestic animal (e.g.,
cat, dog, ferret, etc.). In particular embodiments, the subject is
a primate subject, a non-human primate subject (e.g., a chimpanzee,
baboon, monkey, gorilla, etc.) or a human. Subjects of the
invention can be a subject known or believed to be at risk of
infection by dengue virus. Alternatively, a subject according to
the invention can also include a subject not previously known or
suspected to be infected by dengue virus or in need of treatment
for dengue virus infection.
[0174] Subjects may be treated for any purpose, such as for
eliciting a protective immune response or for eliciting the
production of antibodies in that subject, which antibodies can be
collected and used for other purposes such as research or
diagnostic purposes or for administering to other subjects to
produce passive immunity therein, etc.
[0175] Subjects include males and/or females of any age, including
neonates, juvenile, mature and geriatric subjects. With respect to
human subjects, in representative embodiments, the subject can be
an infant (e.g., less than about 12 months, 10 months, 9 months, 8
months, 7 months, 6 months, or younger), a toddler (e.g., at least
about 12, 18 or 24 months and/or less than about 36, 30 or 24
months), or a child (e.g., at least about 1, 2, 3, 4 or 5 years of
age and/or less than about 14, 12, 10, 8, 7, 6, 5, or 4 years of
age). In embodiments of the invention, the subject is a human
subject that is from about 0 to 3, 4, 5, 6, 9, 12, 15, 18, 24, 30,
36, 48 or 60 months of age, from about 3 to 6, 9, 12, 15, 18, 24,
30, 36, 48 or 60 months of age, from about 6 to 9, 12, 15, 18, 24,
30, 36, 48 or 60 months of age, from about 9 to 12, 15, 18, 24, 30,
36, 48 or 60 months of age, from about 12 to 18, 24, 36, 48 or 60
months of age, from about 18 to 24, 30, 36, 48 or 60 months of age,
or from about 24 to 30, 36, 48 or 60 months of age.
[0176] In embodiments of the invention, the subject has maternal
antibodies to dengue virus.
[0177] A "subject in need" of the methods of the invention can be a
subject known to be, or suspected of being, infected with, or at
risk of being infected with, dengue virus.
[0178] Pharmaceutical formulations (e.g., immunogenic formulation)
comprising the dengue virus epitopes, polypeptides, chimeric
flavivirus VLPs or chimeric flavivirus particles, nucleic acids,
vectors, cells or compositions of the invention and a
pharmaceutically acceptable carrier are also provided, and can be
formulated for administration in a pharmaceutical carrier in
accordance with known techniques. See, e.g., Remington, The Science
And Practice of Pharmacy (latest edition). In the manufacture of a
pharmaceutical composition according to embodiments of the present
invention, the composition of the invention is typically admixed
with, inter alia, a pharmaceutically acceptable carrier. By
"pharmaceutically acceptable carrier" is meant a carrier that is
compatible with other ingredients in the pharmaceutical composition
and that is not harmful or deleterious to the subject. The carrier
may be a solid or a liquid, or both, and is preferably formulated
with the composition of the invention as a unit-dose formulation,
for example, a tablet, which may contain from about 0.01 or 0.5% to
about 95% or 99% by weight of the composition. The pharmaceutical
compositions are prepared by any of the well-known techniques of
pharmacy including, but not limited to, admixing the components,
optionally including one or more accessory ingredients. In certain
embodiments, the pharmaceutically acceptable carrier is sterile and
would be deemed suitable for administration into human subjects
according to regulatory guidelines for pharmaceutical compositions
comprising the carrier.
[0179] Furthermore, a "pharmaceutically acceptable" component such
as a salt, carrier, excipient or diluent of a composition according
to the present invention is a component that (i) is compatible with
the other ingredients of the composition in that it can be combined
with the compositions of the present invention without rendering
the composition unsuitable for its intended purpose, and (ii) is
suitable for use with subjects as provided herein without undue
adverse side effects (such as toxicity, irritation, and allergic
response). Side effects are "undue" when their risk outweighs the
benefit provided by the composition. Non-limiting examples of
pharmaceutically acceptable components include any of the standard
pharmaceutical carriers such as phosphate buffered saline
solutions, water, emulsions such as oil/water emulsion,
microemulsions and various types of wetting agents.
[0180] In some embodiments, the compositions of the invention can
further comprise one or more than one adjuvant. The adjuvants of
the present invention can be in the form of an amino acid sequence,
and/or in the form or a nucleic acid encoding an adjuvant. When in
the form of a nucleic acid, the adjuvant can be a component of a
nucleic acid encoding the polypeptide(s) or fragment(s) or
epitope(s) and/or a separate component of the composition
comprising the nucleic acid encoding the polypeptide(s) or
fragment(s) or epitope(s) of the invention. According to the
present invention, the adjuvant can also be an amino acid sequence
that is a peptide, a protein fragment or a whole protein that
functions as an adjuvant, and/or the adjuvant can be a nucleic acid
encoding a peptide, protein fragment or whole protein that
functions as an adjuvant. As used herein, "adjuvant" describes a
substance, which can be any immunomodulating substance capable of
being combined with a composition of the invention to enhance,
improve or otherwise modulate an immune response in a subject.
[0181] In further embodiments, the adjuvant can be, but is not
limited to, an immunostimulatory cytokine (including, but not
limited to, GM/CSF, interleukin-2, interleukin-12,
interferon-gamma, interleukin-4, tumor necrosis factor-alpha,
interleukin-1, hematopoietic factor flt3L, CD40L, B7.1
co-stimulatory molecules and B7.2 co-stimulatory molecules), SYNTEX
adjuvant formulation 1 (SAF-1) composed of 5 percent (wt/vol)
squalene (DASF, Parsippany, N.J.), 2.5 percent Pluronic, L121
polymer (Aldrich Chemical, Milwaukee), and 0.2 percent polysorbate
(Tween 80, Sigma) in phosphate-buffered saline. Suitable adjuvants
also include an aluminum salt such as aluminum hydroxide gel
(alum), aluminum phosphate, or algannmulin, but may also be a salt
of calcium, iron or zinc, or may be an insoluble suspension of
acylated tyrosine, or acylated sugars, cationically or anionically
derivatized polysaccharides, or polyphosphazenes.
[0182] Other adjuvants are well known in the art and include
without limitation MF 59, LT-K63, LT-R72 (Pal et al., Vaccine
24(6):766-75 (2005)), QS-21, Freund's adjuvant (complete and
incomplete), aluminum hydroxide,
N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),
N-acetyl-normuramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to
as nor-MDP),
N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dip-
almitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A,
referred to as MTP-PE) and RIBI, which contains three components
extracted from bacteria, monophosphoryl lipid A, trealose
dimycolate and cell wall skeleton (MPL+TDM+CWS) in 2%
squalene/Tween 80 emulsion.
[0183] Additional adjuvants can include, for example, a combination
of monophosphoryl lipid A, preferably 3-de-O-acylated
monophosphoryl. lipid A (3D-MPL) together with an aluminum salt. An
enhanced adjuvant system involves the combination of a
monophosphoryl lipid A and a saponin derivative, particularly the
combination of QS21 and 3D-MPL as disclosed in PCT publication
number WO 94/00153, or a less reactogenic composition where the
QS21 is quenched with cholesterol as disclosed in PCT publication
number WO 96/33739. A particularly potent adjuvant formulation
involving QS21 3D-MPL & tocopherol in an oil in water emulsion
is described in PCT publication number WO 95/17210. In addition,
the nucleic acid compositions of the invention can include an
adjuvant by comprising a nucleotide sequence encoding the antigen
and a nucleotide sequence that provides an adjuvant function, such
as CpG sequences. Such CpG sequences, or motifs, are well known in
the art.
[0184] An adjuvant for use with the present invention, such as, for
example, an immunostimulatory cytokine, can be administered before,
concurrent with, and/or within a few hours, several hours, and/or
1, 2, 3, 4, 5, 6, 7, 8, 9, and/or 10 days before and/or after the
administration of a composition of the invention to a subject.
[0185] Furthermore, any combination of adjuvants, such as
immunostimulatory cytokines, can be co-administered to the subject
before, after and/or concurrent with the administration of an
immunogenic composition of the invention. For example, combinations
of immunostimulatory cytokines, can consist of two or more
immunostimulatory cytokines, such as GM/CSF, interleukin-2,
interleukin-12, interferon-gamma, interleukin-4, tumor necrosis
factor-alpha, interleukin-1, hematopoietic factor flt3L, CD40L,
B7.1 co-stimulatory molecules and B7.2 co-stimulatory molecules.
The effectiveness of an adjuvant or combination of adjuvants can be
determined by measuring the immune response produced in response to
administration of a composition of this invention to a subject with
and without the adjuvant or combination of adjuvants, using
standard procedures, as described herein and as known in the
art.
[0186] In embodiments of the invention, the adjuvant comprises an
alphavirus adjuvant as described, for example in U.S. Pat. No.
7,862,829.
[0187] Boosting dosages can further be administered over a time
course of days, weeks, months or years. In chronic infection,
initial high doses followed by boosting doses may be
advantageous.
[0188] The pharmaceutical formulations of the invention can
optionally comprise other medicinal agents, pharmaceutical agents,
stabilizing agents, buffers, carriers, diluents, salts, tonicity
adjusting agents, wetting agents, and the like, for example, sodium
acetate, sodium lactate, sodium chloride, potassium chloride,
calcium chloride, sorbitan monolaurate, triethanolamine oleate,
etc.
[0189] For injection, the carrier will typically be a liquid. For
other methods of administration, the carrier may be either solid or
liquid. For inhalation administration, the carrier will be
respirable, and is typically in a solid or liquid particulate
form.
[0190] The compositions of the invention can be formulated for
administration in a pharmaceutical carrier in accordance with known
techniques. See, e.g., Remington, The Science And Practice of
Pharmacy (9.sup.th Ed. 1995). In the manufacture of a
pharmaceutical composition according to the invention, the VLPs are
typically admixed with, inter alia, an acceptable carrier. The
carrier can be a solid or a liquid, or both, and is optionally
formulated with the compound as a unit-dose formulation, for
example, a tablet. A variety of pharmaceutically acceptable aqueous
carriers can be used, e.g., water, buffered water, 0.9% saline,
0.3% glycine, hyaluronic acid, pyrogen-free water, pyrogen-free
phosphate-buffered saline solution, bacteriostatic water, or
Cremophor EL[R] (BASF, Parsippany, N.J.), and the like. These
compositions can be sterilized by conventional techniques. The
formulations of the invention can be prepared by any of the
well-known techniques of pharmacy.
[0191] The pharmaceutical formulations can be packaged for use as
is, or lyophilized, the lyophilized preparation generally being
combined with a sterile aqueous solution prior to administration.
The compositions can further be packaged in unit/dose or multi-dose
containers, for example, in sealed ampoules and vials.
[0192] The pharmaceutical formulations can be formulated for
administration by any method known in the art according to
conventional techniques of pharmacy. For example, the compositions
can be formulated to be administered intranasally, by inhalation
(e.g., oral inhalation), orally, buccally (e.g., sublingually),
rectally, vaginally, topically, intrathecally, intraocularly,
transdermally, by parenteral administration (e.g., intramuscular
[e.g., skeletal muscle], intravenous, subcutaneous, intradermal,
intrapleural, intracerebral and intra-arterial, intrathecal), or
topically (e.g., to both skin and mucosal surfaces, including
airway surfaces).
[0193] For intranasal or inhalation administration, the
pharmaceutical formulation can be formulated as an aerosol (this
term including both liquid and dry powder aerosols). For example,
the pharmaceutical formulation can be provided in a finely divided
form along with a surfactant and propellant. Typical percentages of
the composition are 0.01-20% by weight, preferably 1-10%. The
surfactant is generally nontoxic and soluble in the propellant.
Representative of such agents are the esters or partial esters of
fatty acids containing from 6 to 22 carbon atoms, such as caproic,
octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric
and oleic acids with an aliphatic polyhydric alcohol or its cyclic
anhydride. Mixed esters, such as mixed or natural glycerides may be
employed. The surfactant may constitute 0.1-20% by weight of the
composition, preferably 0.25-5%. The balance of the composition is
ordinarily propellant. A carrier can also be included, if desired,
as with lecithin for intranasal delivery. Aerosols of liquid
particles can be produced by any suitable means, such as with a
pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is
known to those of skill in the art. See, e.g., U.S. Pat. No.
4,501,729. Aerosols of solid particles can likewise be produced
with any solid particulate medicament aerosol generator, by
techniques known in the pharmaceutical art. Intranasal
administration can also be by droplet administration to a nasal
surface.
[0194] Injectable formulations can be prepared in conventional
forms, either as liquid solutions or suspensions, solid forms
suitable for solution or suspension in liquid prior to injection,
or as emulsions. Alternatively, one can administer the
pharmaceutical formulations in a local rather than systemic manner,
for example, in a depot or sustained-release formulation.
[0195] Extemporaneous injection solutions and suspensions can be
prepared from sterile powders, granules and tablets of the kind
previously described. For example, an injectable, stable, sterile
formulation of the invention in a unit dosage form in a sealed
container can be provided. The formulation can be provided in the
form of a lyophilizate, which can be reconstituted with a suitable
pharmaceutically acceptable carrier to form a liquid composition
suitable for injection into a subject. The unit dosage form can be
from about 1 .mu.g to about 10 grams of the formulation. When the
formulation is substantially water-insoluble, a sufficient amount
of emulsifying agent, which is pharmaceutically acceptable, can be
included in sufficient quantity to emulsify the formulation in an
aqueous carrier. One such useful emulsifying agent is phosphatidyl
choline.
[0196] Pharmaceutical formulations suitable for oral administration
can be presented in discrete units, such as capsules, cachets,
lozenges, or tables, as a powder or granules; as a solution or a
suspension in an aqueous or non-aqueous liquid; or as an
oil-in-water or water-in-oil emulsion. Oral delivery can be
performed by complexing a compound(s) of the present invention to a
carrier capable of withstanding degradation by digestive enzymes in
the gut of an animal. Examples of such carriers include plastic
capsules or tablets, as known in the art. Such formulations are
prepared by any suitable method of pharmacy, which includes the
step of bringing into association the protein(s) and a suitable
carrier (which may contain one or more accessory ingredients as
noted above). In general, the pharmaceutical formulations are
prepared by uniformly and intimately admixing the compound(s) with
a liquid or finely divided solid carrier, or both, and then, if
necessary, shaping the resulting mixture. For example, a tablet can
be prepared by compressing or molding a powder or granules,
optionally with one or more accessory ingredients. Compressed
tablets are prepared by compressing, in a suitable machine, the
formulation in a free-flowing form, such as a powder or granules
optionally mixed with a binder, lubricant, inert diluent, and/or
surface active/dispersing agent(s). Molded tablets are made by
molding, in a suitable machine, the powdered protein moistened with
an inert liquid binder.
[0197] Pharmaceutical formulations suitable for buccal
(sub-lingual) administration include lozenges comprising the
compound(s) in a flavored base, usually sucrose and acacia or
tragacanth; and pastilles in an inert base such as gelatin and
glycerin or sucrose and acacia.
[0198] Pharmaceutical formulations suitable for parenteral
administration can comprise sterile aqueous and non-aqueous
injection solutions, which preparations are preferably isotonic
with the blood of the intended recipient. These preparations can
contain anti-oxidants, buffers, bacteriostats and solutes, which
render the composition isotonic with the blood of the intended
recipient. Aqueous and non-aqueous sterile suspensions, solutions
and emulsions can include suspending agents and thickening agents.
Examples of nonaqueous solvents are propylene glycol, polyethylene
glycol, vegetable oils such as olive oil, and injectable organic
esters such as ethyl oleate. Aqueous carriers include water,
alcoholic/aqueous solutions, emulsions or suspensions, including
saline and buffered media. Parenteral vehicles include sodium
chloride solution, Ringer's dextrose, dextrose and sodium chloride,
lactated Ringer's, or fixed oils. Intravenous vehicles include
fluid and nutrient replenishers, electrolyte replenishers (such as
those based on Ringer's dextrose), and the like. Preservatives and
other additives may also be present such as, for example,
antimicrobials, anti-oxidants, chelating agents, and inert gases
and the like.
[0199] Pharmaceutical formulations suitable for rectal
administration are optionally presented as unit dose suppositories.
These can be prepared by admixing the active agent with one or more
conventional solid carriers, such as for example, cocoa butter and
then shaping the resulting mixture.
[0200] Pharmaceutical formulations suitable for topical application
to the skin preferably take the form of an ointment, cream, lotion,
paste, gel, spray, aerosol, or oil. Carriers that can be used
include, but are not limited to, petroleum jelly, lanoline,
polyethylene glycols, alcohols, transdermal enhancers, and
combinations of two or more thereof. In some embodiments, for
example, topical delivery can be performed by mixing a
pharmaceutical formulation of the present invention with a
lipophilic reagent (e.g., DMSO) that is capable of passing into the
skin.
[0201] Pharmaceutical formulations suitable for transdermal
administration can be in the form of discrete patches adapted to
remain in intimate contact with the epidermis of the subject for a
prolonged period of time. Formulations suitable for transdermal
administration can also be delivered by iontophoresis (see, for
example, Pharmaceutical Research 3:318 (1986)) and typically take
the form of a buffered aqueous solution of the compound(s).
Suitable formulations can comprise citrate or bis\tris buffer (pH
6) or ethanol/water and can contain from 0.1 to 0.2M active
ingredient.
[0202] In embodiments of the invention, the dosage of a virus
particle of this invention can be in a range of about 10.sup.3 to
about 10.sup.8 plaque forming units/focus forming units
(PFUs/FFUs). In embodiments of this invention, the dosage of a VLP
of this invention can be in a range of about 500 micrograms to
about 5 milligrams. In embodiments of this invention, the dosage of
a protein of this invention can be in a range of about 10.degree.
to about 10.sup.4 micrograms+/-adjuvant.
[0203] Further, the composition can be formulated as a liposomal
formulation. The lipid layer employed can be of any conventional
composition and can either contain cholesterol or can be
cholesterol-free. The liposomes that are produced can be reduced in
size, for example, through the use of standard sonication and
homogenization techniques.
[0204] The liposomal formulations can be lyophilized to produce a
lyophilizate which can be reconstituted with a pharmaceutically
acceptable carrier, such as water, to regenerate a liposomal
suspension.
[0205] The immunogenic formulations of the invention can optionally
be sterile, and can further be provided in a closed
pathogen-impermeable container.
EXAMPLES
Example 1. Transplantation of a Complex Quaternary
Serotype-Specific Neutralizing Antibody Epitope Between Dengue 3
and 4 Reveals Determinants of Polyclonal Neutralization
Responses
[0206] Dengue virus (DENV) is the most significant human arboviral
disease worldwide with upwards of 300 million infections annually;
however the determinants of human immune responses to DENV
infection remain largely unknown. Thus we set out to develop tools
with which to characterize antibody (Ab) responses to DENV
infection in humans. Using reverse genetics we developed infectious
clones (IC) for all 4 DENV serotypes which allow us to study
Ab-virus interactions. Characterization of a panel of monoclonal
Abs (mAb) identified a strongly type-specific neutralizing Ab of
DENV3. Using a structure-guided approach a 12 .ANG. region of the
envelope (E) protein domain I/II (EDI/II) hinge region encompassing
mutations that led to escape of neutralization was identified and
transplanted from DENV4 into DENV3 (rDENV3/4) to assess the
contribution of this epitope to the polyclonal immune response in
humans. Interestingly, this rDENV3/4 gained full sensitivity to
neutralization by human DENV4 immune sera while becoming resistant
to DENV3 sera, indicating that this EDI/II hinge region contains
major determinants of type-specific neutralization responses. When
the reciprocal transplant was made into DENV4, mAb binding was not
retained and there was not a significant shift in neutralization
profiles, indicating that the adjacent residues in the recipient
DENV serotype play a role in epitope presentation on the virion
surface. The addition of 5 amino acid residues from DENV3 into
DENV4 was able to restore mAb binding and neutralization, however
polyclonal serum neutralization remained largely unchanged.
Finally, we moved a complex quaternary epitope encompassing
residues spanning multiple E dimers into DENV4 (rDENV4/3). This
DENV4/3 was viable and grew to high infectious titers and exhibited
sensitivity to DENV3 immune sera, while neutralization responses to
DENV4 remained largely unchanged. These results provide insights
into the determinants of type specific neutralization responses
that could guide future development of rationally designed DENV
vaccine platforms.
Example 2. Development and Characterization of a Recombinant Dengue
4 Virus that Captures Type-Specific Neutralization Determinants of
Both Dengue 3 and Dengue 4
Development of a Reverse Genetics Platform for Recombinant DENT74
Generation
[0207] We have previously described the generation and
characterization of a reverse genetics system for production of
recombinant DENV3 (rDENV3) (FIG. 1, Panel A). Utilizing similar
techniques we have developed a cDNA infectious clone (IC) system
for a clinical isolate of DENV4 isolated in Sri Lanka in 1989 and
belonging to genogroup I. In order to circumvent instability and
toxicity during bacterial plasmid amplification in E coli, the
DENV4 genome was subcloned into 4 distinct fragments (FIG. 1, Panel
A). Naturally occurring class IIs restriction endonuclease sites in
the DENV4 genome at nucleotide (NT) position 3216 (PflMI;
recognition sequence: CCAAACAGTGG, SEQ ID NO:7), 5482 (DraIII;
CACCAGGTG), and 8855 (PflMI; CCAGATTTTGG, SEQ ID NO:8) were
utilized to divide the genomic cDNA. Additionally, an EcoRV site in
the bacterial vector and upstream of a T7 promoter sequence was
used to generate the 5' end of the genome, while a BsmBI site in
the vector was used for the 3' genomic end (FIG. 1, Panel A).
Following bacterial amplification of plasmids containing genomic
cDNA fragments, plasmids were digested with appropriate restriction
endonucleases, purified by agarose gel electrophoresis, ligated
with T4 DNA ligase, and transcribed with T7 RNA polymerase
containing 5' cap analogue. In vitro transcribed RNAs were then
electroporated into either Vero-81 or BHK-21 cells. Cells were
cultured for 4-6 days at which time supernatants were collected,
clarified by centrifugation, and passaged onto C6/36 (Aedes
albopictus) cells for an additional 4 days. Supernatants were again
collected and clarified, and titrated for use as working viral
stocks. rDENV4 demonstrated phenotypic properties (growth kinetics,
peak infectious titers, and infectious focus morphology/size)
identical to that of the parental natural isolate.
Transplantation of a Type-Specific Neutralizing DENV3 mAb Epitope
into DENV4
[0208] Previous studies have identified a strongly type-specific
human monoclonal antibody (hmAb) specific for DENV3 (5J7). These
studies, however, only identified single point mutations that led
to escape of DENV3 neutralization from this hmAb. In order to
further characterize this hmAb epitope, we sought to transplant the
amino acid (AA) residues encompassing this epitope from DENV3 into
DENV4 using our novel reverse genetics platform. Using both the
published and unpublished escape mutations as a guide, an
approximately 12 angstrom circumference encompassing the envelope
domain I/II (EDI/II) hinge region was superimposed upon the DENV3 E
protein crystal structure to approximate the footprint of an
antibody epitope:paratope binding region. Following AA and NT
alignments between DENV3 and DENV4, interserotypic variant AA were
identified and selected for transplantation from DENV3 into DENV4.
NT sequences in the DENV4 IC were modified to facilitate AA changes
to match DENV3, and subgenomic cDNAs capturing these changes were
synthesized (BioBasic; Amherst, N.Y.). rDENV were generated as
described above, and recovered virus used for phenotypic
characterization. In order to maximize probability of successful
epitope transplantation, 3 distinct rDENV were generated each
containing sequentially additional DENV3 residues and thus
transplanting larger theoretical epitope footprints. These rDENV
have been designated DENV4 M12, DENV4 M14, and DENV4 M16, with
increasing sizes of DENV3 sequence transplanted respectively (FIG.
1, Panels B-C). Of note, the DENV3 transplantation into DENV4 M16
encompasses a hypothetical complex quaternary epitope of 5J7, and
to our knowledge represents the first time an epitope of this
nature has been transplanted between distinct viruses.
rDENV4/3 Viruses are Viable and Demonstrate Distinct Fitness
Characteristics In Vitro
[0209] All 3 of the rDENV4/3 viruses (DENV4 M12, M14, and M16) were
successfully recovered following electroporation and subsequent
passage on C6/36 cells. Peak infectious titers from C6/36 cells
(and measured by focus formation assay on Vero-81 cells) were found
to be comparable to that of the parental WT DENV3 and DENV4 IC
(FIG. 2, Panel A). DENV4 M12 and M14 demonstrated a peak titer
similar to that of WT DENV3, all of which are approximately 1
log.sub.10 lower than that of WT DENV4 in this system. DENV4 M16,
however, displayed a more attenuated growth phenotype with peak
titers reaching about 2.times.10.sup.6 ffu/ml, about 50-fold less
than WT DENV3 and 300-fold less than WT DENV4 (FIG. 2, Panel A).
Correspondingly, infectious foci size was also smaller in the rDENV
as compared to their WT parents. DENV4 M12 and M14 foci are smaller
than WT, but still significantly larger than DENV4 M16, which forms
very small pinpoint foci on Vero-81 cells (FIG. 2, Panel B).
[0210] Similar fitness analyses were carried out on C6/36 mosquito
cells. Multi-step growth curves (MOI=0.01) were performed on DENV4
M12, M14, M16, and parental WT DENV3 and DENV4 (FIG. 3, Panel A).
In general, no significant fitness defects were seen at early time
points (<96 hr post-inoculation (hpi)) however DENV4 M14 lagged
behind WT at 96 and 120 hpi before demonstrating a burst at 144
hpi. Additionally, DENV4 M16 displayed decreased growth kinetics at
120 hpi and later with infectious titers about 2 log.sub.10 lower
than other strains. In each case cell health could have played a
role in this attenuation and as such further investigation is
required. These data do, however, indicate that at least at early
time points in infection the rDENV do not demonstrate significant
growth attenuation in arthropod cells as compared to WT DENV.
Interestingly, in contrast to Vero cells, infectious foci of DENV4
M12, M14, and M16 (FIG. 3, Panel B) do not show substantial
differences in size or morphology as compared to WT DENV3 or 4, or
to each other. This correlated well with growth curve data, and
suggests that determinants of rDENV attenuation may be cell type
specific to Vero-81 and/or mammalian cells in general. These data
indicate that rDENV4 viruses containing transplanted regions of
DENV3 are viable and demonstrate suitable growth characteristics
for further characterization.
rDENV4/3 Display Varying Degrees of Reactivity to hmAb 5J7
[0211] Assays were performed to determine the level to which the
epitope for hmAb 5J7 was transplanted from DENV3 into DENV4 in the
3 rDENV. ELISAs were undertaken to assess binding of the
DENV3-specific hmAb 5J7 to both WT and rDENV viruses. These
revealed that 5J7 bound WT DENV3, but not DENV4, consistent with
previous data. Interestingly, 5J7 was completely unable to bind
DENV4 M12, while both DENV4 M14 and M16 displayed enough of the
DENV3 epitope to facilitate 5J7 binding at levels near or exceeding
that of WT DENV3 (FIG. 4, Panel A). These data indicate that no
more than 4 AA (the difference in transplanted AA between DENV4 M12
and M14) were responsible for conferring 5J7 binding to DENV4 M14.
As a corollary to these binding studies, virus neutralization
assays were performed using 5J7 to assess sensitivity to
neutralization of the rDENV4 panel. In agreement with the ELISA
binding data, DENV4 M12 was incapable of neutralization with 5J7,
while both DENV4 M14 and M16 were neutralized by 5J7 at Ab
concentrations comparable to that of WT DENV3 (FIGS. 4B and C).
Significantly, these results were consistent (for DENV4 M14) in 2
distinct cell lines (Vero-81 and U937 expressing DC-SIGN) believed
to capture neutralization sensitivities for highly distinct (mature
vs. immature) virus particles, indicating particle maturation state
of these rDENV may not affect 5J7 neutralization.
rDENV4/3 have Bivalent Sensitivity to Polyclonal Serum
Neutralization
[0212] In order to assess sensitivity to polyclonal antibody
neutralization of our rDENV4/3 panel, donor sera collected from
convalescent patients following primary DENV infection was used in
focus reduction (Vero-81) and flow cytometry-based (U937-DC-SIGN)
assays. As with ELISA binding and 5J7 hmAb neutralization assays,
DENV4 M12 did not demonstrate an increased sensitivity to
neutralization by DENV3-specific sera in Vero cells (FIG. 5, Panel
D). DENV4 M14, however, displayed a neutralization phenotype nearly
identical to that of WT DENV3 and significantly greater than that
of WT DENV4 (FIG. 5, Panels A-C) in Vero cells indicating that this
rDENV4/3 virus had gained sensitivity to neutralization by
polyclonal antibody responses generated by natural DENV3 infection
in humans. Furthermore, this phenotype was confirmed in
U937-DC-SIGN cells, and extended to DENV4 M16 (FIG. 5, Panels E-G)
where for both rDENV polyclonal neutralization by DENV3 antisera
was comparable to WT DENV3 while WT DENV4 was not neutralized at
even the lowest serum dilution (1:20). Because of the small focus
phenotype of DENV4 M16 on Vero cells, neutralization assays in this
cell type were technically challenging and as such neutralization
data for this rDENV is limited to U937-DC-SIGN, as the flow
cytometry-based assay is easily performed on even attenuated
viruses. Taken together these date indicate that DENV4 M14 and M16
have captured polyclonal determinants of DENV3 type-specific
neutralization and demonstrate bivalency in neutralization
sensitivity.
[0213] In addition to the gain of sensitivity to DENV3 polyclonal
neutralization of our rDENV, we were interested in determining the
retention and/or loss of DENV4 neutralization sensitivity of DENV4
M12, M14, and M16. To this end neutralization assays were performed
in Vero (FIG. 6, Panel A) and U937-DC-SIGN (FIG. 6, Panels B-D)
with sera collected from convalescent primary DENV4 patients. While
DENV4 M12 demonstrated a slightly lower neutralization titer than
WT DENV4 in Vero cells (FIG. 6, Panel A), DENV4 M14 and M16 had
neutralization titers equal to or exceeding WT DENV4 in both cell
types (FIG. 6, Panels A-D). This significant finding suggests that
the determinants of type-specific neutralization for DENV3 and
DENV4 are discreet elements on the E glycoprotein, and that
determinant AA sequences of the 2 can be combined without altering
each other. As such DENV4 M14 and M16 have the potential to be
utilized as important reagents for both vaccine diagnostics or to
guide the development of new and/or improved vaccine
candidates.
rDENV4/3 Polyclonal Neutralization Sensitivity is Specific
[0214] To eliminate the possibility that the panel of rDENV4/3
viruses had been modified in such a way as to increase their
sensitivity to neutralization in a non-specific manner,
neutralization assays with primary DENV1 and DENV2 sera collected
from convalescent human patients were performed. Primary DENV1 sera
were completely incapable of neutralizing either DENV4 M12 or M14
in Vero cells, in direct contrast to WT DENV1 which was neutralized
to high levels (FIG. 7, Panels A-B). Additionally, DENV2 sera was
also incapable of neutralizing DENV4 M14, although one sample
tested did neutralize DENV4 M12, albeit at levels far lower than
that of WT DENV2 (FIG. 7, Panels C-D). Taken together these results
indicate that the gain of DENV3 neutralization sensitivity in the
DENV4 background is specific for DENV3 and not the result of global
structural changes that make the rDENV panel more sensitive to
neutralization by heterotypic sera.
Example 3. Development and Characterization of a Recombinant Dengue
2 Virus that Captures Type-Specific Neutralization Determinants of
Both Dengue 1 and Dengue 2
Development of a Reverse Genetics Platform for Recombinant DENV1
and DENV2 Generation
[0215] We have previously described the generation and
characterization of a reverse genetics system for production of
recombinant DENV3 (rDENV3). Utilizing similar techniques we have
developed a cDNA infectious clone (IC) system for DENV1 Western
Pacific 1974 (WestPac74) along with a clinical isolate of DENV2
isolated from an epidemic in Nicaragua in 2007 (V1210). In order to
circumvent instability and toxicity during bacterial plasmid
amplification in E coli, both genomes were subcloned into 4
distinct fragments (FIG. 8, Panel A). Naturally occurring class IIs
restriction endonuclease sites in the DENV1 genome at nucleotide
(NT) position 2052 (PflMI; recognition sequence: CCACCTTTTGG, SEQ
ID NO:9), 4215 (PflMI; CCACTAGCTGG, SEQ ID NO:10), and 8563 (PflMI;
CCAAACCATGG, SEQ ID NO:11) were utilized to divide the genomic
cDNA. Additionally, an EcoRV site in the bacterial vector and
upstream of a T7 promoter sequence was used to generate the 5' end
of the genome, while a SapI site in the vector was used for the 3'
genomic end (FIG. 8, Panel A). For DENV2, the first genomic
division was produced at position 2340 (DraIII between fragment A
and vector; recognition sequence: CACTGTGTG). In order to preserve
genomic sequence, a DraIII site (CACnnnGTG) was utilized for the 3'
end of the A fragment, while an AlwNI (CAGnnnCTG) site was used for
the 5' end of the B fragment. By mutating the endonuclease
recognition sequence in the vector region of the recognition site
(and not the DENV genomic sequence), the ligated product of these
two restriction endonuclease digests preserves the native DENV2
genomic sequence without the introduction of mutations into the
DENV genome to facilitate digestion. Additional genomic junctions
at NT 4662 (DraIII; CACGTGGTG), and 7414 (DraIII; CACACTGTG) were
utilized to divide the genomic cDNA. Additionally, a SpeI site in
the bacterial vector and upstream of a T7 promoter sequence was
used to generate the 5' end of the genome, while an EciI site in
the vector was used for the 3' genomic end (FIG. 8, Panel A).
Following bacterial amplification of plasmids containing genomic
cDNA fragments, plasmids were digested with appropriate restriction
endonucleases, purified by agarose gel electrophoresis, ligated
with T4 DNA ligase, and transcribed with T7 RNA polymerase
containing 5' cap analogue. In vitro transcribed RNAs were then
electroporated into either Vero-81 or BHK-21 cells. Cells were
cultured for 4-6 days at which time supernatants were collected,
clarified by centrifugation, and passaged onto C6/36 (Aedes
albopictus) cells for an additional 4 days. Supernatants were again
collected and clarified, and titrated for use as working viral
stocks. rDENV1 and rDENV2 demonstrated phenotypic properties
(growth kinetics, peak infectious titers, and infectious focus
morphology/size) identical to that of the parental natural isolate
(data not shown).
Transplantation of a Strongly Neutralizing DENV1 mAb Epitope into
DENT72 IC
[0216] Previous studies have identified a strongly type-specific
human monoclonal antibody (hmAb) specific for DENV1 (1F4).
Utilizing the crystal structure of this mAb bound to DENV1, and the
contact amino acid (AA) residues identified, we sought to
transplant the AA residues encompassing this epitope from DENV1
into DENV2 using our novel reverse genetics platform. Following AA
and NT alignments between DENV1 and DENV2, interserotypic variant
AA were identified and selected for transplantation from DENV1 into
DENV2. NT sequences in the DENV2 IC were modified to facilitate AA
changes to match DENV1 (FIG. 8, Panels B-C), and subgenomic cDNAs
capturing these changes were synthesized (BioBasic; Amherst, N.Y.).
rDENV were generated as described above, and recovered virus used
for phenotypic characterization. This rDENV has been designated
DENV2-1F4E (FIG. 8, Panels B-C).
rDENV2/1 Viruses are Viable and Demonstrate Distinct Fitness
Characteristics In Vitro
[0217] rDENV2/1 was successfully recovered following
electroporation and subsequent passage on C6/36 cells. Peak
infectious titers from C6/36 cells were measured and found to be
comparable to that of the parental WT DENV1 and DENV2 IC on C6/36
cells (FIG. 9, Panel B), although highly attenuated (approximately
3 log.sub.10) on Vero cells (FIG. 9, Panel A). Fitness analyses
were carried out on C6/36 mosquito cells, with multi-step growth
curves (MOI=0.01) (FIG. 9, Panel C). In general, no significant
fitness defects were seen at early time points (<96 hr
post-inoculation (hpi)). DENV2-1F4E Showed a drop in titer at 96
hpi however this was an isolated lag as by 120 hpi and beyond
titers were equivalent to WT DENV1 and 2 (FIG. 9, Panel C). Cell
health could have played a role in this isolated attenuated time
point and as such further investigation is required. These data do,
however, indicate that DENV2-1F4E does not demonstrate significant
growth attenuation in arthropod cells as compared to WT DENV1 and
2. Correspondingly to growth kinetic data, DENV2-1F4E (FIG. 9D)
does, Panel not show a substantial difference in size or morphology
of infectious foci as compared to WT DENV1 or 2. These data
indicate that rDENV2-1F4E containing a transplanted region of DENV1
is viable and demonstrates suitable growth characteristics for
further characterization.
hmAb 1F4 Binds rDENV2/1
[0218] Assays were performed to determine the level to which the
epitope for hmAb 1F4 was transplanted from DENV1 into DENV2 in
DENV2-1F4E. ELISAs were undertaken to assess binding of the
DENV1-specific hmAb 1F4 to both WT and rDENV viruses. These
revealed that 1F4 bound WT DENV1, but not DENV2, consistent with
previous data. Interestingly, 1F4 bound DENV2-1F4E at levels
comparable to WT DENV1 (FIG. 10, Panel A). These data indicate that
residues identified in the crystal structure of 1F4 bound to DENV1
are sufficient to transplant monoclonal Ab binding between DENV1
and 2. As a corollary to these binding studies, virus
neutralization assays were performed using 1F4 and DENV2-1F4E. In
agreement with the ELISA binding data, DENV2-1F4E was neutralized
by 1F4 at Ab concentrations comparable to that of WT DENV1 (FIG.
10, Panels B-C). Significantly, these results were consistent 2
distinct cell lines (C6/36 and U937 expressing DC-SIGN). rDENV2/1
has bivalent sensitivity to polyclonal serum neutralization
[0219] In order to assess sensitivity to polyclonal antibody
neutralization of our rDENV2/1 virus, donor sera collected from
convalescent patients following primary DENV1 infection was used in
flow cytometry-based (U937-DC-SIGN) assays. Because of the small
focus phenotype of DENV2-1F4E on Vero cells, neutralization assays
in this cell type were technically challenging and as such
neutralization data for this rDENV is limited to U937-DC-SIGN, as
the flow cytometry-based assay is easily performed on even
attenuated viruses. As with ELISA binding and 1F4 hmAb
neutralization assays, DENV2-1F4E displayed a neutralization
phenotype nearly identical to that of WT DENV1 and significantly
greater than that of WT DENV2 in U937-DC-SIGN cells (FIG. 11,
Panels A-B), indicating that this rDENV2/1 virus had gained
sensitivity to neutralization by polyclonal antibody responses
generated by natural DENV1 infection in humans. These data along
with the hmAb 1F4 data indicate that DENV2-1F4E captured polyclonal
determinants of DENV1 type-specific neutralization and demonstrates
bivalency in neutralization sensitivity.
[0220] In addition to the gain of sensitivity to DENV1 polyclonal
neutralization of our rDENV, we were interested in determining the
retention and/or loss of DENV2 neutralization sensitivity of
DENV2-1F4E. To this end neutralization assays were performed in
U937-DC-SIGN (FIG. 11, Panels C-E) with sera collected from
convalescent primary DENV2 patients. Significantly, DENV2-1F4E had
neutralization titers equal to or exceeding WT DENV2 in all cases.
This finding suggests that the determinants of type-specific
neutralization for DENV1 and DENV2 are discreet elements on the E
glycoprotein, and that determinant AA sequences of the 2 can be
combined without altering each other. As such DENV2-1F4E has the
potential to be utilized as important reagents for both vaccine
diagnostics or to guide the development of new and/or improved
vaccine candidates.
rDENV2/1 is Attenuated in a Murine Model of DENV Pathogenesis
[0221] In order to assess the level of attenuation of our chimeric
rDENV, we compared lethality of DENV2-1F4E to its parental WT DENV1
and DENV1 in an immunocompromised mouse model of DENV disease.
C57BL/6 deficient in both the interferon .alpha./.beta. receptor
and the interferon .gamma. receptor were inoculated
intraperitoneally with 3.3.times.10.sup.6 ffu (C6/36 titer) of
DENV1, DENV2, or DENV2-1F4E. Mice were weighed and monitored for 56
dpi until termination of the study. As shown in FIG. 12, while mice
inoculated with WT DENV1 and DENV2 displayed a >80% mortality
rate, no mice receiving an equivalent dose of DENV2-1F4E succumbed
to infection (p=0.0076) demonstrating a high degree of attenuation
for this rDENV. These data indicate that chimerization of DENV to
generate bivalent viruses introduces a level of in vivo attenuation
that may be suitable for vaccine development.
Example 4. Use of Chimeric Recombinant Dengue Virus to Map the
Serotype 2 Neutralizing Human Antibody Response
[0222] Dengue virus (DENV; DV) is the most significant human
arboviral pathogen worldwide with an estimated 390 million
infections and 96 million symptomatic cases annually. Nearly half
the global population is at risk of disease, yet there are no
licensed vaccines or therapeutics to treat or prevent dengue
disease. Dengue infection can manifest as dengue fever, a
self-limiting febrile illness characterized by severe bone and
joint pain, or more severe forms known as dengue hemorrhagic fever
and dengue shock syndrome which are punctuated by improper
clotting, vascular leakage, and in the most severe instances
multiple organ failure that is typically fatal. Dengue virus exists
as four distinct serotypes, and infection with one serotype does
not confer protection from subsequent infection with others. In
fact, immunity to a single dengue serotype is associated with an
increased risk of severe disease upon infection with another
serotype, a confounding factor for vaccine design. Traditional
vaccination strategies have utilized a cocktail of four distinct
viruses to elicit equivalent immune responses to each serotype,
however none to date have consistently achieved this goal. As such
there is a desperate need for diagnostic tools to aid our
understanding of the complex immune response to dengue infection,
and for new technologies to guide and produce new vaccine designs.
This invention report describes the generation of a panel of novel
recombinant chimeric dengue viruses containing critical antigenic
components of heterologous serotypes that can be used to
characterize human antibody responses to multiple serotypes and
also to generate new multivalent vaccine candidates capable of
eliciting immune responses to multiple serotypes within the context
of a single virus inoculum. We believe that this strategy of
antigen transplantation is compatible with multiple vaccine
platforms for other human and animal pathogens, and importantly,
represents a major breakthrough in dengue virus vaccine
development.
Generation of rDENV4/2 Virus
[0223] To identify amino acids residues that differ between DENV2
and DENV4, amino acid sequences of the envelope domain III (EDIII)
region (amino acid positions 296-395) were aligned (FIG. 13, Panel
A). Residues differing between DENV2 and DENV4 were highlighted, 40
total, and those residues from DENV4 were replaced with those from
DENV2 by making the fewest nucleotide changes as possible. The 40
differing amino acids span the entire EDIII, including surface
exposed residues, internal residues, and residues on the edges of
the domain, likely which interact with other monomers, and dimers
(FIG. 13, Panel B). Generation of recombinant virus utilizes
four-fragment cloning strategy used to create parental wild-type
viruses. DENV-4 A plasmid cassette contains envelope glycoprotein,
with EDIII highlighted in grey (FIG. 13, Panel C). Using DENV-4 B,
C, and D plasmid cassettes with recombinant DENV-4 A, DV4-EDIII-DV2
virus can be generated. Of 40 amino acid changes introduced into
the recombinant virus, 14 of the amino acids introduce a change of
charge (Table 1). Six residues increase negative charge, and eight
residues introduce a more positive charge.
Recombinant virus has similar maturation profile to parental
DENV4
[0224] Immunoblotting was performed on virus to measure ratio of E
and prM proteins present on virus (FIG. 14). DENV2 shows high
levels of prM relative to E, indicating a highly immature virus,
due to either incomplete furin processing or prM dissociation. Both
DENV4 and DV4-EDIII-DV2 have no detectable prM, suggesting these
viruses are highly mature. However, because of significant
differences in amount of E protein detected between DENV2 and the 2
DENV4 backboned viruses, we cannot preclude to presence of some prM
on the surface of these virions.
Recombinant Virus is Attenuated in Vero Cells, but not Mosquito
Cells
[0225] Upon examination using a multi-step growth curve,
DV4-EDIII-DV2 is has a 2 log.sub.10 growth attenuation in Vero
cells compared to both DENV2 and DENV4 parental viruses (FIG. 15,
Panel A). DV4-EDIII-DV2 forms infectious foci in Vero cells, with a
morphology between both parental viruses (FIG. 1, Panel 5B).
Despite 1-2 additional days of infection in Vero cells,
DV4-EDIII-DV2 foci do not reach the size of parental virus
foci.
[0226] Despite the growth attenuation in Vero cells, DV4-EDIII-DV2
shows no attenuation in C6/36 cells (FIG. 16, Panel A). As observed
in Vero cells, DV4-EDIII-DV2 C6/36 infectious foci display a
morphology between both parental viruses. With an additional 1-2
days of infection, these foci reach a comparable size to both
wild-type viruses.
Transplantation of DENV2 EDIII, is Sufficient to Transfer 2D22
Binding and Neutralization
[0227] 2D22 is a human monoclonal antibody (MAb) that is highly
type-specific for DENV2 (FIG. 17, Panel A). Previously, an escape
mutant was generated by passaging DENV2 in the presence of 2D22 in
Vero cells. This escape mutant has one point mutation, R323G, in
the middle of EDIII (FIG. 17, Panel B), indicating this region of
DENV E may be included in the 2D22 epitope. ELISA binding shows
DV4-EDIII-DV2 has gained partial binding to 2D22, above DV4 levels,
but not to DV2 levels (FIG. 17, Panel C). Binding to 2J20 (FIG. 17,
Panel D) a cross-reactive DENV MAb, shows comparable levels of
virus are present in binding assay, and that DV4-EDIII-DV2
morphology is maintained.
[0228] Neutralization by 2D22 was analyzed using two cell types and
two assays. Vero-81 cells were infected in the presence of 2D22,
and the amount of antibody required to neutralize 50% of foci
(FRNT.sub.50) was calculated. DENV2 requires .about.0.1 ng/ul of
2D22 to neutralize 50% of virus, whereas DENV4 is not neutralized
at the maximum concentration of antibody used, 5 ng/ul (FIG. 17,
Panel E). Transplantation of EDIII is sufficient to transfer
sensitivity to neutralization by 2D22, as can be seen by the
.about.0.01 ng/ul FRNT.sub.50 value. These results are confirmed
using the U937+DC-SIGN flow-cytometry based neutralization assay
(FIG. 17, Panel F), which measures neutralization by a reduction in
the number of cells infected in the presence of antibody. These
data further suggest that 2D22 contains EDIII as part of its
epitope.
DV4-EDIII-DV2 has Gained Sensitivity to Neutralization by
Additional DENV2 MAbs
[0229] A panel of 6 additional DENV2 MAbs was used to further
characterize DV4-EDIII-DV2 (Table 2). Many of these MAbs do not
bind recombinant EDIII (rEDIII), including 2D22, which we have
shown contains EDIII as part of its epitope (FIG. 17). It is
possible that 2D22 uses a complex epitope, only present in entire E
monomers, E dimers, or complete virus structures, explaining the
lack of binding to rEDIII alone. It is possible other MAbs in this
panel have the same requirements. Additional information such as
residues important for binding, determined by either generating
escape mutants, or through alanine scanning mutations, is included
in the table.
[0230] One point mutation was generated for DVC3.7, V382G, which
maps to the lateral ridge of EDIII (FIG. 18, Panel A).
DV4-EDIII-DV2 is sensitive to neutralization by DVC3.7, similar to
DENV2, whereas parental DENV4 is not (FIG. 18, Panel C). One point
mutation was generated for DVC10.16, E311K, which maps to the
A-strand of EDIII (FIG. 18, Panel B). As seen with DVC3.7,
DV4-EDIII-DV2 gains neutralization to DVC10.16, from the parental
DENV4, below levels required for DENV2 neutralization. Scanning
alanine mutagenesis revealed positions 101 and 108 of the fusion
loop in EDII, to be required for DVC13.6 binding (FIG. 18, Panel
E). DV4-EDIII-DV2 is neutralized by DVC13.6 (FIG. 18, Panel F).
These data suggest that the DVC13.6 DENV2 epitope could span from
EDIII into the fusion loop region of EDII. Two additional MAbs
neutralize DV4-EDIII-DV2 similar to DENV2 and not DENV4 (FIG. 18,
Panels G-H). Surprisingly, 3F9 which binds rEDIII (Table 2), does
not bind or neutralize DV4-EDIII-DV2, despite the transplanted
domain (FIG. 18, Panel I). This suggests that 3F9's epitope
requires EDIII, but perhaps additional residues outside of EDIII,
present only in DENV2, and not DV4-EDIII-DV2.
[0231] DV4-EDIII-DV2 loses neutralization to DENV4 EDIII specific
MAb DV4-E88 is a mouse DV4 type-specific MAb with a known EDIII
epitope and specific residues, 331 and 361, mapped through escape
mutants (Table 2 and FIG. 19, Panel A). As expected, DV4-E88
neutralizes DV4 and not DV2. Because EDIII of DENV4 was replaced
with that from DENV2, DV4-EDIII-DV2 neutralization by DV4-E88 was
lost.
DV4-EDIII-DV2 Gains Neutralization to DENV2 Polyclonal Immune
Sera
[0232] To test if antibodies present in polyclonal immune sera
recognize EDIII, twelve DENV2 polyclonal immune sera were tested
against DV4-EDIII-DV2 (FIG. 20, Panels A-L). DV4-EDIII-DV2 gains
sensitivity to neutralization by DENV2 sera, comparable to that of
DENV2. DENV4 is not neutralized by any of the sera at the highest
tested concentration. Despite the range in neutralization titers
with the different sera (ranging from .about.50 to 3,000) the
average DV4-EDIII-DV2 neutralization titer is higher than DENV2
(FIG. 22, Panel A).
DV4-EDIII-DV2 Preserves Neutralization to DENV4 Polyclonal Immune
Sera
[0233] DENV4 polyclonal immune sera neutralizes DV4-EDIII-DV2 with
neutralization titers similar to that of DENV4 (FIG. 21, Panels
A-F). These data suggest that the major DENV4 neutralizing epitope
is distinct from DENV2, and is not disrupted when DENV2 EDIII is
introduced into DENV4. As seen with DENV2 polyclonal immune sera,
DV4-EDIII-DV2 average neutralization titer is comparable to that of
DENV4 (FIG. 22, Panel B). DV4-EDIII-DV2 does not gain
neutralization to heterotypic polyclonal immune sera
[0234] To test if DV4-EDIII-DV2 is neutralized by heterotypic DENV1
or DENV3 polyclonal immune sera, the same FRNT assay was performed
using sera from convalescent DENV1 and DENV3 donors. While in some
cases DV4-EDIII-DV2 gains slight sensitivity to neutralization
above levels of parental DENV4 neutralization titers, it does not
exceed levels of DENV2 neutralization, and is in each case
substantially lower than homotypic neutralization (FIG. 23, Panels
A-B).
[0235] DV4-EDIII-DV2 appears to identify the major DENV2
type-specific neutralizing epitope to be a quaternary epitope
containing EDIII. This recombinant virus gains neutralization to
DENV2 polyclonal immune sera, without losing sensitivity to DENV4
sera, suggesting DENV4 has a different neutralizing epitope. This
virus can be used as a diagnostic tool to probe for either DENV2 or
DENV4 antibodies. In particular because of the isolation of the
DENV2 EDIII in the heterogenous DENV4 background, relative
abundance of EDIII-specific Abs from naturally infected or
vaccinated individuals can be assayed. This is significant in light
of our finding that EDIII of DENV2 appears to be critical for
type-specific neutralizing responses after infection. This virus
contains domains from both DENV2 and DENV4, and is sensitive to
neutralization by both DENV2 and DENV4 antibodies, suggesting this
virus might be useful as a bivalent vaccine capable of eliciting
antibody responses against both serotypes. Furthermore, a
tetravalent vaccine formulation may be achievable if used in
concert with DENV1/3 or DENV3/1 recombinant viruses, demonstrating
a significant advance in the dengue vaccine field.
Virus Construction
[0236] Recombinant viruses are constructed using a four-fragment
cloning strategy, the same strategy used to create wild-type DENV
infectious clones. DENV-4 genome is subcloned into four separate
DNA plasmids. T7 promoter was introduced into the 5' end of the A
fragment, and unique type IIS restriction sites are introduced into
the 5' and 3' end of each fragment. These restriction sites ensure
plasmids will only be assembled in the correct direction to
generate DENV genomic sequence.
[0237] The EDIII residues from DENV2 were introduced into DENV4, by
replacing nucleotides in DENV4 A fragment, with nucleotides
encoding for DENV2 amino acids. The new A fragment with nucleotides
from DENV2, was synthesized and inserted into pUC-57 plasmid
(BioBasic). The new A plasmid, in addition to DENV4 B, C and D
plasmids were grown in E. coli, purified, digested with
corresponding type IIS restriction enzymes, ligated using T4 DNA
ligase to create full length cDNA dengue viral genome. cDNA was
transcribed using T7 polymerase. Recombinant RNA was electroporated
into BHK-21 cells and cell culture supernatant containing viable
virus was harvested. Virus was then passaged two times on C6/36
cells, centrifuged to removed cellular debris, and stored at
-80.degree. C.
Cells
[0238] Mosquito Ae. albopictus C6/36 cells were grown in MEM
(Gibco) media at 32.degree. C. Vero-81 cells were maintained in
DMEM at 37.degree. C. The human monocyte lymphoma cell line U937,
stably expressing DC-SIGN (U937+DC-SIGN) via retroviral
transduction was maintained in RPMI-1640 (Gibco) at 37.degree. C.
and supplemented with 50 mM .beta.-mercaptoethanol. Media was
supplemented FBS (10% for Vero-81 and U937+DC-SIGN cells, 5% for
C6/36), which was lowered to 2% to make infection media. All media
were additionally supplemented with 100U/ml penicillin and 100
mg/ml streptomycin. U937+DC-SIGN was additionally supplemented with
0.1 mM nonessential amino acids, and 2 mM glutamine. All cells were
incubated in 5% CO.sub.2.
Binding ELISA
[0239] Equal quantities of virus (as previously titrated by ELISA)
were captured using anti-E antibodies. The primary antibodies 2D22
and 2J20 were diluted fourfold starting to generate dilution
series. Alkaline phosphatase-conjugated secondary antibodies were
used to detect binding of primary antibodies with P-nitrophenyl
phosphate substrate, and reaction color changes were quantified
using spectrophotometry.
DENV Immune Sera
[0240] Human DENV immune sera were collected from individuals with
confirmed previous natural DENV infections. Additional human immune
sera were collected from individuals given DENV vaccines. Non-human
primate immune sera were collected following DENV infection.
Virus Titration and Focus Reduction Neutralization Test (FRNT)
[0241] One day prior to infections, 24-well plates were seeded with
either 5.times.10.sup.4 Vero-81 or 1.times.10.sup.5 C6/36 cells.
Prior to infection, growth media was removed. Virus titrations were
performed by serially diluting virus stocks 10-fold, then incubated
for lhr at 37.degree. C. After incubation, virus dilutions were
added to cells for lhr at 37.degree. C., then overlaid with lml 1%
methylcellulose in OptiMEM (Gibco), supplemented with 2% FBS,
100U/ml penicillin and 100 mg/ml streptomycin. After 3-6 days
incubation at 37.degree. C., overlay was removed, cells were washed
with PBS and fixed in 80% methanol. Plates were blocked with 5%
instant milk made in PBS, then incubated with anti-E MAb 4G2 and
anti-PrM MAb 2H2, both diluted 1:500 in blocking buffer. Plates
were then washed, and incubated with HRP-conjugated goat anti-mouse
Ab (Sigma), diluted 1:2500 in blocking buffer. Plates were then
washed, and foci were developed with TrueBlue HRP substrate (KPL),
and foci were counted.
[0242] For FRNT assay, either MAbs or sera were diluted four-fold
and mixed with .about.40 FFUs virus, then incubated for lhr at
37.degree. C. After incubation, virus and MAb/sera dilutions were
added to cells for lhr at 37.degree. C., then overlay was added and
processed as above.
Growth Curves
[0243] Either Vero or C6/36 cells were infected at a multiplicity
of infection (MOI) of 0.01. Every 24 hrs culture supernatant was
harvested, and centrifuged to remove cellular debris. Samples were
frozen at -80.degree. C. until use. Fresh media was replaced each
day. Viruses were tittered on their propagating cell type as
described above.
U937+DC-SIGN Neutralization Assay
[0244] As in FRNT assay, virus is diluted in U937+DC-SIGN infection
media and mixed with four-fold dilution series of MAb. Virus and
MAb mixture were incubated for lhr at 37.degree. C. Virus and Mab
mixture was then added to 5.times.10.sup.4 U937+DC-SIGN cells per
well of 96-well round bottom plate and incubated for 2 hr at
37.degree. C. After incubation, cells were centrifuged and washed
twice with infection media, then resuspended in growth media. One
day post infection, cells were centrifuged to collect, washed with
PBS and fixed with 4% paraformaldehyde. Cells were then
permeabilized and blocked in 1% normal mouse sera. Cells were
stained with 1:400 dilution of anti-E 2H2 directly labeled with
Alex Fluor 488. Percentage of positively staining cells was
measured Guava easyCyte Flow Cytometer (Millipore).
Immunoblotting
[0245] Virus stocks were diluted in PBS, mixed with 4.times.
Laemmli Sample Buffer (Bio-Rad), and heated for 10 minutes at
50.degree. C. Samples were run on 12% PROTEAN TGX Gels (Bio-Rad),
transferred to PVDF membrane and blocked in 5% instant milk in
PBS+0.05% Tween overnight at 4.degree. C. Membranes were probed
with 0.5 ug/ml anti-E 4G2, 0.5 ug/ml anti-PrM 2H12 and 5L20 in
blocking buffer for 2 hr at 37.degree. C. After washing
HRP-conjugated anti-mouse and anti-human secondary antibodies were
diluted 1:10,000 in blocking buffer, and incubated lhr at room
temperature. Membrane was exposed to chemiluminescent substrate,
and developed on film.
Example 5. Use of Chimeric Recombinant Dengue Viruses to Map the
Serotype 2 Neutralizing Human Antibody Response
[0246] Primary infection with one of the four dengue virus (DENV)
serotypes (DENV1-4) results in antibodies that neutralize the
infecting serotype, but not other serotypes Our group has
previously reported on the isolation of serotype specific, strongly
neutralizing monoclonal antibodies (hMAbs) from people exposed to
natural DENV infections. We have demonstrated that these hMAbs bind
to complex quaternary structure epitopes that are only expressed on
intact virus particles. Recently we reported that it is possible to
create viable recombinant DENVs in which these complex epitopes
have been transplanted between serotypes. By using DENV3/4
chimeras, we observed that the hinge region between domains I/II of
the envelope (E) protein contains epitopes that are the main target
of type-specific antibodies that neutralize serotypes 3 and 4. In
the current study we have used a similar approach to map sites of
DENV2 recognized by neutralizing hMAbs and primary DENV2 human
immune sera. Our studies have led to the identification of a novel
quaternary structure-dependent DENV2 epitope that is distinct from
EDI/II hinge region epitopes previously defined for serotypes 3 and
4. Importantly, we use gain and loss of function studies to
demonstrate that different locations in the DENV1-4 E glycoprotein
encode unique long-lived neutralizing epitopes, which are portable
between serotypes. The location of a DENV2 epitope and its relative
importance as a target for neutralizing antibodies in people
exposed to natural infections and vaccines was examined.
Design and Construction of rDENV4/2 Virus
[0247] Residues from DENV2 (right) were moved into DENV4 backbone
to generate a recombinant DENV4/2 virus (rDENV4/2, FIG. 24, Panel
A). A reverse genetics system for manipulating the DENV genome was
used (FIG. 24, Panel B). Top=DENV2, bottom=DENV4. The DENV genome
is divided into four plasmid cassettes which can be individually
mutated, ligated together, and electroporated into cells to
generate recombinant virus. The DENV4-A cassette contains the
envelope gene where mutations are made. Replacing the DENV4
residues with those from DENV2 creates an rDENV4/2 virus, built
entirely on the DENV4 genetic backbone.
A New Method for Serotype Identification by RT-PCR and Confirmation
of DENV4 Backbone Recombinant Virus
[0248] RT-PCT primers were designed for serotype-specific RT-PCR
(FIG. 25, Panel A). The primers utilized included a common sense
oligonucleotide targeting the highly conserved 3' end NS1 gene and
serotype-specific antisense primers target the highly divergent
NS2A gene. Viruses were grown in C6/36 cells, culture supernatant
was collected and centrifuged to remove any cellular debris. Viral
RNA was isolated using QIAGEN QIAmp Viral RNA Miniprep Kit. PCR was
run for 35 cycles, and PCR product was analyzed on a 1.5% Ultrapure
agarose gel. Control RNA (DV1/DV2/DV3/DV4) and water are run as
positive and negative controls (FIG. 25, Panel B). Expected product
sizes: DV1=205 bp, DV2=539 bp, DV3=455 bp, DV4=401 bp.
Restriction Fragment Length Polymorphism Distinguishes rDENV4/2
from Parental DENV4
[0249] Restriction fragment length polymorphism (RFLP) analysis was
used to distinguish rDENV4/2 (bottom) from parental DENV4 (top).
Mutations (represented as asterisks) introduced into the DENV4 E
genome to generate rDENV4/2 disrupt an XmnI restriction enzyme site
present in DENV4 (FIG. 26, Panel A). PCR products were gel purified
and digested with XmnI. Digest products were analyzed on a 1.5%
Ultrapure agarose gel (FIG. 26, Panel B). Expected product sizes:
full length undigested=1031 bp, digested products=931 bp and 113
bp.
DENV4 and rDENV4/2 Virions have Similar Maturation Profiles
[0250] Viruses were grown in C6/36 cells, and culture supernatants
were collected and centrifuged to remove any cellular debris.
Samples were run on a 12% SDS-PAGE gel and blots were probed with
anti-E (4G2) and anti-PrM (2H12 and 5L20) antibodies (FIG. 27).
DENV2 has substantial levels of PrM present, indicating either
incomplete Furin processing or PrM dissociation. PrM bands are not
detected in either DENV4 or rDENV4/2 samples.
rDENV4/2 has a 2 Log Growth Attenuation in Vero Cells Relative to
Parental Viruses.
[0251] Vero-81 cells were infected at an MOI=0.01 with DENV2, DENV4
and rDENV4/2. Viral supernatants were collected every 24 hours and
subsequently titered on Vero-81 cells (FIG. 28, Panel A). DENV
forms infectious foci in Vero-81 cells. DENV2, DENV4, and rDENV4/2
were fixed 5, 4, and 6 days post-infection, respectively (FIG. 28,
Panel B). rDENV4/2 exhibited foci that were smaller than both
parental viruses.
rDENV4/2 has No Growth Attenuation in C6/36 Cells and Forms Similar
Infectious Foci Relative to Parental Viruses
[0252] C6/36 cells were infected at an MOI=0.01 with DENV2, DENV4
and rDENV4/2. Viral supernatants were collected every 24 hours and
subsequently titered on C6/36 cells (FIG. 29, Panel A). DENV forms
infectious foci on C6/36 cells. DENV2, DEVN4, and rDENV4/2 fixed 4,
3, and 5 days post-infection, respectively (FIG. 29, Panel B). With
additional day(s) of growth, rDENV4/2 foci reach sizes comparable
with parental viruses. FIG. 30. Transfer of binding and
neutralization of rDENV4/2 by type-specific DENV2 human MAb
[0253] A summary of the binding of human MAb 2D22, a strongly
neutralizing DV2 MAb, that binds to a quaternary epitope is shown
in FIG. 30, Panel A. 2D22 shows great specificity for neutralizing
DENV2. ELISA assays show a transfer of partial binding of 2D22 to
rDENV4/2, above levels of parental DV4 but not to DV2 levels (FIG.
30, Panel B). ELISA binding of the cross-reactive control antibody,
2J20, showed comparable levels of virus present and maintained
virus integrity (FIG. 20, Panel C). A Vero-81 based Focus Reduction
Neutralization Test (FRNT) was performed using 2D22 and FRNT.sub.50
(concentration of antibody required to neutralize 50% of infection)
values were calculated (FIG. 30, Panel D). A U937+DC-SIGN based
neutralization assay (Neut) was performed using 2D22 and
Neut.sub.50 values were calculated (FIG. 30, Panel E). In both
assays (FIG. 30, Panels D-E), rDENV4/2 gained neutralization to
2D22 to levels higher than DV2. DV4 was not neutralized with the
maximum concentration of 2D22 in either assay.
rDENV4/2 Gains Neutralization to DENV2 Polyclonal Immune Sera while
Preserving Neutralization to DENV4 Polyclonal Sera
[0254] A Vero-81 FRNT assay showed that rDENV4/2 gained
neutralization to DENV2 polyclonal immune sera to levels comparable
to parental DENV2 (FIG. 31, Panel A). rDENV4/2 showed no loss to
neutralization by DENV4 polyclonal immune sera (FIG. 31, Panel B).
rDENV4/2 showed no gain of neutralization to heterotypic DENV1
(FIG. 31, Panel C) and DENV3 (FIG. 31, Panel D) polyclonal immune
sera above either parental DENV2 or DENV4 neutralization titers.
Sera from individuals with either nature infection, or experimental
vaccination are coded as indicated. Samples with FRNT.sub.50<20
graphed at sera dilution factor of 19.
[0255] In this study, a recombinant DENV virus was generated
comprised of envelope residues from two DENV serotypes (DENV2 and
DENV4), and in characterizing this virus have identified several
key findings: a viable recombinant virus by transplanting regions
from one DENV serotype to another can be created; rDENV4/2 growth
is attenuated in mammalian cells, but not insect cells; rDENV4/2
has no detectable PrM protein present, indicating it is fully
processed and highly mature; binding and neutralization was
transferred to the human DENV2 type-specific MAb 2D22 in two
different cell types and neutralizing assays; rDENV4/2 gains
neutralization to DENV2 polyclonal immune sera without losing
neutralization to DENV4 polyclonal immune sera; rDENV4/2 gains no
neutralization to heterotypic polyclonal immune sera; and rDENV4/2
may be developed as a bivalent vaccine to elicit protective
antibody responses to both DENV2 and DENV4.
Example 6. Amino Acid Alignments of Recombinant DENV with Wild-Type
DENV Sequences
[0256] An amino acid sequence alignment of DV4-EDIII-DV2 with
wild-type DENV4 and DENV2 is presented in FIG. 32A. An amino acid
alignment of DENV2-1F4E with wild-type
[0257] DENV2 and DENV1 is presented in FIG. 32B. Lastly, an amino
acid alignment of DENV4 M12, DENV4 M14 and DENV4 M16 with wild-type
DENV4 and DENV3 is presented in FIG. 32B.
[0258] The foregoing is illustrative of the present invention, and
is not to be construed as limiting thereof. The invention is
defined by the following claims, with equivalents of the claims to
be included therein.
[0259] All publications, patent applications, patents and other
references cited herein are incorporated by reference in their
entireties for the teachings relevant to the sentence and/or
paragraph in which the reference is presented.
TABLE-US-00008 TABLE 1 Summary of amino acid changes in recombinant
DV4-EDIII-DV2 virus Position DV2 DV4 AA change 307 K S positive
charge .fwdarw. polar uncharged Of 40aa residues that were 309 V D
hydrophobic uncharged .fwdarw. negative charge changed in
recombinant 320 I T hydrophobic uncharged .fwdarw. polar uncharged
virus, 14 introduced a 325 Q K polar uncharged .fwdarw. positive
charge change of charge. Six 329 D A negative charge .fwdarw.
hydrophobic uncharged residues increase negative 331 S A polar
uncharged .fwdarw. hydrophobic uncharged charge (light red =
positive 340 T R polar uncharged .fwdarw. positive charge .fwdarw.
uncharged, dark red = 343 E N negative charge .fwdarw. polar
uncharged uncharged .fwdarw. negative), 345 R E positive charge
.fwdarw. negative charge while eight residues 353 V S hydrophobic
uncharged .fwdarw. polar uncharged increase positive charge 358 T E
polar uncharged .fwdarw. negative charge (light blue = negative
.fwdarw. 359 E N negative charge .fwdarw. polar uncharged
uncharged, dark blue = 360 K T positive charge .fwdarw. polar
uncharged uncharged .fwdarw. positive). 361 D N negative charge
.fwdarw. polar uncharged Additional residue changes 364 V T
hydrophobic uncharged .fwdarw. polar uncharged replace hydrophobic
amino 382 E G negative charge .fwdarw. hydrophobic uncharged acids
with polar amino 383 P N hydrophobic uncharged .fwdarw. polar
uncharged acids, and vice versa. 384 G S hydrophobic uncharged
.fwdarw. polar uncharged 385 Q A polar unchargd .fwdarw.
hydrophobic uncharged 387 K T positive charge .fwdarw. polar
uncharged 389 N H polar uncharged .fwdarw. positive charge
TABLE-US-00009 TABLE 2 Mabs used to probe surface topology of
DV4-EDIII-DV2 binding binds specificity MAb rEDIII additional notes
DV2 type-specific 2D22 - escape mutant, R323F (EDIII) 3F9 + -- 1L12
- -- DVC3.7 + EDIII lateral ridge epitope DV subcomplex DVC10.16 +
EDIII A-strand epitope DV complex DVC13.6 - scanning alanine
mutations = 101 and 108 (fusion loop) DVC23.13 - -- DV4
type-specific DV4-E88 + mouse MAb, known EDIII epitope, scanning
alanine mutations = 331 and 361 (EDIII) Additional MAbs used in
subsequent experiments. A subset of DENV2 type-specific MAbs bind
recombinant EDIII. Some MAbs that do not bind rEDIII are suspected
to contain EDIII in their epitope.
TABLE-US-00010 SEQUENCES >Parent_WT_DENV3: 115-773 E [Dengue
virus 3, SEQ ID NO: 12]
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEAT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYTVIITVHTGDQHQVGN
ETQ--GVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLELKGMSYAMCTNTF
VLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNGRLITANPV
VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIGI
GVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA >DENV4_M12: 115-775 E (SEQ
ID NO: 2) MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGPIEGKVVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA >DENV4_M14: 115-775 E (SEQ
ID NO: 3) MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEAT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA >DENV4_M16: 115-775 E (SEQ
ID NO: 4) MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTEAT
QLATLRKLCIEASISNITTDTRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCLEPIEGKVVQYENLEYTVVVTVHNGDQHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGATTSEPHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIKKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSPTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA >Parent_WT_DENV4: 115-775 E
[Dengue virus 4, SEQ ID NO: 1]
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAK
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGDGNHMFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA >Parent_WT_DENV2: 115-775
[Dengue virus 2, SEQ ID NO: 13]
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAK
QPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWG
NGCGLFGKGGIVTCAMFTCKKNMEGKVVQPENLEYTIVITPHSGEEHAVGN
DTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMEDK
AWLVHRQWFLDLPLPWLPGADTQESNWIQKETLVTFKNPHAKKQDVVVLGS
QEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRG
AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILI
GVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA >DV4-EDIII-DV2: 115-775
[Dengue virus 4/2, SEQ ID NO: 5]
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAK
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGDGNHMFAGHLKCKVRMEKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA >Parent_WT_DENV1: 115-775 E
[Dengue virus 1, SEQ ID NO: 14]
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVT
NPAVLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGN
ETTEHGTTATITPQAPTSEIQLTDYGALTLDCSPRTGLDFNEMVLLTMEKK
SWLVHKQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKLTLKGMSYVMCTGSF
KLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGRLITANPI
VTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGI
GILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA >DENV2-1F4E: 115-775 (SEQ
ID NO: 6) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVT
NPAVLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWG
NGCGLFGKGGIVTCAMFTCKKNMEGKVVQPENLKYSVIVTVHSGEEHAVGN
DTTEHGTTATITPQAPTSEIQLTDYGALTLECSPRTGLDFNEMVLLQMEDK
AWLVHRQWFLDLPLPWLPGADTQESNWIQKETLVTFKNPHAKKQDVVVLGS
QEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMDKLQLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRG
AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILI
GVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA DENV1/4(5H2) (SEQ ID NO: 15)
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVT
NPAVLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGN
EATEHGVTAMITPQSPSVEVKLPDYGELTLDCSPRTGLDFNEMVLLTMKKK
SWLVHKQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKLRLKGMSYVMCTGSF
KLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGRLITANPI
VTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKNIFEATAR
GARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIG
IGILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA DENV2/4(5H2) (SEQ ID NO: 16)
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAK
QPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFICKHSMVDRGWG
NGCGLFGKGGIVTCANIFTCKKNMEGKVVQPENLEYTIVITPHSGEEHAVG
NDAGKHGVTAMITPQSSSVEVKLPDYGEVTMECSPRTGLDFNEMVLLQMED
KAWLVHRQWFLDLPLPWLPGADTQESNWIQKETLVTFKNPHAKKQDVVVLG
SQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMDKLRLKGMSYSMCTGK
FKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNP
IVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQNIFETTM
RGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKI
LIGVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA DENV2-1F4E (Strain 16803)
(SEQ ID NO: 17) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVT
NPAVLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWG
NGCGLFGKGGIVTCANIFTCKKNMEGKVVQPENLKYSVIVTVHSGEEHAVG
NDTTEHGTTATVTPQAPTSEIQLTDYGALTLECSPRTGLDFNEMVLLQMEN
KAWLVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLG
SQEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMDKLQLKGMSYSMCTGK
FKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNP
IVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQNIFETTM
RGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKI
LIGVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA The following changes could
also be made to generate 2 viruses with smaller regions of DENV1
transplanted into DENV2: 1. N52Q, V55T, S138T, V1391 2. A1685,
P169S, A180T, L181V, L183M (in addition to those listed in #1)
DENV4-1F4E (SEQ ID NO: 18)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVT
NPAVLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLKYSVIVTVHNGDTHAVGN
DTTEHGTTATITPRAPTSEIQLTDYGALTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDTGGTTTNIFAGHLKCKVRMEKLRIKGMSYTMCSGK
FSIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTP
LAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKNIFESTY
RGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRI
LIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA The following changes could
also be made to generate 2 viruses with smaller regions of DENV1
transplanted into DENV2: 1. N52E, P53V, V55L, S138T 2. A168S, A180E
(in addition to those listed in #1) DENV1-3M14 (SEQ ID NO: 19)
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEAT
QLATLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCLEPIEGKVVQYENLKYSVIVTVHTGDQHQVGN
ETTEHGTIATITPQAPTSEIQLTDYGALTLDCSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLTLKGMSYVMCTGSF
KLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGRLITANPI
VTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKNIFEATAR
GARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIG
IGILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA The following changes could
also be made to generate a virus with a larger region of DENV3
transplanted into DENV1 (designated DENV1-3M16): 1. S225T, E229P,
E307K DENV2/3 M12 (Strain 16803) (SEQ ID NO: 20)
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAT
QLATLRKLCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWG
NGCGLFGKGGIVTCANIFTCKEPIEGKVVQPENLEYTIVVTPHSGEEHAVG
NDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLTMKN
KAWMVHRQWFFDLPLPWTSTADTQGPNWIQKETLVTFKNPHAKKQDVVVLG
SQEGAMHTALTGATEIQNSGGTSIFAGHLKCRLRMDKLQLKGMSYSMCTGK
FKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNP
IVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMR
GAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKIL
IGVIITWIGMNSRSTSLSVSLVLVGIVTLYLGVMVQA The following changes could
also be made to generate 2 viruses with a larger region of DENV3
transplanted into DENV2 (designated DENV2-M14(#1) and
DENV2-M16(#2)): 1. K122L, K123E, P132Y 2. E71D, E148Q, D225T,
S229P, V307K (in addition to those listed in #1) DENV3/4(5H2) (SEQ
ID NO: 21) MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEAT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYTVIITVHTGDQHQVGN
EASNQGVTAMITPQSSSVEVKLPDYGELGLECSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLRLKGMSYAMCTNTF
VLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNGRLITANPV
VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIGI
GVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA DV4-EDIII-DV2) (SEQ ID NO: 22)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAK
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGDGNHMFAGHLKCKVRMEKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA The following changes could
also be made to generate 2 viruses with a larger region of DENV2
transplanted into DENV4: 1. Y81S, K835, V242N, R247K 2. I68T, A71E,
T72S, R93K, R94H, D95S, V96M, V113I (in addition to those listed in
#1) DV1-EDIII-DV2 (SEQ ID NO: 23)
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVT
NPAVLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGN
ETTEHGTTATITPQAPTSEIQLTDYGALTLDCSPRTGLDFNEMVLLTMEKK
SWLVHKQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKLTLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGI
GILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA The following changes could
also be made to generate 2 viruses with a larger region of DENV2
transplanted into DENV1: 1. I68T, D71E, A80P, T81S, V83N, T242N,
A243P, E249D 2. R93K, R94H, T95S, F96M, S112G, L113I, I114V (in
addition to those listed in #1) DV3-EDIII-DV2 (SEQ ID NO: 24)
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEAT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYTVIITVHTGDQHQVGN
ETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFNEMILLTMKNKAW
MVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGSQE
GAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLELKGMSYSMCTGKFKI
VKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPIVT
EKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWYKKGSSIGKMFEATARGAR
RMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIGIGV
LLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA The following changes could also
be made to generate 2 viruses with a larger region of DENV2
transplanted into DENV3: 1. D71E, A80P, V81S, P83N, A243P, E249D 2.
I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)
DENV2/1/3 (Strain 16803) (SEQ ID NO: 25)
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVT
QLATLRKLCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWG
NGCGLFGKGGIVTCAMFTCKKPIEGKVVQPENLKYTIIVTVHSGEEHAVGN
DTTEHGTTATVTPQSSTSEIQLTDYGTVTMECSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGS
QEGAMHTALTGATEIQTSSTTTIFAGHLKCRLRMDKLQLKGMSYSMCTGKF
KVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRG
AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILI
GVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272
could be a T or N, AA #275 could be a T or G, AA #276 could be a T
or N, AA #277 could be a T or L The following changes could also be
made to generate viruses with larger regions of DENV1 and/ or DENV3
transplanted into DENV2: 1. Q52N, T55V, T138S, I139V 2. S168A,
S169P, T180A, V181L, M183L (in addition to those listed in #1) 3.
K122L, K123E, P132Y 4. E71D, E148Q, D225T, S227P, V307K (in
addition to those listed in #3) 5. Any and all combinations of 1,
2, 3, 4 and the original sequence (i.e., 1 + 3, 1 + 4, 2 + 3, 2 +
4) DENV2/1/4 (SEQ ID NO: 26)
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVT
QPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWG
NGCGLFGKGGIVTCAMFTCKKNMEGKVVQPENLKYTIIVTVHSGEEHAVGN
DATEHGVTAMVTPQSSTVEVKLPDYGEVTMECSPRTGLDFNEMVLLQMENK
AWLVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGS
QEGAMHTALTGATEIQTSGTTTLFTGHLKCRLRMDKLRLKGMSYSMCTGKF
KVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRG
AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILI
GVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA Note: AA #160 could be a T or
V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170
could be a T or S, AA #171 could be a S or V, AA #173 could be a V
or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180
could be a E or A The following changes could also be made to
generate viruses with larger regions of DENV1 transplanted into
DENV2: 1. Q52N, T55V, T138S, I139V 2. S168A, S169P, T180A, V181L,
M183L (in addition to those listed in #1) DENV2/3/4 (Strain 16803)
(SEQ ID NO: 27) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAT
QLATLRKLCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWG
NGCGLFGKGGIVTCAMFTCKEPIEGKVVQPENLEYTIVVTPHSGEEHAVGN
DAGKHGVTAMVTPQSSSVEVKLPDYGEVTMECSPRTGLDFNEMVLLTMKNK
AWMVHRQWFFDLPLPWTSTADTQGPNWIQKETLVTFKNPHAKKQDVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLRMDKLRLKGMSYSMCTGKF
KVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQMFETTMRG
AKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILI
GVIITWIGMNSRSTSLSVSLVLVGIVTLYLGVMVQA The following changes could
also be made to generate 2 viruses with a larger region of DENV3
transplanted into DENV2: 1. K122L, K123E, P132Y 2. E71D, E148Q,
D225T, S229P, V307K (in addition to those listed in #1) DENV2/1/3/4
(Strain 16803) (SEQ ID NO: 28)
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELFKTEVT
QLATLRKLCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWG
NGCGLFGKGGIVTCANIFTCKKPIEGKVVQPENLKYTIIVTVHSGEEHAVG
NDATEHGVTAMVTPQASSVEVKLPDYGEVTMECSPRTGLDFNEMILLTMKN
KAWMVHRQWFFDLPLPWTSGADTQGSNWIQKETLVTFKNPHAKKQDVVVLG
SQEGAMHTALTGATEIQTSSTTTIFAGHLKCRLRMDKLRLKGMSYSMCTGK
FKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNP
IVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKKGSSIGQNIFETTM
IRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMK
ILIGVIITWIGMNSRSTSLSVSLVLVGVVTLYLGAVVQA Note: AA #50 could be a V
or A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160
could be a T or V, AA #163 could be a T or M, AA #168 could be a S
or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173
could be a V or I, AA #174 could be a Q or K, AA #176 could be a P
or T, AA #180 a E or A, AA #272 could be a T or N, AA #275 could be
a T or G, AA #276 could be a T or N, AA #277 could be a T or L The
following changes could also be made to generate viruses with
larger regions of DENV1 and/ or DENV3 transplanted into DENV2: 1.
Q52N, T55V, T138S, I139V 2. S168A, S169P, T180A, V181L, M183L (in
addition to those listed in #1) 3. K122L, K123E, P132Y 4. E71D,
E148Q, D225T, S227P, V307K (in addition to those listed in #3) 5.
Any and all combinations of 1, 2, 3, 4 and the original sequence
DENV1/3/4 (SEQ ID NO: 29)
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEAT
QLATLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKIEGKVVQYENLKYSVIVTVHTGDQHQVGN
EATEHGVTAMITPQSPSVEVKLPDYGELTLDCSPRTGLDFNEMILLTMKNK
AWMVHRQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLRLKGMSYVMCTGSF
KLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGRLITANPI
VTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKGSSIGKNIFEATAR
GARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIG
IGILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272
could be a T or N, AA #275 could be a T or G, AA #276 could be a T
or N, AA #277 could be a T or L The following changes could also be
made to generate viruses with a larger region of DENV3 transplanted
into DENV1: 1. V122L, T123E, K124P, L214F 2. S225T, E229P, E307K
(in addition to those listed in #1) DENV1/2/3 (SEQ ID NO: 30)
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEAT
QLATLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKIEGKVVQYENLKYSVIVTVHTGDQHQVGN
ETTEHGTTATITPQAPTSEIQLTDYGALTLDCSPRTGLDFNEMILLTMKNK
AWMVHRQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLTLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGI
GILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272
could be a T or N, AA #275 could be a T or G, AA #276 could be a T
or N, AA #277 could be a T or L The following changes could also be
made to generate viruses with larger transplanted regions of DENV2
and/or DENV3 into DENV1: 1. I68T, D71E, A80P, T81S, V83N, T242N,
A243P, E249D 2. R93K, R94H, T95S, F96M, S112G, L113I, I114V (in
addition to those listed in #1) 3. V122L, T123E, K124P, L214F 4.
S225T, E229P, E307K (in addition to those listed in #3) 5. Any and
all combinations of 1, 2, 3, 4 and the original sequence DENV1/2/4
(SEQ ID NO: 31) MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVT
NPAVLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGN
EATEHGVTAMITPQSPSVEVKLPDYGELTLDCSPRTGLDFNEMVLLTMEKK
SWLVHKQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGI
GILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA Note: AA #160 could be a T or
V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170
could be a T or S, AA #171 could be a S or V, AA #173 could be a V
or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180
could be a E or A The following changes could also be made to
generate 2 viruses with a larger region of DENV2 transplanted into
DENV1: 1. I68T, D71E, A80P, T81S, V83N, T242N, A243P, E249D 2.
R93K, R94H, T95S, F96M, S112G, L113I, I114V (in addition to those
listed in #1) DENV1/2/3/4 (SEQ ID NO: 32)
MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEAT
QLATLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRGWG
NGCGLFGKGSLITCAKFKCVTKIEGKVVQYENLKYSVIVTVHTGDQHQVGN
EATEHGVTAMITPQSPSVEVKLPDYGELTLDCSPRTGLDFNEMILLTMKNK
AWMVHRQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGGTSIFAGHLKCRLKMDKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWTMKIGI
GILLTWLGLNSRSTSLSMTCIAVGMVTLYLGVMVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160
could be a T or V, AA #163 could be a T or M, AA #168 could be a S
or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173
could be a V or I, AA #174 could be a Q or K, AA #176 could be a P
or T, AA #180 could be a E or A, AA #272 could be a T or N, #275
could be a T or G, #276 could be a T or N, #277 could be a T or L
The following changes could also be made to generate 2 viruses with
a larger region of DENV2 and/or DENV3 transplanted into DENV1: 1.
I68T, D71E, A80P, T81S, V83N, T242N, A243P, E249D 2. R93K, R94H,
T95S, F96M, S112G, L113I, 1114V (in addition to those listed in #1)
3. V122L, T123E, K124P, L214F 4. S225T, E229P, E307K (in addition
to those listed in #3)
5. Any and all combinations of 1, 2, 3, 4 and the original sequence
DENV3/1/4 (SEQ ID NO: 33)
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELFKTEVT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYSVIITVHTGDQHQVGN
EATEHGVTAMITPQSSSVEVKLPDYGELGLECSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGS
QEGAMHTALTGATEIQNSGTTSIFAGHLKCRLKMDKLRLKGMSYAMCTNTF
VLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNGRLITANPV
VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARG
ARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIGI
GVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160
could be a T or V, AA #163 could be a T or M, AA #168 could be a S
or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173
could be a V or I, AA #174 could be a Q or K, AA #176 could be a P
or T, AA #180 could be a E or A, AA #272 could be a T or N, AA #275
could be a T or G, AA #276 could be a T or N, AA #277 could be a T
or L The following changes could also be made to generate viruses
with larger regions of DENV1 transplanted into DENV3: 1. S169P,
T180A 2. Q52N, L53P, T55V (in addition to those listed in #1)
DENV3/1/2 (SEQ ID NO: 34)
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELFKTEVT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYTVIVTVHTGDQHQVGN
ETTEHGTTATITPQASTSEIQLTDYGTLGLECSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGS
QEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKLELKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWYKKGSSIGKNIFEATAR
GARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIG
IGVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #272 a T
or N, AA #275 could be a T or G, AA #276 could be a T or N, AA #277
could be a T or L The following changes could also be made to
generate 2 viruses with a larger region of DENV2 and/or DENV1
transplanted into DENV3: 1. D71E, A80P, V81S, P83N, A243P, E249D 2.
I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)
3. S169P, T180A 4. Q52N, L53P, T55V (in addition to those listed in
#3) 5. Any and all combinations of 1, 2, 3, 4 and the original
sequence DENV3/2/4 (SEQ ID NO: 35)
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELQKTEAT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYTVIITVHTGDQHQVGN
EAQGVTAMITPQSSSVEVKLPDYGELGLECSPRTGLDFNEMILLTMKNKAW
MVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGSQE
GAMEITALTGATEIQNSGGTSIFAGHLKCRLKMDKLRLKGMSYSMCTGKFK
IVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPIV
TEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWYKKGSSIGKNIFEATARG
ARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIGI
GVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA The following changes could
also be made to generate 2 viruses with a larger region of DENV2
transplanted into DENV3: 1. D71E, A80P, V81S, P83N, A243P, E249D 2.
I68T, T95S, Y96M, S112G, L113I (in addition to those listed in #1)
DENV3/1/2/4 (SEQ ID NO: 36)
MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIELFKTEVT
QLATLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWG
NGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKYTVIVTVHTGDQHQVGN
EATEHGVTAMITPQSSSVEVKLPDYGELGLECSPRTGLDFNEMILLTMKNK
AWMVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVVVLGS
QEGAMHTALTGATEIQTSGTTTIFAGHLKCRLKMDKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWYKKGSSIGKNIFEATAR
GARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIG
IGVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAVVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160
could be a T or V, AA #163 could be a T or M, AA #168 could be a S
or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173
could be a V or I, AA #174 could be a Q or K, AA #176 could be a P
or T, AA #180 could be a E or A, AA #272 could be a T or N, AA #275
could be a T or G, AA #276 could be a T or N, AA #277 could be a T
or L The following changes could also be made to generate 2 viruses
with a larger region of DENV2 and/or DENV1 transplanted into DENV3:
1. D71E, A80P, V81S, P83N, A243P, E249D 2. I68T, T955, Y96M, S112G,
L113I (in addition to those listed in #1) 3. S169P, T180A 4. Q52N,
L53P, T55V (in addition to those listed in #3) 5. Any and all
combinations of 1, 2, 3, 4 and the original sequence DENV4/1/3 (SEQ
ID NO: 37) MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGPIEGKVVQIENLKYTVIVTVHNGDTHAVGN
DTTEHGTTATITPRSPTSEIQLTDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRIKGMSYTMCSGKF
SIDKEMAETQHGTTVVKVKYEGAGAPCKVPIEIRDVNKEKVVGRVISSTPL
AENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160
could be a T or V, #163 could be a T or M, AA #168 could be a S or
A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173
could be a V or I, AA #174 could be a Q or K, AA #176 could be a P
or T, AA #180 could be a E or A, AA #272 could be a T or N, AA #275
could be a T or G, AA #276 could be a T or N, AA #277 could be a T
or L The following changes could also be made to generate viruses
with a larger region of DENV1 and/ or DENV3 transplanted into
DENV4: 1. T49E, S122L, G123E, I132Y 2. A71D, T148Q, D225T, V229P,
D307K, K321Q, V362P (in addition to those listed in #1) 3. S168A,
E180A 4. E52N, V53P, L55V, T138S (in addition to those listed in
#3) 5. Any and all combinations of 1, 2, 3, 4 and the original
sequence DENV4/1/2 (SEQ ID NO: 38)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVT
EVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLKYTVIVTVHNGDTHAVGN
DTTEHGTTATITPRSPTSEIQLTDYGELTLDCEPRSGIDFNEMILMKMKKK
TWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEVDSGGTTTMFAGHLKCKVRMEKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA Note: AA #160 could be a T or
V, AA #163 could be a T or M, AA #168 could be a S or A, AA #170
could be a T or S, AA #171 could be a S or V, AA #173 could be a V
or I, AA #174 could be a Q or K, AA #176 could be a P or T, AA #180
could be a E or A The following changes could also be made to
generate 2 viruses with a larger region of DENV1 and/or DENV2
transplanted into DENV4: 1. Y81S, K83S, V242N, R247K 2. I68T, A71E,
T72S, R93K, R94H, D95S, V96M, V113I (in addition to those listed in
#1) 3. S168A, E180A 4. E52N, V53P, L55V, T138S (in addition to
those listed in #3) 5. Any and all combinations of 1, 2, 3, 4 and
the original sequence DENV4/2/3 (SEQ ID NO: 39)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGPIEGKVVQIENLEYTVVVTVHNGDTHAVGN
DTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMEISALAGATEIQNSGGTSIFAGHLKCKVRMEKLRLKGMSYSMCTGK
FKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNP
IVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYR
GAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRIL
IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA The following changes could
also be made to generate 2 viruses with a larger region of DENV2
and/or DENV3 transplanted into DENV4: 1. Y81S, K83S, V242N, R247K
2. I68T, A71E, T72S, R93K, R94H, D95S, V96M, V113I (in addition to
those listed in #1) 3. T49E, S122L, G123E, I132Y 4. A71D, T148Q,
D225T, V229P, D307K, K321Q, V362P (in addition to those listed in
#3) 5. Any and all combinations of 1, 2, 3, 4 and the original
sequence DENV4/1/2/3 (SEQ ID NO: 40)
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELFKTTVT
QLATLRKLCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGWG
NGCGLFGKGGVVTCAKFSCSGPIEGKVVQIENLKYTVIVTVHNGDTHAVGN
DTTEHGTTATITPRSPSVEVKLTDYGELTLDCEPRSGIDFNEMILLTMKKK
AWMVHRQWFFDLPLPWTSGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGS
QEGAMHSALAGATEIQNSGGTSIFAGHLKCKVRMEKLRLKGMSYSMCTGKF
KIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEITDLEKRHVLGRLITVNPI
VTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGKMFESTYRG
AKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILI
GFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA Note: AA #50 could be a V or
A, AA #52 could be a Q or N, AA #55 could be a T or V, AA #160
could be a T or V, AA #163 could be a T or M, AA #168 could be a S
or A, AA #170 could be a T or S, AA #171 could be a S or V, AA #173
could be a V or I, AA #174 could be a Q or K, AA #176 could be a P
or T, AA #180 could be a E or A, AA #272 could be a T or N, #275
could be a T or G, #276 could be a T or N, #277 could be a T or L
The following changes could also be made to generate 2 viruses with
a larger region of DENV1, DENV2, and/or DENV3 transplanted into
DENV4: 1. Y81S, K83S, V242N, R247K 2. I68T, A71E, T72S, R93K, R94H,
D95S, V96M, V113I (in addition to those listed in #1) 3. T49E,
S122L, G123E, I132Y 4. A71D, T148Q, D225T, V229P, D307K, K321Q,
V362P (in addition to those listed in #3) 5. S168A, E180A 6. E52N,
V53P, L55V, T138S 7. Any and all combinations of 1, 2, 3, 4, 5, 6
and the original sequence
Sequence CWU 1
1
401495PRTDengue virus type 4 1Met Arg Cys Val Gly Val Gly Asn Arg
Asp Phe Val Glu Gly Val Ser1 5 10 15Gly Gly Ala Trp Val Asp Leu Val
Leu Glu His Gly Gly Cys Val Thr 20 25 30Thr Met Ala Gln Gly Lys Pro
Thr Leu Asp Phe Glu Leu Thr Lys Thr 35 40 45Thr Ala Lys Glu Val Ala
Leu Leu Arg Thr Tyr Cys Ile Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr
Thr Ala Thr Arg Cys Pro Thr Gln Gly Glu Pro65 70 75 80Tyr Leu Lys
Glu Glu Gln Asp Gln Gln Tyr Ile Cys Arg Arg Asp Val 85 90 95Val Asp
Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105
110Val Val Thr Cys Ala Lys Phe Ser Cys Ser Gly Lys Ile Thr Gly Asn
115 120 125Leu Val Gln Ile Glu Asn Leu Glu Tyr Thr Val Val Val Thr
Val His 130 135 140Asn Gly Asp Thr His Ala Val Gly Asn Asp Thr Ser
Asn His Gly Val145 150 155 160Thr Ala Thr Ile Thr Pro Arg Ser Pro
Ser Val Glu Val Lys Leu Pro 165 170 175Asp Tyr Gly Glu Leu Thr Leu
Asp Cys Glu Pro Arg Ser Gly Ile Asp 180 185 190Phe Asn Glu Met Ile
Leu Met Lys Met Lys Lys Lys Thr Trp Leu Val 195 200 205His Lys Gln
Trp Phe Leu Asp Leu Pro Leu Pro Trp Thr Ala Gly Ala 210 215 220Asp
Thr Ser Glu Val His Trp Asn Tyr Lys Glu Arg Met Val Thr Phe225 230
235 240Lys Val Pro His Ala Lys Arg Gln Asp Val Thr Val Leu Gly Ser
Gln 245 250 255Glu Gly Ala Met His Ser Ala Leu Ala Gly Ala Thr Glu
Val Asp Ser 260 265 270Gly Asp Gly Asn His Met Phe Ala Gly His Leu
Lys Cys Lys Val Arg 275 280 285Met Glu Lys Leu Arg Ile Lys Gly Met
Ser Tyr Thr Met Cys Ser Gly 290 295 300Lys Phe Ser Ile Asp Lys Glu
Met Ala Glu Thr Gln His Gly Thr Thr305 310 315 320Val Val Lys Val
Lys Tyr Glu Gly Ala Gly Ala Pro Cys Lys Val Pro 325 330 335Ile Glu
Ile Arg Asp Val Asn Lys Glu Lys Val Val Gly Arg Val Ile 340 345
350Ser Ser Thr Pro Leu Ala Glu Asn Thr Asn Ser Val Thr Asn Ile Glu
355 360 365Leu Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val Ile Gly Val
Gly Asn 370 375 380Ser Ala Leu Thr Leu His Trp Phe Arg Lys Gly Ser
Ser Ile Gly Lys385 390 395 400Met Phe Glu Ser Thr Tyr Arg Gly Ala
Lys Arg Met Ala Ile Leu Gly 405 410 415Glu Thr Ala Trp Asp Phe Gly
Ser Val Gly Gly Leu Phe Thr Ser Leu 420 425 430Gly Lys Ala Val His
Gln Val Phe Gly Ser Val Tyr Thr Thr Met Phe 435 440 445Gly Gly Val
Ser Trp Met Ile Arg Ile Leu Ile Gly Phe Leu Val Leu 450 455 460Trp
Ile Gly Thr Asn Ser Arg Asn Thr Ser Met Ala Met Thr Cys Ile465 470
475 480Ala Val Gly Gly Ile Thr Leu Phe Leu Gly Phe Thr Val Gln Ala
485 490 4952495PRTArtificialDENV4 M12 E glycoprotein sequence 2Met
Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1 5 10
15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val Thr
20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Thr Lys
Thr 35 40 45Thr Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile Glu
Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr Gln
Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr Ile
Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys Gly
Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe Ser
Cys Ser Gly Pro Ile Glu Gly Lys 115 120 125Val Val Gln Ile Glu Asn
Leu Glu Tyr Thr Val Val Val Thr Val His 130 135 140Asn Gly Asp Thr
His Ala Val Gly Asn Asp Thr Ser Asn His Gly Val145 150 155 160Thr
Ala Thr Ile Thr Pro Arg Ser Pro Ser Val Glu Val Lys Leu Pro 165 170
175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly Ile Asp
180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Lys Lys Ala Trp
Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu Pro Trp
Thr Ser Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp Asn Tyr Lys
Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala Lys Arg
Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala Met His
Ser Ala Leu Ala Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser Gly Gly
Thr Ser Ile Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280 285Met
Glu Lys Leu Arg Ile Lys Gly Met Ser Tyr Thr Met Cys Ser Gly 290 295
300Lys Phe Ser Ile Asp Lys Glu Met Ala Glu Thr Gln His Gly Thr
Thr305 310 315 320Val Val Lys Val Lys Tyr Glu Gly Ala Gly Ala Pro
Cys Lys Val Pro 325 330 335Ile Glu Ile Arg Asp Val Asn Lys Glu Lys
Val Val Gly Arg Val Ile 340 345 350Ser Ser Thr Pro Leu Ala Glu Asn
Thr Asn Ser Val Thr Asn Ile Glu 355 360 365Leu Glu Pro Pro Phe Gly
Asp Ser Tyr Ile Val Ile Gly Val Gly Asn 370 375 380Ser Ala Leu Thr
Leu His Trp Phe Arg Lys Gly Ser Ser Ile Gly Lys385 390 395 400Met
Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly 405 410
415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr Ser Leu
420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr Thr Thr
Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu Ile Gly
Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg Asn Thr Ser
Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly Ile Thr Leu
Phe Leu Gly Phe Thr Val Gln Ala 485 490 4953495PRTArtificialDENV4
M14 E glycoprotein sequence 3Met Arg Cys Val Gly Val Gly Asn Arg
Asp Phe Val Glu Gly Val Ser1 5 10 15Gly Gly Ala Trp Val Asp Leu Val
Leu Glu His Gly Gly Cys Val Thr 20 25 30Thr Met Ala Gln Gly Lys Pro
Thr Leu Asp Phe Glu Leu Thr Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala
Thr Leu Arg Lys Leu Cys Ile Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr
Thr Ala Thr Arg Cys Pro Thr Gln Gly Glu Pro65 70 75 80Tyr Leu Lys
Glu Glu Gln Asp Gln Gln Tyr Ile Cys Arg Arg Asp Val 85 90 95Val Asp
Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105
110Val Val Thr Cys Ala Lys Phe Ser Cys Leu Glu Pro Ile Glu Gly Lys
115 120 125Val Val Gln Tyr Glu Asn Leu Glu Tyr Thr Val Val Val Thr
Val His 130 135 140Asn Gly Asp Thr His Ala Val Gly Asn Asp Thr Ser
Asn His Gly Val145 150 155 160Thr Ala Thr Ile Thr Pro Arg Ser Pro
Ser Val Glu Val Lys Leu Pro 165 170 175Asp Tyr Gly Glu Leu Thr Leu
Asp Cys Glu Pro Arg Ser Gly Ile Asp 180 185 190Phe Asn Glu Met Ile
Leu Leu Thr Met Lys Lys Lys Ala Trp Met Val 195 200 205His Arg Gln
Trp Phe Phe Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala 210 215 220Asp
Thr Ser Glu Val His Trp Asn Tyr Lys Glu Arg Met Val Thr Phe225 230
235 240Lys Val Pro His Ala Lys Arg Gln Asp Val Thr Val Leu Gly Ser
Gln 245 250 255Glu Gly Ala Met His Ser Ala Leu Ala Gly Ala Thr Glu
Ile Gln Asn 260 265 270Ser Gly Gly Thr Ser Ile Phe Ala Gly His Leu
Lys Cys Lys Val Arg 275 280 285Met Glu Lys Leu Arg Ile Lys Gly Met
Ser Tyr Thr Met Cys Ser Gly 290 295 300Lys Phe Ser Ile Asp Lys Glu
Met Ala Glu Thr Gln His Gly Thr Thr305 310 315 320Val Val Lys Val
Lys Tyr Glu Gly Ala Gly Ala Pro Cys Lys Val Pro 325 330 335Ile Glu
Ile Arg Asp Val Asn Lys Glu Lys Val Val Gly Arg Val Ile 340 345
350Ser Ser Thr Pro Leu Ala Glu Asn Thr Asn Ser Val Thr Asn Ile Glu
355 360 365Leu Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val Ile Gly Val
Gly Asn 370 375 380Ser Ala Leu Thr Leu His Trp Phe Arg Lys Gly Ser
Ser Ile Gly Lys385 390 395 400Met Phe Glu Ser Thr Tyr Arg Gly Ala
Lys Arg Met Ala Ile Leu Gly 405 410 415Glu Thr Ala Trp Asp Phe Gly
Ser Val Gly Gly Leu Phe Thr Ser Leu 420 425 430Gly Lys Ala Val His
Gln Val Phe Gly Ser Val Tyr Thr Thr Met Phe 435 440 445Gly Gly Val
Ser Trp Met Ile Arg Ile Leu Ile Gly Phe Leu Val Leu 450 455 460Trp
Ile Gly Thr Asn Ser Arg Asn Thr Ser Met Ala Met Thr Cys Ile465 470
475 480Ala Val Gly Gly Ile Thr Leu Phe Leu Gly Phe Thr Val Gln Ala
485 490 4954495PRTArtificialDENV4 M16 E glycoprotein sequence 4Met
Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1 5 10
15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val Thr
20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Thr Lys
Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile Glu
Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Asp Thr Arg Cys Pro Thr Gln
Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr Ile
Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys Gly
Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe Ser
Cys Leu Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu Asn
Leu Glu Tyr Thr Val Val Val Thr Val His 130 135 140Asn Gly Asp Gln
His Ala Val Gly Asn Asp Thr Ser Asn His Gly Val145 150 155 160Thr
Ala Thr Ile Thr Pro Arg Ser Pro Ser Val Glu Val Lys Leu Pro 165 170
175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly Ile Asp
180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Lys Lys Ala Trp
Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu Pro Trp
Thr Ser Gly Ala 210 215 220Thr Thr Ser Glu Pro His Trp Asn Tyr Lys
Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala Lys Arg
Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala Met His
Ser Ala Leu Ala Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser Gly Gly
Thr Ser Ile Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280 285Met
Glu Lys Leu Arg Ile Lys Gly Met Ser Tyr Thr Met Cys Ser Gly 290 295
300Lys Phe Ser Ile Lys Lys Glu Met Ala Glu Thr Gln His Gly Thr
Thr305 310 315 320Val Val Lys Val Lys Tyr Glu Gly Ala Gly Ala Pro
Cys Lys Val Pro 325 330 335Ile Glu Ile Arg Asp Val Asn Lys Glu Lys
Val Val Gly Arg Val Ile 340 345 350Ser Ser Thr Pro Leu Ala Glu Asn
Thr Asn Ser Pro Thr Asn Ile Glu 355 360 365Leu Glu Pro Pro Phe Gly
Asp Ser Tyr Ile Val Ile Gly Val Gly Asn 370 375 380Ser Ala Leu Thr
Leu His Trp Phe Arg Lys Gly Ser Ser Ile Gly Lys385 390 395 400Met
Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly 405 410
415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr Ser Leu
420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr Thr Thr
Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu Ile Gly
Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg Asn Thr Ser
Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly Ile Thr Leu
Phe Leu Gly Phe Thr Val Gln Ala 485 490
4955495PRTArtificialDV4-EDIII-DV2 E glycoprotein sequence 5Met Arg
Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1 5 10 15Gly
Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val Thr 20 25
30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Thr Lys Thr
35 40 45Thr Ala Lys Glu Val Ala Leu Leu Arg Thr Tyr Cys Ile Glu Ala
Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr Gln Gly
Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr Ile Cys
Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu
Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe Ser Cys
Ser Gly Lys Ile Thr Gly Asn 115 120 125Leu Val Gln Ile Glu Asn Leu
Glu Tyr Thr Val Val Val Thr Val His 130 135 140Asn Gly Asp Thr His
Ala Val Gly Asn Asp Thr Ser Asn His Gly Val145 150 155 160Thr Ala
Thr Ile Thr Pro Arg Ser Pro Ser Val Glu Val Lys Leu Pro 165 170
175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly Ile Asp
180 185 190Phe Asn Glu Met Ile Leu Met Lys Met Lys Lys Lys Thr Trp
Leu Val 195 200 205His Lys Gln Trp Phe Leu Asp Leu Pro Leu Pro Trp
Thr Ala Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp Asn Tyr Lys
Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala Lys Arg
Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala Met His
Ser Ala Leu Ala Gly Ala Thr Glu Val Asp Ser 260 265 270Gly Asp Gly
Asn His Met Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280 285Met
Glu Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly 290 295
300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly Thr
Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser Pro
Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg His
Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr Glu
Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe Gly
Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu Lys
Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395 400Met
Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly 405 410
415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr Ser Leu
420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr Thr Thr
Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu Ile Gly
Phe Leu Val Leu 450
455 460Trp Ile Gly Thr Asn Ser Arg Asn Thr Ser Met Ala Met Thr Cys
Ile465 470 475 480Ala Val Gly Gly Ile Thr Leu Phe Leu Gly Phe Thr
Val Gln Ala 485 490 4956495PRTArtificialDENV2-1F4E E glycoprotein
sequence 6Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly
Val Ser1 5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser
Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu
Leu Phe Lys Thr 35 40 45Glu Val Thr Asn Pro Ala Val Leu Arg Lys Tyr
Cys Ile Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys
Pro Thr Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu Gln Asp Lys
Arg Phe Ile Cys Lys His Ser Met 85 90 95Val Asp Arg Gly Trp Gly Asn
Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val Thr Cys Ala
Met Phe Thr Cys Lys Lys Asn Met Glu Gly Lys 115 120 125Val Val Gln
Pro Glu Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Ser
Gly Glu Glu His Ala Val Gly Asn Asp Thr Thr Glu His Gly Thr145 150
155 160Thr Ala Thr Ile Thr Pro Gln Ala Pro Thr Ser Glu Ile Gln Leu
Thr 165 170 175Asp Tyr Gly Ala Leu Thr Leu Glu Cys Ser Pro Arg Thr
Gly Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Gln Met Glu Asp
Lys Ala Trp Leu Val 195 200 205His Arg Gln Trp Phe Leu Asp Leu Pro
Leu Pro Trp Leu Pro Gly Ala 210 215 220Asp Thr Gln Glu Ser Asn Trp
Ile Gln Lys Glu Thr Leu Val Thr Phe225 230 235 240Lys Asn Pro His
Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly
Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265
270Ser Gly Thr Thr Thr Leu Phe Thr Gly His Leu Lys Cys Arg Leu Arg
275 280 285Met Asp Lys Leu Gln Leu Lys Gly Met Ser Tyr Ser Met Cys
Thr Gly 290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln
His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp
Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu
Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile
Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro
Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly
Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Gln385 390
395 400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg Met Ala Ile Leu
Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu Gly Gly Val Phe
Thr Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val Phe Gly Ala Ile
Tyr Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile
Leu Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly Met Asn Ser Arg
Ser Thr Ser Leu Ser Val Ser Leu Val465 470 475 480Leu Val Gly Val
Val Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
495711DNAArtificialPflMI restriction site 7ccaaacagtg g
11811DNAArtificialPflMI restriction site 8ccagattttg g
11911DNAArtificialPflMI restriction site 9ccaccttttg g
111011DNAArtificialPflMI restriction site 10ccactagctg g
111111DNAArtificialPflMI restriction site 11ccaaaccatg g
1112493PRTDengue virus type 3 12Met Arg Cys Val Gly Ile Gly Asn Arg
Asp Phe Val Glu Gly Leu Ser1 5 10 15Gly Ala Thr Trp Val Asp Val Val
Leu Glu His Gly Gly Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys Pro
Thr Leu Asp Ile Glu Leu Gln Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala
Thr Leu Arg Lys Leu Cys Ile Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr
Thr Asp Ser Arg Cys Pro Thr Gln Gly Glu Ala65 70 75 80Val Leu Pro
Glu Glu Gln Asp Gln Asn Tyr Val Cys Lys His Thr Tyr 85 90 95Val Asp
Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser 100 105
110Leu Val Thr Cys Ala Lys Phe Gln Cys Leu Glu Pro Ile Glu Gly Lys
115 120 125Val Val Gln Tyr Glu Asn Leu Lys Tyr Thr Val Ile Ile Thr
Val His 130 135 140Thr Gly Asp Gln His Gln Val Gly Asn Glu Thr Gln
Gly Val Thr Ala145 150 155 160Glu Ile Thr Pro Gln Ala Ser Thr Thr
Glu Ala Ile Leu Pro Glu Tyr 165 170 175Gly Thr Leu Gly Leu Glu Cys
Ser Pro Arg Thr Gly Leu Asp Phe Asn 180 185 190Glu Met Ile Leu Leu
Thr Met Lys Asn Lys Ala Trp Met Val His Arg 195 200 205Gln Trp Phe
Phe Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala Thr Thr 210 215 220Glu
Thr Pro Thr Trp Asn Arg Lys Glu Leu Leu Val Thr Phe Lys Asn225 230
235 240Ala His Ala Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln Glu
Gly 245 250 255Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln
Asn Ser Gly 260 265 270Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys
Arg Leu Lys Met Asp 275 280 285Lys Leu Glu Leu Lys Gly Met Ser Tyr
Ala Met Cys Thr Asn Thr Phe 290 295 300Val Leu Lys Lys Glu Val Ser
Glu Thr Gln His Gly Thr Ile Leu Ile305 310 315 320Lys Val Glu Tyr
Lys Gly Glu Asp Ala Pro Cys Lys Ile Pro Phe Ser 325 330 335Thr Glu
Asp Gly Gln Gly Lys Ala His Asn Gly Arg Leu Ile Thr Ala 340 345
350Asn Pro Val Val Thr Lys Lys Glu Glu Pro Val Asn Ile Glu Ala Glu
355 360 365Pro Pro Phe Gly Glu Ser Asn Ile Val Ile Gly Ile Gly Asp
Asn Ala 370 375 380Leu Lys Ile Asn Trp Tyr Lys Lys Gly Ser Ser Ile
Gly Lys Met Phe385 390 395 400Glu Ala Thr Ala Arg Gly Ala Arg Arg
Met Ala Ile Leu Gly Asp Thr 405 410 415Ala Trp Asp Phe Gly Ser Val
Gly Gly Val Leu Asn Ser Leu Gly Lys 420 425 430Met Val His Gln Ile
Phe Gly Ser Ala Tyr Thr Ala Leu Phe Ser Gly 435 440 445Val Ser Trp
Val Met Lys Ile Gly Ile Gly Val Leu Leu Thr Trp Ile 450 455 460Gly
Leu Asn Ser Lys Asn Thr Ser Met Ser Phe Ser Cys Ile Ala Ile465 470
475 480Gly Ile Ile Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485
49013495PRTDengue virus type 2 13Met Arg Cys Ile Gly Ile Ser Asn
Arg Asp Phe Val Glu Gly Val Ser1 5 10 15Gly Gly Ser Trp Val Asp Ile
Val Leu Glu His Gly Ser Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys
Pro Thr Leu Asp Phe Glu Leu Ile Lys Thr 35 40 45Glu Ala Lys Gln Pro
Ala Thr Leu Arg Lys Tyr Cys Ile Glu Ala Lys 50 55 60Leu Thr Asn Thr
Thr Thr Glu Ser Arg Cys Pro Thr Gln Gly Glu Pro65 70 75 80Ser Leu
Asn Glu Glu Gln Asp Lys Arg Phe Ile Cys Lys His Ser Met 85 90 95Val
Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105
110Ile Val Thr Cys Ala Met Phe Thr Cys Lys Lys Asn Met Glu Gly Lys
115 120 125Val Val Gln Pro Glu Asn Leu Glu Tyr Thr Ile Val Ile Thr
Pro His 130 135 140Ser Gly Glu Glu His Ala Val Gly Asn Asp Thr Gly
Lys His Gly Lys145 150 155 160Glu Ile Lys Ile Thr Pro Gln Ser Ser
Ile Thr Glu Ala Glu Leu Thr 165 170 175Gly Tyr Gly Thr Val Thr Met
Glu Cys Ser Pro Arg Thr Gly Leu Asp 180 185 190Phe Asn Glu Met Val
Leu Leu Gln Met Glu Asp Lys Ala Trp Leu Val 195 200 205His Arg Gln
Trp Phe Leu Asp Leu Pro Leu Pro Trp Leu Pro Gly Ala 210 215 220Asp
Thr Gln Glu Ser Asn Trp Ile Gln Lys Glu Thr Leu Val Thr Phe225 230
235 240Lys Asn Pro His Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser
Gln 245 250 255Glu Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu
Ile Gln Met 260 265 270Ser Ser Gly Asn Leu Leu Phe Thr Gly His Leu
Lys Cys Arg Leu Arg 275 280 285Met Asp Lys Leu Gln Leu Lys Gly Met
Ser Tyr Ser Met Cys Thr Gly 290 295 300Lys Phe Lys Ile Val Lys Glu
Ile Ala Glu Thr Gln His Gly Thr Ile305 310 315 320Val Ile Arg Val
Gln Tyr Glu Gly Asp Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu
Ile Thr Asp Leu Glu Lys Arg His Val Leu Gly Arg Leu Ile 340 345
350Thr Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu
355 360 365Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val
Glu Pro 370 375 380Gly Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser
Ser Ile Gly Gln385 390 395 400Met Phe Glu Thr Thr Met Arg Gly Ala
Lys Arg Met Ala Ile Leu Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly
Ser Leu Gly Gly Val Phe Thr Ser Ile 420 425 430Gly Lys Ala Leu His
Gln Val Phe Gly Ala Ile Tyr Gly Ala Ala Phe 435 440 445Ser Gly Val
Ser Trp Thr Met Lys Ile Leu Ile Gly Val Ile Ile Thr 450 455 460Trp
Ile Gly Met Asn Ser Arg Ser Thr Ser Leu Ser Val Ser Leu Val465 470
475 480Leu Val Gly Val Val Thr Leu Tyr Leu Gly Ala Val Val Gln Ala
485 490 49514495PRTDengue virus type 1 14Met Arg Cys Val Gly Ile
Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1 5 10 15Gly Ala Thr Trp Val
Asp Val Val Leu Glu His Gly Ser Cys Val Thr 20 25 30Thr Met Ala Lys
Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu Lys Thr 35 40 45Glu Val Thr
Asn Pro Ala Val Leu Arg Lys Leu Cys Ile Glu Ala Lys 50 55 60Ile Ser
Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr Gln Gly Glu Ala65 70 75
80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe Val Cys Arg Arg Thr Phe
85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly
Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe Lys Cys Val Thr Lys Leu
Glu Gly Lys 115 120 125Ile Val Gln Tyr Glu Asn Leu Lys Tyr Ser Val
Ile Val Thr Val His 130 135 140Thr Gly Asp Gln His Gln Val Gly Asn
Glu Thr Thr Glu His Gly Thr145 150 155 160Thr Ala Thr Ile Thr Pro
Gln Ala Pro Thr Ser Glu Ile Gln Leu Thr 165 170 175Asp Tyr Gly Ala
Leu Thr Leu Asp Cys Ser Pro Arg Thr Gly Leu Asp 180 185 190Phe Asn
Glu Met Val Leu Leu Thr Met Glu Lys Lys Ser Trp Leu Val 195 200
205His Lys Gln Trp Phe Leu Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala
210 215 220Ser Thr Ser Gln Glu Thr Trp Asn Arg Gln Asp Leu Leu Val
Thr Phe225 230 235 240Lys Thr Ala His Ala Lys Lys Gln Glu Val Val
Val Leu Gly Ser Gln 245 250 255Glu Gly Ala Met His Thr Ala Leu Thr
Gly Ala Thr Glu Ile Gln Thr 260 265 270Ser Gly Thr Thr Thr Ile Phe
Ala Gly His Leu Lys Cys Arg Leu Lys 275 280 285Met Asp Lys Leu Thr
Leu Lys Gly Met Ser Tyr Val Met Cys Thr Gly 290 295 300Ser Phe Lys
Leu Glu Lys Glu Val Ala Glu Thr Gln His Gly Thr Val305 310 315
320Leu Val Gln Val Lys Tyr Glu Gly Thr Asp Ala Pro Cys Lys Ile Pro
325 330 335Phe Ser Ser Gln Asp Glu Lys Gly Val Thr Gln Asn Gly Arg
Leu Ile 340 345 350Thr Ala Asn Pro Ile Val Thr Asp Lys Glu Lys Pro
Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe Gly Glu Ser Tyr Ile
Val Val Gly Ala Gly Glu 370 375 380Lys Ala Leu Lys Leu Ser Trp Phe
Lys Lys Gly Ser Ser Ile Gly Lys385 390 395 400Met Phe Glu Ala Thr
Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly 405 410 415Asp Thr Ala
Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Thr Ser Val 420 425 430Gly
Lys Leu Ile His Gln Ile Phe Gly Thr Ala Tyr Gly Val Leu Phe 435 440
445Ser Gly Val Ser Trp Thr Met Lys Ile Gly Ile Gly Ile Leu Leu Thr
450 455 460Trp Leu Gly Leu Asn Ser Arg Ser Thr Ser Leu Ser Met Thr
Cys Ile465 470 475 480Ala Val Gly Met Val Thr Leu Tyr Leu Gly Val
Met Val Gln Ala 485 490 49515495PRTArtificialChimeric Dengue virus
E glycoprotein sequence 15Met Arg Cys Val Gly Ile Gly Asn Arg Asp
Phe Val Glu Gly Leu Ser1 5 10 15Gly Ala Thr Trp Val Asp Val Val Leu
Glu His Gly Ser Cys Val Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr
Leu Asp Ile Glu Leu Leu Lys Thr 35 40 45Glu Val Thr Asn Pro Ala Val
Leu Arg Lys Leu Cys Ile Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr
Asp Ser Arg Cys Pro Thr Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu
Glu Gln Asp Thr Asn Phe Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg
Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu
Ile Thr Cys Ala Lys Phe Lys Cys Val Thr Lys Leu Glu Gly Lys 115 120
125Ile Val Gln Tyr Glu Asn Leu Lys Tyr Ser Val Ile Val Thr Val His
130 135 140Thr Gly Asp Gln His Gln Val Gly Asn Glu Ala Thr Glu His
Gly Val145 150 155 160Thr Ala Met Ile Thr Pro Gln Ser Pro Ser Val
Glu Val Lys Leu Pro 165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys
Ser Pro Arg Thr Gly Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu
Thr Met Lys Lys Lys Ser Trp Leu Val 195 200 205His Lys Gln Trp Phe
Leu Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser
Gln Glu Thr Trp Asn Arg Gln Asp Leu Leu Val Thr Phe225 230 235
240Lys Thr Ala His Ala Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln
245 250 255Glu Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile
Gln Thr 260 265 270Ser Gly Thr Thr Thr Ile Phe Ala Gly His Leu Lys
Cys Arg Leu Lys 275 280 285Met Asp Lys Leu Arg Leu Lys Gly Met Ser
Tyr Val Met Cys Thr Gly 290 295 300Ser Phe Lys Leu Glu Lys Glu Val
Ala Glu Thr Gln His Gly Thr Val305 310 315 320Leu Val Gln Val Lys
Tyr Glu Gly Thr Asp Ala Pro Cys Lys Ile Pro 325 330 335Phe Ser Ser
Gln Asp Glu Lys Gly Val Thr Gln Asn Gly Arg Leu Ile
340 345 350Thr Ala Asn Pro Ile Val Thr Asp Lys Glu Lys Pro Val Asn
Ile Glu 355 360 365Ala Glu Pro Pro Phe Gly Glu Ser Tyr Ile Val Val
Gly Ala Gly Glu 370 375 380Lys Ala Leu Lys Leu Ser Trp Phe Lys Lys
Gly Ser Ser Ile Gly Lys385 390 395 400Met Phe Glu Ala Thr Ala Arg
Gly Ala Arg Arg Met Ala Ile Leu Gly 405 410 415Asp Thr Ala Trp Asp
Phe Gly Ser Ile Gly Gly Val Phe Thr Ser Val 420 425 430Gly Lys Leu
Ile His Gln Ile Phe Gly Thr Ala Tyr Gly Val Leu Phe 435 440 445Ser
Gly Val Ser Trp Thr Met Lys Ile Gly Ile Gly Ile Leu Leu Thr 450 455
460Trp Leu Gly Leu Asn Ser Arg Ser Thr Ser Leu Ser Met Thr Cys
Ile465 470 475 480Ala Val Gly Met Val Thr Leu Tyr Leu Gly Val Met
Val Gln Ala 485 490 49516495PRTArtificialChimeric Dengue virus E
glycoprotein sequence 16Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe
Val Glu Gly Val Ser1 5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu
His Gly Ser Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu
Asp Phe Glu Leu Ile Lys Thr 35 40 45Glu Ala Lys Gln Pro Ala Thr Leu
Arg Lys Tyr Cys Ile Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu
Ser Arg Cys Pro Thr Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu
Gln Asp Lys Arg Phe Ile Cys Lys His Ser Met 85 90 95Val Asp Arg Gly
Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val
Thr Cys Ala Met Phe Thr Cys Lys Lys Asn Met Glu Gly Lys 115 120
125Val Val Gln Pro Glu Asn Leu Glu Tyr Thr Ile Val Ile Thr Pro His
130 135 140Ser Gly Glu Glu His Ala Val Gly Asn Asp Ala Gly Lys His
Gly Val145 150 155 160Thr Ala Met Ile Thr Pro Gln Ser Ser Ser Val
Glu Val Lys Leu Pro 165 170 175Asp Tyr Gly Glu Val Thr Met Glu Cys
Ser Pro Arg Thr Gly Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu
Gln Met Glu Asp Lys Ala Trp Leu Val 195 200 205His Arg Gln Trp Phe
Leu Asp Leu Pro Leu Pro Trp Leu Pro Gly Ala 210 215 220Asp Thr Gln
Glu Ser Asn Trp Ile Gln Lys Glu Thr Leu Val Thr Phe225 230 235
240Lys Asn Pro His Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln
245 250 255Glu Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile
Gln Met 260 265 270Ser Ser Gly Asn Leu Leu Phe Thr Gly His Leu Lys
Cys Arg Leu Arg 275 280 285Met Asp Lys Leu Arg Leu Lys Gly Met Ser
Tyr Ser Met Cys Thr Gly 290 295 300Lys Phe Lys Ile Val Lys Glu Ile
Ala Glu Thr Gln His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln
Tyr Glu Gly Asp Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile
Thr Asp Leu Glu Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr
Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360
365Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro
370 375 380Gly Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile
Gly Gln385 390 395 400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg
Met Ala Ile Leu Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu
Gly Gly Val Phe Thr Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val
Phe Gly Ala Ile Tyr Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp
Thr Met Lys Ile Leu Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly
Met Asn Ser Arg Ser Thr Ser Leu Ser Val Ser Leu Val465 470 475
480Leu Val Gly Val Val Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485
490 49517495PRTArtificialChimeric Dengue virus E glycoprotein
sequence 17Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly
Val Ser1 5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser
Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu
Leu Phe Lys Thr 35 40 45Glu Val Thr Asn Pro Ala Val Leu Arg Lys Tyr
Cys Ile Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys
Pro Thr Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu Gln Asp Lys
Arg Phe Val Cys Lys His Ser Met 85 90 95Val Asp Arg Gly Trp Gly Asn
Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val Thr Cys Ala
Met Phe Thr Cys Lys Lys Asn Met Glu Gly Lys 115 120 125Val Val Gln
Pro Glu Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Ser
Gly Glu Glu His Ala Val Gly Asn Asp Thr Thr Glu His Gly Thr145 150
155 160Thr Ala Thr Val Thr Pro Gln Ala Pro Thr Ser Glu Ile Gln Leu
Thr 165 170 175Asp Tyr Gly Ala Leu Thr Leu Glu Cys Ser Pro Arg Thr
Gly Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Gln Met Glu Asn
Lys Ala Trp Leu Val 195 200 205His Arg Gln Trp Phe Leu Asp Leu Pro
Leu Pro Trp Leu Pro Gly Ala 210 215 220Asp Thr Gln Gly Ser Asn Trp
Ile Gln Lys Glu Thr Leu Val Thr Phe225 230 235 240Lys Asn Pro His
Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly
Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265
270Ser Gly Thr Thr Thr Leu Phe Thr Gly His Leu Lys Cys Arg Leu Arg
275 280 285Met Asp Lys Leu Gln Leu Lys Gly Met Ser Tyr Ser Met Cys
Thr Gly 290 295 300Lys Phe Lys Val Val Lys Glu Ile Ala Glu Thr Gln
His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp
Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Met Asp Leu Glu
Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile
Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro
Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Asp Pro 370 375 380Gly
Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Gln385 390
395 400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg Met Ala Ile Leu
Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu Gly Gly Val Phe
Thr Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val Phe Gly Ala Ile
Tyr Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile
Leu Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly Met Asn Ser Arg
Ser Thr Ser Leu Ser Val Ser Leu Val465 470 475 480Leu Val Gly Val
Val Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
49518495PRTArtificialChimeric Dengue virus E glycoprotein sequence
18Met Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Phe
Lys Thr 35 40 45Thr Val Thr Asn Pro Ala Val Leu Arg Thr Tyr Cys Ile
Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr
Ile Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe
Ser Cys Ser Gly Lys Ile Thr Gly Asn 115 120 125Leu Val Gln Ile Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Asn Gly Asp
Thr His Ala Val Gly Asn Asp Thr Thr Glu His Gly Thr145 150 155
160Thr Ala Thr Ile Thr Pro Arg Ala Pro Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Ala Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly
Ile Asp 180 185 190Phe Asn Glu Met Ile Leu Met Lys Met Lys Lys Lys
Thr Trp Leu Val 195 200 205His Lys Gln Trp Phe Leu Asp Leu Pro Leu
Pro Trp Thr Ala Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp Asn
Tyr Lys Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala
Lys Arg Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Ser Ala Leu Ala Gly Ala Thr Glu Val Asp Thr 260 265 270Gly
Gly Thr Thr Thr Met Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280
285Met Glu Lys Leu Arg Ile Lys Gly Met Ser Tyr Thr Met Cys Ser Gly
290 295 300Lys Phe Ser Ile Asp Lys Glu Met Ala Glu Thr Gln His Gly
Thr Thr305 310 315 320Val Val Lys Val Lys Tyr Glu Gly Ala Gly Ala
Pro Cys Lys Val Pro 325 330 335Ile Glu Ile Arg Asp Val Asn Lys Glu
Lys Val Val Gly Arg Val Ile 340 345 350Ser Ser Thr Pro Leu Ala Glu
Asn Thr Asn Ser Val Thr Asn Ile Glu 355 360 365Leu Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Val Ile Gly Val Gly Asn 370 375 380Ser Ala Leu
Thr Leu His Trp Phe Arg Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly
405 410 415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr
Ser Leu 420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr
Thr Thr Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu
Ile Gly Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg Asn
Thr Ser Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly Ile
Thr Leu Phe Leu Gly Phe Thr Val Gln Ala 485 490
49519495PRTArtificialChimeric Dengue virus E glycoprotein sequence
19Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe
Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe
Lys Cys Leu Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Thr Thr Glu His Gly Thr145 150 155
160Ile Ala Thr Ile Thr Pro Gln Ala Pro Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Ala Leu Thr Leu Asp Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser Gln Glu Thr Trp Asn
Arg Gln Asp Leu Leu Val Thr Phe225 230 235 240Lys Thr Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Thr Leu Lys Gly Met Ser Tyr Val Met Cys Thr Gly
290 295 300Ser Phe Lys Leu Glu Lys Glu Val Ala Glu Thr Gln His Gly
Thr Val305 310 315 320Leu Val Gln Val Lys Tyr Glu Gly Thr Asp Ala
Pro Cys Lys Ile Pro 325 330 335Phe Ser Ser Gln Asp Glu Lys Gly Val
Thr Gln Asn Gly Arg Leu Ile 340 345 350Thr Ala Asn Pro Ile Val Thr
Asp Lys Glu Lys Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Glu Ser Tyr Ile Val Val Gly Ala Gly Glu 370 375 380Lys Ala Leu
Lys Leu Ser Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Thr
Ser Val 420 425 430Gly Lys Leu Ile His Gln Ile Phe Gly Thr Ala Tyr
Gly Val Leu Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Gly
Ile Gly Ile Leu Leu Thr 450 455 460Trp Leu Gly Leu Asn Ser Arg Ser
Thr Ser Leu Ser Met Thr Cys Ile465 470 475 480Ala Val Gly Met Val
Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49520495PRTArtificialChimeric Dengue virus E glycoprotein sequence
20Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu Leu Ile
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu Gln Asp Lys Arg Phe
Val Cys Lys His Ser Met 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val Thr Cys Ala Met Phe
Thr Cys Lys Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Pro Glu
Asn Leu Glu Tyr Thr Ile Val Val Thr Pro His 130 135 140Ser Gly Glu
Glu His Ala Val Gly Asn Asp Thr Gly Lys His Gly Lys145 150 155
160Glu Ile Lys Val Thr Pro Gln Ser Ser Ile Thr Glu Ala Glu Leu Thr
165 170 175Gly Tyr Gly Thr Val Thr Met Glu Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Thr Ala 210 215 220Asp Thr Gln Gly Pro Asn Trp Ile
Gln Lys Glu Thr Leu Val Thr Phe225 230 235 240Lys Asn Pro His Ala
Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Arg 275 280
285Met Asp Lys Leu Gln Leu Lys
Gly Met Ser Tyr Ser Met Cys Thr Gly 290 295 300Lys Phe Lys Val Val
Lys Glu Ile Ala Glu Thr Gln His Gly Thr Ile305 310 315 320Val Ile
Arg Val Gln Tyr Glu Gly Asp Gly Ser Pro Cys Lys Ile Pro 325 330
335Phe Glu Ile Met Asp Leu Glu Lys Arg His Val Leu Gly Arg Leu Ile
340 345 350Thr Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn
Ile Glu 355 360 365Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile Ile Ile
Gly Val Asp Pro 370 375 380Gly Gln Leu Lys Leu Asn Trp Phe Lys Lys
Gly Ser Ser Ile Gly Gln385 390 395 400Met Phe Glu Thr Thr Met Arg
Gly Ala Lys Arg Met Ala Ile Leu Gly 405 410 415Asp Thr Ala Trp Asp
Phe Gly Ser Leu Gly Gly Val Phe Thr Ser Ile 420 425 430Gly Lys Ala
Leu His Gln Val Phe Gly Ala Ile Tyr Gly Ala Ala Phe 435 440 445Ser
Gly Val Ser Trp Thr Met Lys Ile Leu Ile Gly Val Ile Ile Thr 450 455
460Trp Ile Gly Met Asn Ser Arg Ser Thr Ser Leu Ser Val Ser Leu
Val465 470 475 480Leu Val Gly Ile Val Thr Leu Tyr Leu Gly Val Met
Val Gln Ala 485 490 49521495PRTArtificialChimeric Dengue virus E
glycoprotein sequence 21Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe
Val Glu Gly Leu Ser1 5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu
His Gly Gly Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu
Asp Ile Glu Leu Gln Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu
Arg Lys Leu Cys Ile Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr Thr Asp
Ser Arg Cys Pro Thr Gln Gly Glu Ala65 70 75 80Val Leu Pro Glu Glu
Gln Asp Gln Asn Tyr Val Cys Lys His Thr Tyr 85 90 95Val Asp Arg Gly
Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Val
Thr Cys Ala Lys Phe Gln Cys Leu Glu Pro Ile Glu Gly Lys 115 120
125Val Val Gln Tyr Glu Asn Leu Lys Tyr Thr Val Ile Ile Thr Val His
130 135 140Thr Gly Asp Gln His Gln Val Gly Asn Glu Ala Ser Asn Gln
Gly Val145 150 155 160Thr Ala Met Ile Thr Pro Gln Ser Ser Ser Val
Glu Val Lys Leu Pro 165 170 175Asp Tyr Gly Glu Leu Gly Leu Glu Cys
Ser Pro Arg Thr Gly Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu
Thr Met Lys Asn Lys Ala Trp Met Val 195 200 205His Arg Gln Trp Phe
Phe Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala 210 215 220Thr Thr Glu
Thr Pro Thr Trp Asn Arg Lys Glu Leu Leu Val Thr Phe225 230 235
240Lys Asn Ala His Ala Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln
245 250 255Glu Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile
Gln Asn 260 265 270Ser Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys
Cys Arg Leu Lys 275 280 285Met Asp Lys Leu Arg Leu Lys Gly Met Ser
Tyr Ala Met Cys Thr Asn 290 295 300Thr Phe Val Leu Lys Lys Glu Val
Ser Glu Thr Gln His Gly Thr Ile305 310 315 320Leu Ile Lys Val Glu
Tyr Lys Gly Glu Asp Ala Pro Cys Lys Ile Pro 325 330 335Phe Ser Thr
Glu Asp Gly Gln Gly Lys Ala His Asn Gly Arg Leu Ile 340 345 350Thr
Ala Asn Pro Val Val Thr Lys Lys Glu Glu Pro Val Asn Ile Glu 355 360
365Ala Glu Pro Pro Phe Gly Glu Ser Asn Ile Val Ile Gly Ile Gly Asp
370 375 380Asn Ala Leu Lys Ile Asn Trp Tyr Lys Lys Gly Ser Ser Ile
Gly Lys385 390 395 400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg
Met Ala Ile Leu Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Val
Gly Gly Val Leu Asn Ser Leu 420 425 430Gly Lys Met Val His Gln Ile
Phe Gly Ser Ala Tyr Thr Ala Leu Phe 435 440 445Ser Gly Val Ser Trp
Val Met Lys Ile Gly Ile Gly Val Leu Leu Thr 450 455 460Trp Ile Gly
Leu Asn Ser Lys Asn Thr Ser Met Ser Phe Ser Cys Ile465 470 475
480Ala Ile Gly Ile Ile Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485
490 49522495PRTArtificialChimeric Dengue virus E glycoprotein
sequence 22Met Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly
Val Ser1 5 10 15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly
Cys Val Thr 20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu
Leu Thr Lys Thr 35 40 45Thr Ala Lys Glu Val Ala Leu Leu Arg Thr Tyr
Cys Ile Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys
Pro Thr Gln Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln
Gln Tyr Ile Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn
Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala
Lys Phe Ser Cys Ser Gly Lys Ile Thr Gly Asn 115 120 125Leu Val Gln
Ile Glu Asn Leu Glu Tyr Thr Val Val Val Thr Val His 130 135 140Asn
Gly Asp Thr His Ala Val Gly Asn Asp Thr Ser Asn His Gly Val145 150
155 160Thr Ala Thr Ile Thr Pro Arg Ser Pro Ser Val Glu Val Lys Leu
Pro 165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser
Gly Ile Asp 180 185 190Phe Asn Glu Met Ile Leu Met Lys Met Lys Lys
Lys Thr Trp Leu Val 195 200 205His Lys Gln Trp Phe Leu Asp Leu Pro
Leu Pro Trp Thr Ala Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp
Asn Tyr Lys Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His
Ala Lys Arg Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly
Ala Met His Ser Ala Leu Ala Gly Ala Thr Glu Val Asp Ser 260 265
270Gly Asp Gly Asn His Met Phe Ala Gly His Leu Lys Cys Lys Val Arg
275 280 285Met Glu Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys
Thr Gly 290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln
His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp
Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu
Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile
Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro
Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly
Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390
395 400Met Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu
Gly 405 410 415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe
Thr Ser Leu 420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val
Tyr Thr Thr Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile
Leu Ile Gly Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg
Asn Thr Ser Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly
Ile Thr Leu Phe Leu Gly Phe Thr Val Gln Ala 485 490
49523495PRTArtificialChimeric Dengue virus E glycoprotein sequence
23Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu
Lys Thr 35 40 45Glu Val Thr Asn Pro Ala Val Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe
Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe
Lys Cys Val Thr Lys Leu Glu Gly Lys 115 120 125Ile Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Thr Thr Glu His Gly Thr145 150 155
160Thr Ala Thr Ile Thr Pro Gln Ala Pro Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Ala Leu Thr Leu Asp Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Thr Met Glu Lys Lys
Ser Trp Leu Val 195 200 205His Lys Gln Trp Phe Leu Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser Gln Glu Thr Trp Asn
Arg Gln Asp Leu Leu Val Thr Phe225 230 235 240Lys Thr Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265 270Ser
Gly Thr Thr Thr Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Thr Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Thr
Ser Val 420 425 430Gly Lys Leu Ile His Gln Ile Phe Gly Thr Ala Tyr
Gly Val Leu Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Gly
Ile Gly Ile Leu Leu Thr 450 455 460Trp Leu Gly Leu Asn Ser Arg Ser
Thr Ser Leu Ser Met Thr Cys Ile465 470 475 480Ala Val Gly Met Val
Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49524493PRTArtificialChimeric Dengue virus E glycoprotein sequence
24Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Ile Glu Leu Gln
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Val Leu Pro Glu Glu Gln Asp Gln Asn Tyr
Val Cys Lys His Thr Tyr 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Val Thr Cys Ala Lys Phe
Gln Cys Leu Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Thr Val Ile Ile Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Thr Gln Gly Val Thr Ala145 150 155
160Glu Ile Thr Pro Gln Ala Ser Thr Thr Glu Ala Ile Leu Pro Glu Tyr
165 170 175Gly Thr Leu Gly Leu Glu Cys Ser Pro Arg Thr Gly Leu Asp
Phe Asn 180 185 190Glu Met Ile Leu Leu Thr Met Lys Asn Lys Ala Trp
Met Val His Arg 195 200 205Gln Trp Phe Phe Asp Leu Pro Leu Pro Trp
Thr Ser Gly Ala Thr Thr 210 215 220Glu Thr Pro Thr Trp Asn Arg Lys
Glu Leu Leu Val Thr Phe Lys Asn225 230 235 240Ala His Ala Lys Lys
Gln Glu Val Val Val Leu Gly Ser Gln Glu Gly 245 250 255Ala Met His
Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn Ser Gly 260 265 270Gly
Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys Met Asp 275 280
285Lys Leu Glu Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly Lys Phe
290 295 300Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly Thr Ile
Val Ile305 310 315 320Arg Val Gln Tyr Glu Gly Asp Gly Ser Pro Cys
Lys Ile Pro Phe Glu 325 330 335Ile Thr Asp Leu Glu Lys Arg His Val
Leu Gly Arg Leu Ile Thr Val 340 345 350Asn Pro Ile Val Thr Glu Lys
Asp Ser Pro Val Asn Ile Glu Ala Glu 355 360 365Pro Pro Phe Gly Asp
Ser Tyr Ile Ile Ile Gly Val Glu Pro Gly Gln 370 375 380Leu Lys Leu
Asn Trp Tyr Lys Lys Gly Ser Ser Ile Gly Lys Met Phe385 390 395
400Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly Asp Thr
405 410 415Ala Trp Asp Phe Gly Ser Val Gly Gly Val Leu Asn Ser Leu
Gly Lys 420 425 430Met Val His Gln Ile Phe Gly Ser Ala Tyr Thr Ala
Leu Phe Ser Gly 435 440 445Val Ser Trp Val Met Lys Ile Gly Ile Gly
Val Leu Leu Thr Trp Ile 450 455 460Gly Leu Asn Ser Lys Asn Thr Ser
Met Ser Phe Ser Cys Ile Ala Ile465 470 475 480Gly Ile Ile Thr Leu
Tyr Leu Gly Ala Val Val Gln Ala 485 49025495PRTArtificialChimeric
Dengue virus E glycoprotein sequence 25Met Arg Cys Ile Gly Ile Ser
Asn Arg Asp Phe Val Glu Gly Val Ser1 5 10 15Gly Gly Ser Trp Val Asp
Ile Val Leu Glu His Gly Ser Cys Val Thr 20 25 30Thr Met Ala Lys Asn
Lys Pro Thr Leu Asp Phe Glu Leu Phe Lys Thr 35 40 45Glu Val Thr Gln
Leu Ala Thr Leu Arg Lys Leu Cys Ile Glu Ala Lys 50 55 60Leu Thr Asn
Thr Thr Thr Glu Ser Arg Cys Pro Thr Gln Gly Glu Pro65 70 75 80Ser
Leu Asn Glu Glu Gln Asp Lys Arg Phe Val Cys Lys His Ser Met 85 90
95Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Gly
100 105 110Ile Val Thr Cys Ala Met Phe Thr Cys Lys Lys Pro Ile Glu
Gly Lys 115 120 125Val Val Gln Pro Glu Asn Leu Lys Tyr Thr Ile Ile
Val Thr Val His 130 135 140Ser Gly Glu Glu His Ala Val Gly Asn Asp
Thr Thr Glu His Gly Thr145 150 155 160Thr Ala Thr Val Thr Pro Gln
Ser Ser Thr Ser Glu Ile Gln Leu Thr 165 170 175Asp Tyr Gly Thr Val
Thr Met Glu Cys Ser Pro Arg Thr Gly Leu Asp 180 185 190Phe Asn Glu
Met Ile Leu Leu Thr Met Lys Asn Lys Ala Trp Met Val 195 200 205His
Arg Gln Trp Phe Phe Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala 210 215
220Asp Thr Gln Gly Ser Asn Trp Ile Gln Lys Glu Thr Leu Val Thr
Phe225 230 235
240Lys Asn Pro His Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln
245 250 255Glu Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile
Gln Thr 260 265 270Ser Ser Thr Thr Thr Ile Phe Ala Gly His Leu Lys
Cys Arg Leu Arg 275 280 285Met Asp Lys Leu Gln Leu Lys Gly Met Ser
Tyr Ser Met Cys Thr Gly 290 295 300Lys Phe Lys Val Val Lys Glu Ile
Ala Glu Thr Gln His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln
Tyr Glu Gly Asp Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile
Met Asp Leu Glu Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr
Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360
365Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Asp Pro
370 375 380Gly Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile
Gly Gln385 390 395 400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg
Met Ala Ile Leu Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu
Gly Gly Val Phe Thr Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val
Phe Gly Ala Ile Tyr Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp
Thr Met Lys Ile Leu Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly
Met Asn Ser Arg Ser Thr Ser Leu Ser Val Ser Leu Val465 470 475
480Leu Val Gly Val Val Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485
490 49526495PRTArtificialChimeric Dengue virus E glycoprotein
sequence 26Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly
Val Ser1 5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser
Cys Val Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu
Leu Phe Lys Thr 35 40 45Glu Val Thr Gln Pro Ala Thr Leu Arg Lys Tyr
Cys Ile Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys
Pro Thr Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu Gln Asp Lys
Arg Phe Val Cys Lys His Ser Met 85 90 95Val Asp Arg Gly Trp Gly Asn
Gly Cys Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val Thr Cys Ala
Met Phe Thr Cys Lys Lys Asn Met Glu Gly Lys 115 120 125Val Val Gln
Pro Glu Asn Leu Lys Tyr Thr Ile Ile Val Thr Val His 130 135 140Ser
Gly Glu Glu His Ala Val Gly Asn Asp Ala Thr Glu His Gly Val145 150
155 160Thr Ala Met Val Thr Pro Gln Ser Ser Thr Val Glu Val Lys Leu
Pro 165 170 175Asp Tyr Gly Glu Val Thr Met Glu Cys Ser Pro Arg Thr
Gly Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Gln Met Glu Asn
Lys Ala Trp Leu Val 195 200 205His Arg Gln Trp Phe Leu Asp Leu Pro
Leu Pro Trp Leu Pro Gly Ala 210 215 220Asp Thr Gln Gly Ser Asn Trp
Ile Gln Lys Glu Thr Leu Val Thr Phe225 230 235 240Lys Asn Pro His
Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly
Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265
270Ser Gly Thr Thr Thr Leu Phe Thr Gly His Leu Lys Cys Arg Leu Arg
275 280 285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys
Thr Gly 290 295 300Lys Phe Lys Val Val Lys Glu Ile Ala Glu Thr Gln
His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp
Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Met Asp Leu Glu
Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile
Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro
Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Asp Pro 370 375 380Gly
Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Gln385 390
395 400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg Met Ala Ile Leu
Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu Gly Gly Val Phe
Thr Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val Phe Gly Ala Ile
Tyr Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile
Leu Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly Met Asn Ser Arg
Ser Thr Ser Leu Ser Val Ser Leu Val465 470 475 480Leu Val Gly Val
Val Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
49527495PRTArtificialChimeric Dengue virus E glycoprotein sequence
27Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu Leu Ile
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu Gln Asp Lys Arg Phe
Val Cys Lys His Ser Met 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val Thr Cys Ala Met Phe
Thr Cys Lys Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Pro Glu
Asn Leu Glu Tyr Thr Ile Val Val Thr Pro His 130 135 140Ser Gly Glu
Glu His Ala Val Gly Asn Asp Ala Gly Lys His Gly Val145 150 155
160Thr Ala Met Val Thr Pro Gln Ser Ser Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Val Thr Met Glu Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Thr Ala 210 215 220Asp Thr Gln Gly Pro Asn Trp Ile
Gln Lys Glu Thr Leu Val Thr Phe225 230 235 240Lys Asn Pro His Ala
Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Arg 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Val Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Met Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Asp Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Gln385 390 395
400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu Gly Gly Val Phe Thr
Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val Phe Gly Ala Ile Tyr
Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Leu
Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly Met Asn Ser Arg Ser
Thr Ser Leu Ser Val Ser Leu Val465 470 475 480Leu Val Gly Ile Val
Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49528495PRTArtificialChimeric Dengue virus E glycoprotein sequence
28Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu Leu Phe
Lys Thr 35 40 45Glu Val Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Ser Leu Asn Glu Glu Gln Asp Lys Arg Phe
Val Cys Lys His Ser Met 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Ile Val Thr Cys Ala Met Phe
Thr Cys Lys Lys Pro Ile Glu Gly Lys 115 120 125Val Val Gln Pro Glu
Asn Leu Lys Tyr Thr Ile Ile Val Thr Val His 130 135 140Ser Gly Glu
Glu His Ala Val Gly Asn Asp Ala Thr Glu His Gly Val145 150 155
160Thr Ala Met Val Thr Pro Gln Ala Ser Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Val Thr Met Glu Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Asp Thr Gln Gly Ser Asn Trp Ile
Gln Lys Glu Thr Leu Val Thr Phe225 230 235 240Lys Asn Pro His Ala
Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265 270Ser
Ser Thr Thr Thr Ile Phe Ala Gly His Leu Lys Cys Arg Leu Arg 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Val Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Met Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Asp Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Gln385 390 395
400Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Leu Gly Gly Val Phe Thr
Ser Ile 420 425 430Gly Lys Ala Leu His Gln Val Phe Gly Ala Ile Tyr
Gly Ala Ala Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Leu
Ile Gly Val Ile Ile Thr 450 455 460Trp Ile Gly Met Asn Ser Arg Ser
Thr Ser Leu Ser Val Ser Leu Val465 470 475 480Leu Val Gly Val Val
Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
49529495PRTArtificialChimeric Dengue virus E glycoprotein sequence
29Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe
Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe
Lys Cys Val Thr Lys Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Ala Thr Glu His Gly Val145 150 155
160Thr Ala Met Ile Thr Pro Gln Ser Pro Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Leu Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser Gln Glu Thr Trp Asn
Arg Gln Asp Leu Leu Val Thr Phe225 230 235 240Lys Thr Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Val Met Cys Thr Gly
290 295 300Ser Phe Lys Leu Glu Lys Glu Val Ala Glu Thr Gln His Gly
Thr Val305 310 315 320Leu Val Gln Val Lys Tyr Glu Gly Thr Asp Ala
Pro Cys Lys Ile Pro 325 330 335Phe Ser Ser Gln Asp Glu Lys Gly Val
Thr Gln Asn Gly Arg Leu Ile 340 345 350Thr Ala Asn Pro Ile Val Thr
Asp Lys Glu Lys Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Glu Ser Tyr Ile Val Val Gly Ala Gly Glu 370 375 380Lys Ala Leu
Lys Leu Ser Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Thr
Ser Val 420 425 430Gly Lys Leu Ile His Gln Ile Phe Gly Thr Ala Tyr
Gly Val Leu Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Gly
Ile Gly Ile Leu Leu Thr 450 455 460Trp Leu Gly Leu Asn Ser Arg Ser
Thr Ser Leu Ser Met Thr Cys Ile465 470 475 480Ala Val Gly Met Val
Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49530495PRTArtificialChimeric Dengue virus E glycoprotein sequence
30Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe
Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe
Lys Cys Val Thr Lys Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Thr Thr Glu His Gly Thr145 150 155
160Thr Ala Thr Ile Thr Pro Gln Ala Pro Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Ala Leu Thr Leu Asp Cys Ser Pro Arg
Thr Gly Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys
Asn Lys Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Leu Asp Leu
Pro Leu Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser Gln Glu Thr
Trp Asn Arg Gln Asp Leu Leu Val Thr Phe225 230 235 240Lys Thr Ala
His Ala Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu
Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265
270Ser Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys
275 280 285Met Asp Lys Leu Thr Leu Lys Gly Met Ser Tyr Ser Met Cys
Thr Gly 290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln
His Gly Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp
Gly Ser Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu
Lys Arg His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile
Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro
Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly
Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390
395 400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu
Gly 405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe
Thr Ser Val 420 425 430Gly Lys Leu Ile His Gln Ile Phe Gly Thr Ala
Tyr Gly Val Leu Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile
Gly Ile Gly Ile Leu Leu Thr 450 455 460Trp Leu Gly Leu Asn Ser Arg
Ser Thr Ser Leu Ser Met Thr Cys Ile465 470 475 480Ala Val Gly Met
Val Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49531495PRTArtificialChimeric Dengue virus E glycoprotein sequence
31Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu
Lys Thr 35 40 45Glu Val Thr Asn Pro Ala Val Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe
Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe
Lys Cys Val Thr Lys Leu Glu Gly Lys 115 120 125Ile Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Ala Thr Glu His Gly Val145 150 155
160Thr Ala Met Ile Thr Pro Gln Ser Pro Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Val Leu Leu Thr Met Glu Lys Lys
Ser Trp Leu Val 195 200 205His Lys Gln Trp Phe Leu Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser Gln Glu Thr Trp Asn
Arg Gln Asp Leu Leu Val Thr Phe225 230 235 240Lys Thr Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265 270Ser
Gly Thr Thr Thr Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Thr
Ser Val 420 425 430Gly Lys Leu Ile His Gln Ile Phe Gly Thr Ala Tyr
Gly Val Leu Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Gly
Ile Gly Ile Leu Leu Thr 450 455 460Trp Leu Gly Leu Asn Ser Arg Ser
Thr Ser Leu Ser Met Thr Cys Ile465 470 475 480Ala Val Gly Met Val
Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49532495PRTArtificialChimeric Dengue virus E glycoprotein sequence
32Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Ser Cys Val
Thr 20 25 30Thr Met Ala Lys Asp Lys Pro Thr Leu Asp Ile Glu Leu Leu
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Lys 50 55 60Ile Ser Asn Thr Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Thr Leu Val Glu Glu Gln Asp Thr Asn Phe
Val Cys Arg Arg Thr Phe 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Ile Thr Cys Ala Lys Phe
Lys Cys Val Thr Lys Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Ala Thr Glu His Gly Val145 150 155
160Thr Ala Met Ile Thr Pro Gln Ser Pro Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Leu Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Ser Thr Ser Gln Glu Thr Trp Asn
Arg Gln Asp Leu Leu Val Thr Phe225 230 235 240Lys Thr Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Thr
Ser Val 420 425 430Gly Lys Leu Ile His Gln Ile Phe Gly Thr Ala Tyr
Gly Val Leu Phe 435 440 445Ser Gly Val Ser Trp Thr Met Lys Ile Gly
Ile Gly Ile Leu Leu Thr 450 455 460Trp Leu Gly Leu Asn Ser Arg Ser
Thr Ser Leu Ser Met Thr Cys Ile465 470 475 480Ala Val Gly Met Val
Thr Leu Tyr Leu Gly Val Met Val Gln Ala 485 490
49533495PRTArtificialChimeric Dengue virus E glycoprotein sequence
33Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Ile Glu Leu Phe
Lys Thr 35 40 45Glu Val Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Val Leu Pro Glu Glu Gln Asp Gln Asn Tyr
Val Cys Lys His Thr Tyr 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Val Thr Cys Ala Lys Phe
Gln Cys Leu Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Ser Val Ile Ile Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Ala Thr Glu His Gly Val145 150 155
160Thr Ala Met Ile Thr Pro Gln Ser Ser Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Leu Gly Leu Glu Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Thr Thr Glu Thr Pro Thr Trp Asn
Arg Lys Glu Leu Leu Val Thr Phe225 230 235 240Lys Asn Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Thr Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ala Met Cys Thr Asn
290 295 300Thr Phe Val Leu Lys Lys Glu Val Ser Glu Thr Gln His Gly
Thr Ile305 310 315 320Leu Ile Lys Val Glu Tyr Lys Gly Glu Asp Ala
Pro Cys Lys Ile Pro 325 330 335Phe Ser Thr Glu Asp Gly Gln Gly Lys
Ala His Asn Gly Arg Leu Ile 340 345 350Thr Ala Asn Pro Val Val Thr
Lys Lys Glu Glu Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Glu Ser Asn Ile Val Ile Gly Ile Gly Asp 370 375 380Asn Ala Leu
Lys Ile Asn Trp Tyr Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Val Leu Asn
Ser Leu 420 425 430Gly Lys Met Val His Gln Ile Phe Gly Ser Ala Tyr
Thr Ala Leu Phe 435 440 445Ser Gly Val Ser Trp Val Met Lys Ile Gly
Ile Gly Val Leu Leu Thr 450 455 460Trp Ile Gly Leu Asn Ser Lys Asn
Thr Ser Met Ser Phe Ser Cys Ile465 470 475 480Ala Ile Gly Ile Ile
Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
49534495PRTArtificialChimeric Dengue virus E glycoprotein sequence
34Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Ile Glu Leu Phe
Lys Thr 35 40 45Glu Val Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Val Leu Pro Glu Glu Gln Asp Gln Asn Tyr
Val Cys Lys His Thr Tyr 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Val Thr Cys Ala Lys Phe
Gln Cys Leu Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Thr Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Thr Thr Glu His Gly Thr145 150 155
160Thr Ala Thr Ile Thr Pro Gln Ala Ser Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Thr Leu Gly Leu Glu Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Thr Thr Glu Thr Pro Thr Trp Asn
Arg Lys Glu Leu Leu Val Thr Phe225 230 235 240Lys Asn Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265 270Ser
Gly Thr Thr Thr Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Glu Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Tyr Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Val Leu Asn
Ser Leu 420 425 430Gly Lys Met Val His Gln Ile Phe Gly Ser Ala Tyr
Thr Ala Leu Phe 435 440 445Ser Gly Val Ser Trp Val Met Lys Ile Gly
Ile Gly Val Leu Leu Thr 450 455 460Trp Ile Gly Leu Asn Ser Lys Asn
Thr Ser Met Ser Phe Ser Cys Ile465 470 475 480Ala Ile Gly Ile Ile
Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
49535493PRTArtificialChimeric Dengue virus E glycoprotein sequence
35Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Ile Glu Leu Gln
Lys Thr 35 40 45Glu Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Val Leu Pro Glu Glu Gln Asp Gln Asn Tyr
Val Cys Lys His Thr Tyr 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Val Thr Cys Ala Lys Phe
Gln Cys Leu Glu Pro Ile Glu Gly Lys 115 120
125Val Val Gln Tyr Glu Asn Leu Lys Tyr Thr Val Ile Ile Thr Val His
130 135 140Thr Gly Asp Gln His Gln Val Gly Asn Glu Ala Gln Gly Val
Thr Ala145 150 155 160Met Ile Thr Pro Gln Ser Ser Ser Val Glu Val
Lys Leu Pro Asp Tyr 165 170 175Gly Glu Leu Gly Leu Glu Cys Ser Pro
Arg Thr Gly Leu Asp Phe Asn 180 185 190Glu Met Ile Leu Leu Thr Met
Lys Asn Lys Ala Trp Met Val His Arg 195 200 205Gln Trp Phe Phe Asp
Leu Pro Leu Pro Trp Thr Ser Gly Ala Thr Thr 210 215 220Glu Thr Pro
Thr Trp Asn Arg Lys Glu Leu Leu Val Thr Phe Lys Asn225 230 235
240Ala His Ala Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln Glu Gly
245 250 255Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Asn
Ser Gly 260 265 270Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Arg
Leu Lys Met Asp 275 280 285Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser
Met Cys Thr Gly Lys Phe 290 295 300Lys Ile Val Lys Glu Ile Ala Glu
Thr Gln His Gly Thr Ile Val Ile305 310 315 320Arg Val Gln Tyr Glu
Gly Asp Gly Ser Pro Cys Lys Ile Pro Phe Glu 325 330 335Ile Thr Asp
Leu Glu Lys Arg His Val Leu Gly Arg Leu Ile Thr Val 340 345 350Asn
Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu Ala Glu 355 360
365Pro Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro Gly Gln
370 375 380Leu Lys Leu Asn Trp Tyr Lys Lys Gly Ser Ser Ile Gly Lys
Met Phe385 390 395 400Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala
Ile Leu Gly Asp Thr 405 410 415Ala Trp Asp Phe Gly Ser Val Gly Gly
Val Leu Asn Ser Leu Gly Lys 420 425 430Met Val His Gln Ile Phe Gly
Ser Ala Tyr Thr Ala Leu Phe Ser Gly 435 440 445Val Ser Trp Val Met
Lys Ile Gly Ile Gly Val Leu Leu Thr Trp Ile 450 455 460Gly Leu Asn
Ser Lys Asn Thr Ser Met Ser Phe Ser Cys Ile Ala Ile465 470 475
480Gly Ile Ile Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485
49036495PRTArtificialChimeric Dengue virus E glycoprotein sequence
36Met Arg Cys Val Gly Ile Gly Asn Arg Asp Phe Val Glu Gly Leu Ser1
5 10 15Gly Ala Thr Trp Val Asp Val Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Ile Glu Leu Phe
Lys Thr 35 40 45Glu Val Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Gly Lys 50 55 60Ile Thr Asn Ile Thr Thr Asp Ser Arg Cys Pro Thr
Gln Gly Glu Ala65 70 75 80Val Leu Pro Glu Glu Gln Asp Gln Asn Tyr
Val Cys Lys His Thr Tyr 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Ser 100 105 110Leu Val Thr Cys Ala Lys Phe
Gln Cys Leu Glu Pro Ile Glu Gly Lys 115 120 125Val Val Gln Tyr Glu
Asn Leu Lys Tyr Thr Val Ile Val Thr Val His 130 135 140Thr Gly Asp
Gln His Gln Val Gly Asn Glu Ala Thr Glu His Gly Val145 150 155
160Thr Ala Met Ile Thr Pro Gln Ser Ser Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Leu Gly Leu Glu Cys Ser Pro Arg Thr Gly
Leu Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Asn Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Thr Thr Glu Thr Pro Thr Trp Asn
Arg Lys Glu Leu Leu Val Thr Phe225 230 235 240Lys Asn Ala His Ala
Lys Lys Gln Glu Val Val Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Thr 260 265 270Ser
Gly Thr Thr Thr Ile Phe Ala Gly His Leu Lys Cys Arg Leu Lys 275 280
285Met Asp Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Tyr Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ala Thr Ala Arg Gly Ala Arg Arg Met Ala Ile Leu Gly
405 410 415Asp Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Val Leu Asn
Ser Leu 420 425 430Gly Lys Met Val His Gln Ile Phe Gly Ser Ala Tyr
Thr Ala Leu Phe 435 440 445Ser Gly Val Ser Trp Val Met Lys Ile Gly
Ile Gly Val Leu Leu Thr 450 455 460Trp Ile Gly Leu Asn Ser Lys Asn
Thr Ser Met Ser Phe Ser Cys Ile465 470 475 480Ala Ile Gly Ile Ile
Thr Leu Tyr Leu Gly Ala Val Val Gln Ala 485 490
49537495PRTArtificialChimeric Dengue virus E glycoprotein sequence
37Met Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Phe
Lys Thr 35 40 45Thr Val Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr
Ile Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe
Ser Cys Ser Gly Pro Ile Glu Gly Lys 115 120 125Val Val Gln Ile Glu
Asn Leu Lys Tyr Thr Val Ile Val Thr Val His 130 135 140Asn Gly Asp
Thr His Ala Val Gly Asn Asp Thr Thr Glu His Gly Thr145 150 155
160Thr Ala Thr Ile Thr Pro Arg Ser Pro Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly
Ile Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Lys Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp Asn
Tyr Lys Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala
Lys Arg Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Ser Ala Leu Ala Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280
285Met Glu Lys Leu Arg Ile Lys Gly Met Ser Tyr Thr Met Cys Ser Gly
290 295 300Lys Phe Ser Ile Asp Lys Glu Met Ala Glu Thr Gln His Gly
Thr Thr305 310 315 320Val Val Lys Val Lys Tyr Glu Gly Ala Gly Ala
Pro Cys Lys Val Pro 325 330 335Ile Glu Ile Arg Asp Val Asn Lys Glu
Lys Val Val Gly Arg Val Ile 340 345 350Ser Ser Thr Pro Leu Ala Glu
Asn Thr Asn Ser Val Thr Asn Ile Glu 355 360 365Leu Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Val Ile Gly Val Gly Asn 370 375 380Ser Ala Leu
Thr Leu His Trp Phe Arg Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly
405 410 415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr
Ser Leu 420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr
Thr Thr Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu
Ile Gly Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg Asn
Thr Ser Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly Ile
Thr Leu Phe Leu Gly Phe Thr Val Gln Ala 485 490
49538495PRTArtificialChimeric Dengue virus E glycoprotein sequence
38Met Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Phe
Lys Thr 35 40 45Thr Val Thr Glu Val Ala Leu Leu Arg Thr Tyr Cys Ile
Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr
Ile Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe
Ser Cys Ser Gly Lys Ile Thr Gly Asn 115 120 125Leu Val Gln Ile Glu
Asn Leu Lys Tyr Thr Val Ile Val Thr Val His 130 135 140Asn Gly Asp
Thr His Ala Val Gly Asn Asp Thr Thr Glu His Gly Thr145 150 155
160Thr Ala Thr Ile Thr Pro Arg Ser Pro Thr Ser Glu Ile Gln Leu Thr
165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly
Ile Asp 180 185 190Phe Asn Glu Met Ile Leu Met Lys Met Lys Lys Lys
Thr Trp Leu Val 195 200 205His Lys Gln Trp Phe Leu Asp Leu Pro Leu
Pro Trp Thr Ala Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp Asn
Tyr Lys Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala
Lys Arg Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Ser Ala Leu Ala Gly Ala Thr Glu Val Asp Ser 260 265 270Gly
Gly Thr Thr Thr Met Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280
285Met Glu Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly
405 410 415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr
Ser Leu 420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr
Thr Thr Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu
Ile Gly Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg Asn
Thr Ser Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly Ile
Thr Leu Phe Leu Gly Phe Thr Val Gln Ala 485 490
49539495PRTArtificialChimeric Dengue virus E glycoprotein sequence
39Met Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Thr
Lys Thr 35 40 45Thr Ala Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75 80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr
Ile Cys Arg Arg Asp Val 85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys
Gly Leu Phe Gly Lys Gly Gly 100 105 110Val Val Thr Cys Ala Lys Phe
Ser Cys Ser Gly Pro Ile Glu Gly Lys 115 120 125Val Val Gln Ile Glu
Asn Leu Glu Tyr Thr Val Val Val Thr Val His 130 135 140Asn Gly Asp
Thr His Ala Val Gly Asn Asp Thr Ser Asn His Gly Val145 150 155
160Thr Ala Thr Ile Thr Pro Arg Ser Pro Ser Val Glu Val Lys Leu Pro
165 170 175Asp Tyr Gly Glu Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly
Ile Asp 180 185 190Phe Asn Glu Met Ile Leu Leu Thr Met Lys Lys Lys
Ala Trp Met Val 195 200 205His Arg Gln Trp Phe Phe Asp Leu Pro Leu
Pro Trp Thr Ser Gly Ala 210 215 220Asp Thr Ser Glu Val His Trp Asn
Tyr Lys Glu Arg Met Val Thr Phe225 230 235 240Lys Val Pro His Ala
Lys Arg Gln Asp Val Thr Val Leu Gly Ser Gln 245 250 255Glu Gly Ala
Met His Ser Ala Leu Ala Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser
Gly Gly Thr Ser Ile Phe Ala Gly His Leu Lys Cys Lys Val Arg 275 280
285Met Glu Lys Leu Arg Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly
Thr Ile305 310 315 320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser
Pro Cys Lys Ile Pro 325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg
His Val Leu Gly Arg Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr
Glu Lys Asp Ser Pro Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe
Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu
Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Lys385 390 395
400Met Phe Glu Ser Thr Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly
405 410 415Glu Thr Ala Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr
Ser Leu 420 425 430Gly Lys Ala Val His Gln Val Phe Gly Ser Val Tyr
Thr Thr Met Phe 435 440 445Gly Gly Val Ser Trp Met Ile Arg Ile Leu
Ile Gly Phe Leu Val Leu 450 455 460Trp Ile Gly Thr Asn Ser Arg Asn
Thr Ser Met Ala Met Thr Cys Ile465 470 475 480Ala Val Gly Gly Ile
Thr Leu Phe Leu Gly Phe Thr Val Gln Ala 485 490
49540495PRTArtificialChimeric Dengue virus E glycoprotein sequence
40Met Arg Cys Val Gly Val Gly Asn Arg Asp Phe Val Glu Gly Val Ser1
5 10 15Gly Gly Ala Trp Val Asp Leu Val Leu Glu His Gly Gly Cys Val
Thr 20 25 30Thr Met Ala Gln Gly Lys Pro Thr Leu Asp Phe Glu Leu Phe
Lys Thr 35 40 45Thr Val Thr Gln Leu Ala Thr Leu Arg Lys Leu Cys Ile
Glu Ala Ser 50 55 60Ile Ser Asn Ile Thr Thr Ala Thr Arg Cys Pro Thr
Gln Gly Glu Pro65 70 75
80Tyr Leu Lys Glu Glu Gln Asp Gln Gln Tyr Ile Cys Arg Arg Asp Val
85 90 95Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly
Gly 100 105 110Val Val Thr Cys Ala Lys Phe Ser Cys Ser Gly Pro Ile
Glu Gly Lys 115 120 125Val Val Gln Ile Glu Asn Leu Lys Tyr Thr Val
Ile Val Thr Val His 130 135 140Asn Gly Asp Thr His Ala Val Gly Asn
Asp Thr Thr Glu His Gly Thr145 150 155 160Thr Ala Thr Ile Thr Pro
Arg Ser Pro Ser Val Glu Val Lys Leu Thr 165 170 175Asp Tyr Gly Glu
Leu Thr Leu Asp Cys Glu Pro Arg Ser Gly Ile Asp 180 185 190Phe Asn
Glu Met Ile Leu Leu Thr Met Lys Lys Lys Ala Trp Met Val 195 200
205His Arg Gln Trp Phe Phe Asp Leu Pro Leu Pro Trp Thr Ser Gly Ala
210 215 220Asp Thr Ser Glu Val His Trp Asn Tyr Lys Glu Arg Met Val
Thr Phe225 230 235 240Lys Val Pro His Ala Lys Arg Gln Asp Val Thr
Val Leu Gly Ser Gln 245 250 255Glu Gly Ala Met His Ser Ala Leu Ala
Gly Ala Thr Glu Ile Gln Asn 260 265 270Ser Gly Gly Thr Ser Ile Phe
Ala Gly His Leu Lys Cys Lys Val Arg 275 280 285Met Glu Lys Leu Arg
Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly 290 295 300Lys Phe Lys
Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly Thr Ile305 310 315
320Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser Pro Cys Lys Ile Pro
325 330 335Phe Glu Ile Thr Asp Leu Glu Lys Arg His Val Leu Gly Arg
Leu Ile 340 345 350Thr Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro
Val Asn Ile Glu 355 360 365Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile
Ile Ile Gly Val Glu Pro 370 375 380Gly Gln Leu Lys Leu Asn Trp Phe
Lys Lys Gly Ser Ser Ile Gly Lys385 390 395 400Met Phe Glu Ser Thr
Tyr Arg Gly Ala Lys Arg Met Ala Ile Leu Gly 405 410 415Glu Thr Ala
Trp Asp Phe Gly Ser Val Gly Gly Leu Phe Thr Ser Leu 420 425 430Gly
Lys Ala Val His Gln Val Phe Gly Ser Val Tyr Thr Thr Met Phe 435 440
445Gly Gly Val Ser Trp Met Ile Arg Ile Leu Ile Gly Phe Leu Val Leu
450 455 460Trp Ile Gly Thr Asn Ser Arg Asn Thr Ser Met Ala Met Thr
Cys Ile465 470 475 480Ala Val Gly Gly Ile Thr Leu Phe Leu Gly Phe
Thr Val Gln Ala 485 490 495
* * * * *